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The tissue engineering field and regenerative medicine has emerged as a promising strategy
to overcome the lack of availability of organs and tissue grafts for transplantation. One of the
main challenges in the field is to generate tissue analogues of relevant size with adequate
nutrient and oxygen supply that promote graft integration and long-term functionality. The
main strategies to promote tissue vascularisation are to either deliver bioactive cues such as
growth factors (GFs), which attract the host vessels towards the area of interest, or to directly
generate tissue analogues including a vessel network that can anastomose with the host blood
vessels after implantation.
This thesis aims to develop novel platforms to improve tissue vascularisation by delivering
GFs and generating  in vitro vascularised tissues. Firstly, a literature review summarises the
main strategies to deliver GFs and to generate in vitro vascularised tissues, together with their
present limitations for clinical translation. Next, a GF delivery system based on tyraminated
poly(vinyl alcohol) (PVA-Tyr) is developed, which has the ability to covalently incorporate a
range of native GFs and then release them in a controlled profile and during a tailorable time
frame.  The  flexibility  of  this  GF  delivery  system  allowed  its  adaptation  to  the
revascularisation of the femoral head in an  in vivo model of avascular necrosis, which was
done by adjusting the incorporated GF, the GF release time, the cell-material interactions of
the  system and its  delivery  method.  This  research  is  followed  by the  development  of  a
gelatin-norbornene  (Gel-NOR)  platform  that  allows  biofabrication  of  large  vascularised
tissues. The fabricated tissues combined a controllable pore structure, which mimicked larger
vessels in native tissues, with encapsulated endothelial cells that were able to assemble into
micro-capillary structures, mimicking the capillary beds in native tissues. These fabricated
tissues were used as a model to study how design parameters can affect the behaviour of
endothelial cells, demonstrating that pore diameter and fibre diameter could have an impact
on the ability of endothelial cells to form micro-capillaries. Finally, the developed platforms
were  combined  using  bioassembly,  which  allowed  understanding  how  different  cell
arrangements can affect endothelial cell behaviour within fabricated scaffolds and to develop
tissue analogues that combine GF delivery with pre-vascularisation techniques. Overall, this
thesis  combines  materials  chemistry  and  design  with  advanced  fabrication  techniques  to
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1.1.  Tissue Engineering and the Challenge of Vascularisation
Since tissue and organ transplantation became a widespread medical  procedure,  there has
been a tremendous disparity between the need and the availability of organs and tissue grafts.
The inherent limitations associated with organ transplantation include immune rejection, risk
of  disease  transmission  and  donor-site  morbidity  (1–3).  The  tissue  engineering  and
regenerative medicine (TERM) field, which aims to regenerate or repair tissues or organs, has
emerged as an attractive strategy to overcome these issues.
In order to successfully engineer tissues in the laboratory, it is vital to firstly understand the
physiological processes of tissue development and regeneration. The main components in the
developmental and regenerative microenvironments are cells, extracellular matrix (ECM) and
soluble signalling molecules  (4). Cells are the central unit of the tissue as they proliferate,
migrate and differentiate  in response to certain environmental  inputs. The ECM acts as a
physical  support  to  these  cells,  while  also  providing  the  necessary  biophysical  and
biochemical  cues  for  tissue  homeostasis.  Finally,  soluble  signalling  molecules  circulate
through  the  bloodstream  and/or  diffuse  through  interstitial  fluid  to  modulate  cellular
behaviour.  Tissue  engineering  focuses  on  controlling  these  three  aspects  within  the
regenerative  microenvironment  in  order  to  trigger  or  enhance  tissue  regenerative/healing
processes. This can be achieved by either delivering materials, cells and/or soluble signals
directly into the injury site or by using these three components to generate tissue analogues
that are maturated in vitro and implanted into the injury site.
Early stages of tissue regeneration usually involve the generation of a local vessel network
that transports oxygen, cells and soluble signals to the injury site, initiating and promoting the
wound-healing response (5). A good example of this process is bone fracture healing, where
early vascularisation is essential. Reduced or inadequate blood flow during fracture healing
has been associated to impaired regeneration, and reduced blood flow outside of the context
of regeneration has been linked to disorders such as osteoporosis (6). Furthermore, enhancing
the  vascularisation  process  has  consistently  resulted  in  improved  bone  regeneration  (7).
Vascularisation is equally important in other tissues, and therefore promoting this process has
been a major focus in TERM. However, generating a vascular network in tissue engineered
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constructs remains one of the major challenges of the field  (8,9). Vascular insufficiency is
common in thick tissue engineered grafts, leading to poor cell survival and eventual failure of
the graft (10). 
This thesis focuses on promoting tissue vascularisation using two main strategies: delivering
growth factors to the injury site and generating in vitro pre-vascularised tissue constructs. In
this  chapter,  a  brief  introduction  to  vascularisation  in  the  human  body  and  the  general
strategies to promote it is provided, together with the main challenges in the strategies studied
in this thesis. 
1.2.  Vascularisation in the Human Body
To  develop  strategies  that  promote  vascularisation,  it  is  necessary  to  understand  the
physiology of the vascularisation process. Blood vessels in the human body are formed by
two distinct processes named vasculogenesis and angiogenesis (Figure 1.1) (11). 
Vasculogenesis  refers  to  the formation  of a primitive  capillary  network from endothelial
precursor cells (called angioblasts) that happens during embryonic development (Figure 1.1)
(12). This capillary network is formed by the fusion of aggregates of stem cells called blood
islands, which emerge from the mesoderm, in a complex process that involves interactions
between  stem  cells,  growth  factors  such  as  VEGFs  (13,14),  ECM  molecules  such  as
fibronectin  and  laminin  (15) and  cell  adhesion  molecules  such  as  vascular  endothelial
cadherin (VE-cadherin), platelet-endothelial cell adhesion 1 (PECAM-1 or CD31) and CD34
(12). Notably, some studies have provided evidence of postnatal vasculogenesis initiated by
endothelial progenitor cells (EPCs) present in human peripheral blood during wound healing
and tumour development (16–18).
Angiogenesis refers to the formation of new capillaries from pre-existing vessels and is the
predominant mechanism of blood vessel formation in later stages of embryonic development
and in the adult body (11). The first instances of angiogenesis happen after the formation of a
primitive capillary network through vasculogenesis. In this stage, new capillaries are formed
by  either  sprouting  of  the  endothelial  cells  (sprouting  angiogenesis)  or  splitting  of  the
capillaries (intussusceptive or non-sprouting angiogenesis) (Figure 1.1). 
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Figure  1.1.  Vasculogenesis  and  Angiogenesis. The  differentiation  of  angioblasts,  or
endothelial precursor cells, from mesoderm and the formation of primitive vascular plexus
from angioblasts are the two distinct steps during the onset of vascularization that together
constitute vasculogenesis. Angiogenesis refers to the growth of new capillaries from pre-
existing blood vessels either via sprouting or intussusception. Reproduced from (11).  
During sprouting angiogenesis, endothelial cells form sprouts with tip cells at their ending
(polarized migratory endothelial cells that follow angiogenic stimuli, guiding vessel growth)
followed by stalk cells (proliferative endothelial cells that form tubes and branches). This step
is followed by pruning of unnecessary capillaries (19), recruitment of perivascular cells such
as pericytes and smooth muscle cells and deposition of a basement membrane, resulting in a
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more stable and mature vasculature  (20,21). Angiogenesis in the adult body starts in fully
developed blood vessels, therefore requiring an initial degradation of the basement membrane
and detachment of mural cells before the sprouting of endothelial cells.
Non-sprouting angiogenesis  starts  with the protrusion of the vessel  walls  into the lumen,
forming a contact between endothelial cells. This step is followed by the extension of cells
from the interstitial  tissue into this  contact,  the migration of pericytes  and the growth of
interstitial tissue, forming a transluminal pillar. This process has also been observed during
tumour  angiogenesis  and in  adult  tissues  such  as  kidney,  bone,  retina,  heart  and  central
nervous system (22).
1.3.  Main Tissue Engineering Strategies to Promote Vascularisation
Tissue engineering has applied these biology concepts when designing strategies to promote
vascularisation. There is a wide range of possibilities to do so, which are classified here in
relation  to  the  vascularisation  process  that  they  are  trying  to  promote:  angiogenesis  or
vasculogenesis.
In order to  promote angiogenesis, the most extended strategy is to deliver bioactive clues
that trigger angiogenic sprouting and attract tip cells towards the injury site (23,24). Growth
factors that would naturally participate in the process of angiogenesis such as bFGF, VEGF,
Angiopoietin-2 or PDGF have been one of the main focus of study (25). The delivery of cells
is another strategy that is widely extended: mesenchymal stem cells (MSCs) and endothelial
cells have been shown to promote angiogenesis by secreting signalling molecules into the
environment  (26). The use of  biomaterials  as vehicles to deliver these clues is one of the
main pillars of tissue engineering  (27). Biomaterials  can be used to modulate  the way in
which delivered bioactive clues are presented, such as the release profile of growth factors,
and they can also constitute angiogenic triggers by themselves. By using  ECM molecules
that participate in the vascularisation process such as fibrin or laminin as part of the delivery
vehicle, it is possible to promote the penetration of angiogenic sprouts into the injury site
(27). On the other hand, the  physico-mechanical properties and the degradation rate of
the material are huge determinants of the resulting regenerative process. A material that is
too stiff will not allow the penetration of angiogenic sprouts into the area, and the degradation
rate should match the matrix remodelling of cells that participate in tissue regeneration (28).
Finally, the  3D architecture of the scaffold is also an important. The generation of empty
channels within the delivery vehicle through fabrication techniques has been demonstrated to
4
Chapter 1. Introduction
promote angiogenesis by facilitating the penetration of angiogenic sprouts from the body into
the injury site (29).
The  stimulation  of  vasculogenesis in  vitro has  been  another  major  focus  in  tissue
engineering during the last decade (9). It has been demonstrated that the co-encapsulation of
endothelial cells or stem cells in ECM-derived hydrogels can promote their self-organisation
into mature  vessel  networks  including lumen,  a  tunica  media  and a  basement  membrane
(30,31).  This  process  happens  after  in  vitro culture  in  media  including  vascularisation-
promoting  growth  factors  such  as  VEGF  and  bFGF  (31,32).  Furthermore,  these  pre-
vascularised constructs are capable of forming anastomosis with the host vessel network after
implantation,  resulting in levels of tissue vascularisation that are significantly higher than
after delivery of these cells and materials without the in vitro maturation step (33).
1.4.  Challenges in Growth Factor Delivery
Growth factors (GFs) have been a main focus in tissue engineering due to the critical roles
that  they  play  during  tissue  development  and  regeneration.  GFs  are  highly  bioactive
molecules, but they have a very short half-life in the physiological environment (34). Using
biomaterial vehicles to deliver these GFs helps to mitigate the problem by protecting them
from the physiological environment and providing a longer term release into the injury site as
compared to direct injection. One of the main challenges in this field is to provide controlled
release that fits the time frames of the targeted regenerative process. Adapting the GF release
profiles of these delivery vehicles usually requires complex methodologies that may affect
GF bioactivity or require the combination of multiple materials. Additionally, these methods
can be very specific to a small range of GFs, limiting their application.
1.5.  Challenges in the Generation of In Vitro Vascularised Tissue Analogues
The development  of  highly  vascularised  tissues  has  followed two main  directions  during
recent years: top-down and bottom-up strategies (9). 
Top-down strategies aim to use 3D fabrication techniques to generate a pre-designed channel
network that is then seeded with endothelial cells, mimicking native vessels (35–37). While
these techniques  offer  a  lot  of  flexibility  in  the  design of  the  channel  network,  they are
limited  in  the  minimum  diameter  of  the  channel  (50  μm)  due  to  the  resolution  of  the
fabrication techniques and the need of perfusing cells that can clog small channels  (9,38).
Another limitation of these techniques is in the high stiffness that is needed for long term
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shape fidelity of the constructs, which is often in direct conflict with the material properties
required for optimal cell spreading and differentiation.
Bottom-up  approaches  rely  on  the  self-organisation  of  encapsulated  cells  to  form  a
microvessel  network  by  reproducing  the  natural  processes  of  angiogenesis  and
vasculogenesis (32,39). The main limitation of bottom-up approaches to reproduce the native
vessel network of tissues and organs is that the vessels formed are only in the size range of
capillaries, which fails to reproduce the whole architecture of vessel networks. The need to
use  naturally-derived  materials  with  very  low  stiffness  limits  their  application  to  3D
fabrication techniques that would enable generating vessels of larger diameter (100 μm or
larger). Furthermore, the scalability of these techniques also needs to be further studied for
clinical  translation,  as research up to date  only focuses on the generation of small  tissue
analogues.
1.6.  General Aims of the Thesis
The present work aims to develop and study new tools to promote tissue vascularisation by
promoting angiogenesis and vasculogenesis. 
I. Developing a growth factor delivery system to promote vascularisation. 
Aim: To develop a growth factor delivery system that can incorporate a range of
different growth factors and release them in a controlled manner and adapt it to
promote vascularisation in a specific clinical context.
II. Combining top-down and bottom-up approaches for the generation of large
vascularised tissue analogues. 
Aim: To  develop  and  apply  a  material  platform  that  can  promote  in  vitro
vasculogenesis  and  be  biofabricated  with  controllable  endothelialised  porous
networks to generate large vascularised tissue analogues that recapitulate different
architectural resolutions of native vasculature.
III. Combining approaches for tissue vascularisation through bioassembly. 
Aim: To use bioassembly techniques for the biofabrication of large vascularised
tissues that combine the developed growth factor delivery and pre-vascularisation
platforms.




Chapter 2. Literature review:  Strategies to Promote Tissue Vascularisation in Tissue
Engineering and Regenerative Medicine. 
This  chapter  provides  a  thorough  review of  the  present  strategies  and challenges  in  GF
delivery and in the generation of in vitro vascularised tissue analogues. 
Chapter  3. Visible  Light  Mediated  PVA-Tyramine  Hydrogels  for  Covalent
Incorporation and Controlled Release of Functional Growth Factors.
This chapter describes the study of tyraminated poly-vinyl-alcohol (PVA-Tyr) hydrogels as a
growth factor delivery vehicle. It focuses on demonstrating that the system can covalently
incorporate  tyrosine-containing  growth  factors  without  prior  chemical  modification,  and
release them in a controlled manner without altering their bioactivity. The research in this
chapter is part of Aim I.
Chapter  4.  Adaptation  of  the  PVA-Tyr  Growth  Factor  Delivery  System  for  the
Treatment of Perthes Disease.
This chapter describes the adaptation of PVA-Tyr hydrogels to promote angiogenesis in cases
of avascular necrosis by releasing VEGF. The functionality of the system is improved by
covalently  incorporating  gelatin,  which  allows  the  attachment  of  endothelial  cells  to  the
material.  It  is  also  confirmed  that  the  addition  of  gelatin  does  not  alter  the  degradation
properties or release profile of GFs from PVA-Tyr hydrogels. A method for the injection of
the delivery system is developed and the system is tested in an  in vivo  model of avascular
necrosis. The research in this chapter is part of Aim I.
Chapter  5.  Fabrication  of  multi-scale  vascularised  tissues  with  controllable  3D
architecture using Gel-NOR.
In  this  chapter,  the  combination  of  a  top-down  and  a  bottom-up  approach  for  the
biofabrication of vascularised constructs with different levels of vascularisation is reported.
To do that, Gelatin is functionalised with norbornene groups to finely control its mechanical
properties using photo-crosslinking. Hydrogels with low stiffness that promote the assembly
of  endothelial  cells  and  support  cells  into  interconnected  micro-capillary  networks  are
fabricated. This formulation is then used to 3D fabricate large constructs with a controlled
channel  network,  which  allows  studying  the  effects  of  fabrication  parameters  on
endothelialisation of the channels and endothelial cell network formation. The research in this
chapter is part of Aim II.
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Chapter 6. Bioassembly of  Gel-NOR and PVA-Tyr for  Combinatory Approaches  in
Tissue Vascularisation.
In this  chapter,  both PVA-Tyr and Gel-NOR microspheres  are  fabricated  to  enable  their
bioassembly into larger scaffolds. The effects of the fabrication method on the ability of Gel-
NOR  encapsulated  endothelial  cells  to  form  interconnected  networks  is  evaluated.  The
growth factor release profile and degradation time of PVA-Tyr microspheres is also studied.
Pilot experiments are executed to demonstrate the capabilities of bioassembly to generate in
vitro models and to combine strategies for tissue vascularisation. The research in this chapter
is part of Aim III.
Finally, the conclusions and suggestions for future directions are developed in Chapter 7.
1.7.  Publications Arising from this Thesis
1. Atienza-Roca P., Cui X., Hooper G.J., Woodfield T.B.F., Lim K.S. (2018) Growth
Factor Delivery Systems for Tissue Engineering and Regenerative Medicine. In: Chun
H.,  Park  C.,  Kwon  I.,  Khang  G.  (eds)  Cutting-Edge  Enabling  Technologies  for
Regenerative Medicine. Advances in Experimental Medicine and Biology, vol 1078.
Springer, Singapore
Contribution: Pau Atienza wrote the manuscript. Co-authors assisted with literature
search and editing for the final draft. 
2. Atienza-Roca  P.,  Kieser  D.,  Cui  X.,  Ramaswamy  Y.,  Hooper  G.,  Clarkson A.,
Martens P., Wise L., Woodfield T. B. F., Lim K. S. Visible Light Mediated PVA-
Tyramine Hydrogels for Covalent Incorporation and Controlled Release of Functional
Growth Factors (2020).  Biomater. Sci., 2020,8, 5005-5019. This article was selected
for the HOT articles section of Biomaterials Science in August 2020.
Contribution: Pau  Atienza  performed  all  the  experimental  work  and  wrote  the
manuscript. Co-authors assisted with experimental planning, scientific discussion and
editing for final draft.
3. Atienza-Roca P., Soliman B. G., Woodfield T. B. F., Lim K. S.  Biofabrication of




Contribution: Pau Atienza performed most of the experimental work and wrote the
manuscript. Co-authors assisted with experimental planning, execution of some of the
experiments, scientific discussion and editing for final draft.
1.8.  Publications Generated during the Candidature but not Part of the Thesis
1. Lim K. S., Abinzano F., Nuñez Bernal P.,  Albillos-Sanchez A.,  Atienza-Roca P.,
Otto I.,  Woodfield T. B. F.,  Malda J.,  Levato R. One-step crosslinking of a dual-
functionalized  bioink  as  cell  carrier  and  cartilage-binding  glue  for  chondral
regeneration (2020) (Submitted to Advanced Healthcare Materials).
Contribution:  Pau Atienza assisted with execution of some of the experiments and
editing for final draft.
2. Alcala-Orozco  C.,  Mutreja  I.,  Atienza-Roca  P.,  Cui  X.,  Hooper  G.,  Lim  K.  S.
Woodfield T. B. F. Hybrid biofabrication of bone regenerative constructs comprising
nanocomposite  support  scaffolds  and  multi-functional  bioinks  with  enhanced
osteogenic tissue formation and growth factor localisation” (2020). (In preparation) 
Contribution: Pau Atienza assisted with the execution of some of the experiments.
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(2017,  September). Photo-click  gelatin-norbonene  hydrogels  for  biofabrication  of
vascularized tissue. Verbal presentation at the Future Investigators of Regenerative
Medicine (FIRM) Symposium, Girona, Spain.
2. Atienza  Roca,  P.,  Anten,  J.,  Brown,  G.,  Woodfield,  T.,  &  Lim,  K.  (2017,
April). Photo-click  gelatin-norbornene  hydrogels  for  tissue  vascularisation.  Verbal
presentation  at  the  Australasian  Society  for  Biomaterials  and  Tissue  Engineering
(ASBTE)  25th  Annual  Conference  and  the  7th  Indo-Australian  Conference  on
Biomaterials, Implants, Tissue Engineering and Regenerative Medicine (BiTERM),
Canberra, Australia.
3. Atienza Roca, P., Soliman B. G., Anten, J., Brown, G., Woodfield, T., & Lim, K.
(2018,  April). Development  of  a  Visible  Light  Photo-Click  Hydrogel  System  for
Biofabrication  of  Vascularised  Tissue.  Poster  presentation  at  the  Centre  for
Bioengineering  and  Nanomedicine  2018  Showcase,  Dunedin,  New  Zealand.
Awarded the best poster presentation prize.
4. Atienza Roca, P., Soliman B. G., Anten, J., Brown, G., Woodfield, T., & Lim, K.
(2018,  April). Development  of  a  Visible  Light  Photo-Click  Hydrogel  System  for
Biofabrication  of  Vascularised  Tissue.  Poster  presentation  at  the  MedTech  in
Christchurch 2018, Christchurch, New Zealand.
5. Atienza-Roca  P.,  Kieser  D.,  Cui  X.,  Ramaswamy  Y.,  Hooper  G.,  Clarkson A.,
Martens P., Wise L., Woodfield T. B. F., Lim K. S. (2019, October) Visible Light
Mediated  PVA-Tyramine  Hydrogels  for  Covalent  Incorporation  and  Controlled
Release  of  Functional  Growth  Factors.  Poster  presentation  at  the  Centre  for
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Vascularisation in Tissue Engineering and
Regenerative Medicine
2.1. Growth Factor Delivery
2.1.1. Introduction to Growth Factor Delivery
Growth factors (GFs) are defined as secreted, biologically active molecules that can affect the
growth and differentiation of cells. They play critical roles in developmental and regenerative
processes,  and  therefore  have  been  a  main  focus  in  tissue  engineering  and  regenerative
medicine (TERM) strategies. Levi-Montalcini and Cohen firstly discovered GFs by studying
the  effect  of  sarcomas  on axonal  growth from chicken embryos  (1).  They identified  the
signalling  molecule  that  triggered  the  growth  of  neuronal  networks  and  termed  it  nerve
growth factor (NGF) (2). Since then, several GFs that modulate many physiological processes
have been discovered and applied to regenerative medicine (3). Some examples include bone
morphogenetic  proteins  (BMP-2  and  BMP-7)  for  bone  regeneration  (4) and  vascular
endothelial  growth  factor  (VEGF)  (5) or  platelet-derived  growth  factor  (PDGF)  (6) for
diabetic foot ulcers.
GFs act on cells  by binding transmembrane receptors in a highly specific manner,  which
triggers  a transduction cascade that  generally  starts  with phosphorylation of the cytosolic
domain of the receptor. Each GF is unique with specific roles in cellular behaviour (Table
2.1).  For example, BMP-2 is essential for the maintenance of bone density (7). It has been
reported that adult mice lacking BMP-2 showed spontaneous fractures and impaired bone
repair  (8). Due to these characteristics, BMP-2 has been used in clinical settings for spinal
fusion procedures and for non-union fractures  (9). A list of these GFs with their respective
unique characteristics can be found in Table 2.1.
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In the native microenvironment, GF concentrations are usually in the nanomolar to picomolar
range, where their presence is continuous and can last up to several weeks or months  (10).
Initial clinical trials, which involved injection (11) or spraying (12) of GFs directly onto the
wound site,  showed  limited  therapeutic  effects,  mainly  due  to  the  short  presence  of  the
applied GFs at the wound area. To better mimic the natural spatio-temporal concentrations of
GFs, continuous doses of the GF were administered, causing systemic overexposure that can
result in undesirable increase risk of cancer and ectopic tissue formation (13). 
These results led to the realisation of the need for a suitable GF delivery system, which has
been the focus of many research groups in the past decades. This chapter will cover a list of
criteria  that  should  be  followed  when  designing  a  GF  delivery  vehicle  for  a  specific
application, together with the different GF delivery approaches reported in the literature that
aim to mimic key aspects of the regenerative microenvironment by controlling the spatio-
temporal presence of GFs.
2.1.2. Design Criteria for Growth Factor Delivery Systems
When designing of a novel TERM therapy, the first aspect to consider is what GF to deliver.
The selection of an adequate GF will not only depend on the type of organ or tissue that we
are trying to regenerate, but also on the desired cell function. Some GFs trigger proliferation
and differentiation of cells that are already present at the injury site. In other cases where the
cells  required for healing or regeneration  are absent,  chemotactic  GFs are able  to trigger
migration of cells to the wound site (51,52). The ECM is another key factor that needs to be
considered while designing any GF delivery system, since it can modulate the effects of GFs
through different mechanisms. For example, heparan sulphate (53), decorin (54), betaglycan
(55), versican (56), fibronectin (57), collagen (58), vitronectin (59), SPARC (60) and tenascin
D (61) are ECM components that can bind GFs and modulate their diffusion and localization,
further influencing their availability at the cell surface and their receptor-binding kinetics.
Due to the dynamic remodelling of the ECM during regenerative  processes  (62,63),  it  is
important  to  understand the  interaction  between  GFs  and the  ECM for  the  design of  an
optimized  delivery  strategy.  The  interactions  between  cell  receptor,  ECM  and  GFs  are
represented in Figure 2.1.
In order to modulate these complex interactions, different parameters such as the localization
of the GF, the concentrations released and the release pattern have been identified as relevant
design  criteria  to  be  met  when  designing  a  delivery  system.  These  aspects  are  further
discussed in the sections below.
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Figure 2.1. From biosynthesis  to cell  receptor  signalling,  a  growth factor’s  journey
within the physiological ECM. After their biosynthesis, growth factors are secreted into
the ECM, where they interact with ECM components before binding and activating their
cognate receptors. Growth factors mainly signal to cell in autocrine and paracrine fashion,
to  instruct  their  behaviour  during  morphogenetic  processes.  Complexes  formed between
growth  factors,  ECM  components,  and  cell  surface  receptors  may  lead  to  additive  or
synergistic cell signalling events. Reproduced from (64).
2.1.2.1. Localization of the Delivery
GFs can have different effects in different tissues and cell types. For example, EGF promotes
homeostasis in the GI tract (65) and mammary gland (66) but inhibits tissue maturation in the
cartilage  (67). In order to achieve only the desired therapeutic outcome, the GF has to be
delivered and contained spatially at the targeted tissue. Moreover, unnecessary presence of
GFs in non-targeted tissues might also trigger cancer development and progression due to
excessive  cell  proliferation  (13,68,69).  In  order  to  avoid  these  effects,  different  delivery
systems that enable spatial containment of delivered GFs such as nanoparticles or scaffolds
have been studied, which are further discussed in following sections.
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2.1.2.2. Delivered Concentration
A major  challenge  in  designing  GF delivery  approaches  is  optimising  the  concentration
required for the desired therapeutic effect. A recent meta-analysis on the use of FGF-2 and
PDGF-BB for periodontal defects reported thresholds of GF concentration below which the
treatment failed to promote bone regeneration (70). These thresholds changed depending on
the type of defect that was treated. The same study showed that excessive concentrations of
FGF-2  resulted  in  insignificant  promotion  of  bone  growth.  Furthermore,  excessive
concentrations  of  BMP-2  have  been  reported  to  promote  apoptosis  in  osteoblasts,
mesenchymal stem cells (MSCs)  (71) and periosteal cells  (72). Similarly, excessive VEGF
concentrations promote the formation of aberrant and hyper-permeable blood vessels  (73).
Therefore, the optimal concentration of GFs to be delivered onsite has to be evaluated each
TERM application.
The  culmination  of  spatio-temporal  control  over  GFs  is  the  formation  of  concentration
gradients that mimic regenerative and developmental processes. GFs are generally secreted
from a focal spot, which can be a cluster of cells with a specific phenotype or the defined
space of a regenerative process. Cells  at  different  distances from the spot are exposed to
different  concentrations  of  the  secreted  GF,  and specific  concentration  thresholds  strictly
define  spatial  differentiation  patterns  in  many  stages  of  embryonic  development  (74,75).
Individual  cells  are  able  to  detect  spatial  differences  in  the  concentration  of  specific
molecules, which makes gradients of chemotactic GFs a directional signal for cells to migrate
to the wound site  (76,77) and for vascularization  and innervation  of tissues  (14,78).  The
specific characteristics of these gradients are crucial  for organized tissue formation. Thus,
their adequate mimicry would be one of the pinnacles of controlled GF delivery. 
2.1.2.3. Release Patterns
The time period during which the GF is present on site is an essential parameter to achieve
optimal therapeutic effects. The ordered presence and absence of specific factors corresponds
to different stages of regeneration in natural processes  (79,80). During bone regeneration,
GFs that promote recruitment of MSCs and vascularization, such as stromal derived factor 1
(SDF-1)  and VEGF are  firstly  expressed.  This  stage  is  followed by the  generation  of  a
cartilaginous callus in which other GFs such as TGF-β3 are highly expressed, and the process
ends after a prolonged mineralisation and resorption phase in which expressions of TNF-α,
IL-1 and BMP-2 are elevated (80,81). In an attempt to match these GF expression patterns,
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delaying the administration of rhBMP-2-loaded calcium phosphate matrices  for one week
instead of 3 hours post-surgery resulted in accelerated healing in a primate fibular osteotomy
model (82). It has also been reported that delaying the administration of an adenoviral BMP-2
vector by 5 to 10 days after surgery increases bone mineralisation in a rat critical-size defect
model  (83). It is also to be noted that the therapeutic effect of GFs is time-dependant. A 4
weeks sustained delivery of BMP-2 improves ectopic bone formation in comparison to just 5
days delivery (84), which agrees with the fact that the BMP-2 plays a major role in the long-
term  remodelling  phase  of  bone  regeneration  (81).  These  results  indicate  that  matching
specific  GF expression patterns  can result  in improved tissue regeneration and should be
taken into account in designing GF delivery systems.
2.1.3. Use of Biomaterials for Growth Factor Delivery
The main limitations of delivered GFs are their low biochemical stability, short circulating
half-life and rapid rate of cellular internalization. Combining GFs with a biomaterial is an
effective approach to overcome these drawbacks. However, no single material or strategy has
yet  allowed  the  required  spatio-temporal  control  over  the  delivered  GFs  for  optimal
therapeutic effect. In recent years, the convergence of different materials, chemistries and
fabrication techniques  has brought the field one step closer  to  its  goal  by enabling more
complex release patterns, including coordinated release of different GFs. This section will
provide  an  overview  of  all  these  strategies,  focusing  on  the  advanced  materials  and
procedures that enable control over the outlined design criteria.
2.1.3.1. Incorporation Methods
GFs  can  be  incorporated  into  biomaterials  through  different  strategies.  The  simplest
procedure involves directly submerging a material in a GF solution to facilitate the adsorption
of the GF to the material  (85). For example,  GFs have been adsorbed on FDA approved
polymers  such  as  poly(lactic-co-glycolic)  acid  (PLGA)  microspheres  (86) and
poly(caprolactone) (PCL) scaffolds  (87).  Changes in material surface roughness  (88) or the
addition of nanostructured features  (89) can increase the overall  surface area,  resulting in
increased GF adsorption. Another prominent strategy that involves mixing the material with
the  GF in  a  liquid  phase  prior  to  scaffold fabrication  allows the fabrication  of  scaffolds
entrapped with GFs. Common scaffold fabrication techniques include freeze drying, phase
separation, molding or in situ polymerization (90). An important limitation of these strategies
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is the requirement to protect the GFs from harsh conditions during scaffold fabrication in
order  to  maintain  their  bioactivity.  For  example,  melt  molding  can  expose  GFs  to  high
temperatures,  whereas  radical  based  polymerization  systems  can  facilitate  GF
oxidation/denaturation (91).
2.1.3.2. Interaction between Growth Factor and Biomaterial
The interaction between GF and biomaterial plays a key role in all incorporation methods,
affecting not only the release profile  (85,92), but also the biological effects of the GF (92).
The different types of material-GF interaction are summarized in Figure 2.2. 
Figure 2.2.  Types of material-growth factor interaction. (A) Non-covalent interactions
based on surface properties. (B) Affinity-based systems rely on natural interactions between
growth factors and the extracellular matrix. (C) Covalent incorporation methods bind the
growth to the material directly or through added functional groups or amino acids. Adapted
and modified from (64).
Non-covalent interactions are weaker and can be mainly hydrogen bonds (93), Van der Waals
forces, ionic forces or hydrophobic interaction  (94). Modifying the surface charges, charge
density  (95,96) or  available  functional  groups  (97) of  the material  result  in  different  GF
binding affinities and release profiles. For example,  increasing the surface hydrophobicity
and decreasing the isoelectric point (pI) of PLGA microspheres resulted in an increase in the
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amount  of  rhBMP-2  adsorbed,  whereas  changes  in  PLGA  molecular  weight  did  not
significantly  change  BMP-2  adsorption  (98).  Functionalizing  the  material  surface  or  the
polymer  chains  with  amino  (89),  alkyl  (89,99) or  oxygen-terminated  groups  (100) can
increase the adsorption of rhBMP-2 and result in a longer release time. The interaction with
the functional  groups will  also depend on the pI of the GF, and thus each GF will  have
specific release profiles when incorporated in the same material based on this approach (101).
A special case in non-covalent interactions is the use of GF-binding domains from ECM
molecules. These strategies are generally classified as affinity-based, as the affinity of certain
GFs for these domains is  significantly higher and more specific  than for single chemical
groups or surface charges (102). An example of these affinity-based domains are heparin or
heparan sulphate, which have been extensively used for the delivery of specific GFs such as
NGF or  BMP-2  (103,104).  Fibronectin  (105) and  fibrinogen  (106) GF-binding  domains,
which bind to several GFs from the PDGF, VEGF and FGF families and some from the TGF-
β family, have also been used to functionalize scaffolds. The use of affinity-based systems
has been extensively studied and reported in the literature  (107), and the resulting release
profile,  which  is  significantly  more  sustained  than  for  other  non-covalent  incorporation
methods, positioned them as one of the most successful GF incorporation approaches to date.
However, the strategies are limited to the release of GFs that display natural affinity for these
domains, and the release profile differs between different GFs due to their distinct affinities
with  the  system.  In  order  to  further  improve  the  therapeutic  effects,  some  studies  have
engineered GF containing ECM binding domains. Genetically engineered IGF-1 including
the heparin-binding (HB) domain of HB-EGF was able to interact with specific GAGs in
cartilage  matrix  after  injection  to  the  knee  (108).  Through  similar  techniques,  collagen-
binding domains were added to NGF (109) or BDNF (15), promoting their interaction with
collagen scaffolds (110) and the retention of the GF at the wound site.
The  release  profile  for  delivery  systems that  use  non-covalent  incorporation  is  generally
characterized by an initial burst release  (111). The observed burst release profile has been
suggested  to  have  a  role  in  early  post-implantation  complications  (112,113).  In  order  to
reduce or eliminate the burst release, protein immobilization to the matrix through covalent
incorporation has been extensively studied (92). It has been reported that the release of GFs
conjugated  to  the  biomaterial  is  then  dependent  on  the  materials’  degradation  profile.
Moreover, it is possible to have further precise control over the GF release profile by adding
features  such as protease-cleavable sequences to the material  (114) or to the material-GF
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linkage  (115).  Aside  from improved control  over  the  GF release  profile,  presentation  of
covalently bound GFs to cells can result in a differentiated response in comparison to soluble
GFs  by  inhibiting  the  internalization  of  the  GF-receptor  complex  (116).  Covalent
incorporation can also be used for patterning GF  (117), including the formation of gradients
in a material.  Several GFs have been covalently incorporated in biomaterials for different
applications,  leading  to  improved  functions  such  as  endothelial  cell  proliferation  (118),
osteoblast  adhesion  to  titanium  implants  (119) and  even  bone  formation  in  vivo  (120).
Common  reactions  for  GF  immobilization  include  carbodiimide  coupling  (121),  photo-
polymerization methods such as phenyl azide-based (120) or acrylate-based (117), and also
click chemistry  (122,123). One of the main limitations of these approaches is poor control
over the exact reaction site of the GF, which can lead to disruption of the receptor-binding
domain  (92).  In  order  to improve the therapeutic  effects  of  covalently  incorporated  GFs,
some studies have engineered growth factors containing functional groups  (124) or amino
acids (125) at specific sites that do not overlap with the receptor-binding domain. 
2.1.3.3. Delivery Vehicles for GF Administration
The biomaterials used for GF delivery can be fabricated into different types of vehicles, such
as  particles  or  scaffolds.  Each  delivery  vehicle  poses  favourable  characteristics  and  is
adaptable to specific therapeutic strategies or administration procedures. A list of different
GF delivery vehicles is tabulated in Table 2.2 below. 
2.1.3.3.1. Particle Systems
Particle systems, which can be in the range of <1 µm for nanoparticles or <1000 µm for
microparticles, have been used to deliver GF for TERM applications (184). The particle size
affects  the  rate  of  GF  release  due  to  different  surface-to-volume  ratios  and  intracellular
uptake (185).
2.1.3.3.1.1. Nanoparticles
Nanoparticles (NPs) can infiltrate deeper into tissue via capillaries and epithelial lining due to
their small sizes, improving the transport properties and pharmacokinetic prolife of drugs in
vivo.  They are generally  highly soluble  and display low immunogenicity  (186).  Targeted
delivery of GFs to specific tissues can be achieved using surface functionalized NPs or using
electromagnetic  fields  (143).  Surface  functionalization  can  also  enable  NPs  to  cross  the
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blood-brain barrier (BBB), which is not possible for other delivery systems without invasive
procedures  (187). NPs can be classified into polymeric, lipidic and inorganic depending on
their composition. 
Polymeric NPs can be fabricated as nanospheres, nanocapsules, micelles and dendrimers, all
of which have been studied for GF delivery.  PLGA is the most studied material  to form
nanospheres and nanocapsules, and it has been used for IGF-I (127), VEGF (126) and BMP-2
release  (128).  Functionalization  of  PLGA  nanoparticles  with  different  concentrations  of
heparin has also been used to form an affinity-based system, where increasing the heparin
concentration  resulted  in  longer  term release  (126).  Using  this  method,  it  is  possible  to
achieve long-term release: a heparin-conjugated Tetronic®-PCL micellar system was used
for  bFGF delivery,  showing  long-term delivery  up  to  2  months  (133,134).  This  type  of
particles have also been combined with other techniques to promote their penetration into
tissues: Low frequency ultrasound was combined with bFGF-loaded PLGA NPs to increase
microvessel  permeability  for  targeted  skeletal  muscle  angiogenic  therapy  (188).
Apolipoprotein E (ApoE) was adsorbed to poly(butylcyanoacrylate) (PBCA) NPs in order to
cross  the  BBB through  an  ApoE receptor-mediated  response.  NGF was  adsorbed  to  the
PBCA  NP  surface  and  then  delivered  to  rats  by  intraperitoneal  injection.  Symptoms  of
scopolamine-induced  amnesia  were  reduced  after  the  administration,  indicating  targeted
delivery to the brain (131). 
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Tetronic®-PCL (Heparin) bFGF (133,134)
PAMAM EGF,VEGF (135,136)















SPION EGF, BDNF (145,146)
QD BDNF,NGF (147,148)
Scaffolds
Collagen BMP-2, BMP-7 (3)
PLA BDNF (149)
PLGA FGF, BMP-2 (150,151)
Chitosan-glycerophosphate BMP-2, Insulin (152,153)
Fibrin FGF-2, VEGF-A (154)
PEGDA-Heparin
bFGF, TGF-β, KGF, Ang1, PDGF
(155,156)
PEG FGF-2, PlGF-2 (106)
GelMA BMP-2 (157,158)
PEG-PLLA-PEG TGF-β1 (159)
Β-TCP PDGF, GDF-5, BMP-2, hGH (160–163)
Bioglass VEGF, BMP-2 (164,165)
CPC BMP-7,VEGF (166)





PLGA, Gelatin, PPF BMP-2 (171)
PLGA, PEG CNTF, NT-2 (172)
Gelatin, OPF TGF-β1, IGF-1 (173,174)
PLA, alginate BMP-2, VEGF (175)
PLA, chitosan IGF-1, BMP-2 (176)
PHBV, chitosan BMP-2,BMP-7 (177)
Core-shell
Gelatin, PPF BMP-2, VEGF (178)
PLLA,PLGA BMP2-,FGF (179)
Layer by layer
Gelatin BMP-2 IGF-1 (180)
OPF BMP-2,IGF-1 (181)
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Lipid based NPs that have been used for GF delivery are mostly liposomes and solid lipid
nanoparticles (SLNs) (189). The main advantages of these formulations are their inherent low
toxicity and scalable production methods (190). Liposomes are vesicles formed by bilayers of
hydrated phospholipids which enclose an aqueous core (191). Their empty core allows easily
loading  GFs  and  other  nanoparticle  systems,  providing  flexibility  in  their  application.
Phosphatidylcholine  liposomes  loaded  with  magnetite  particles  were  used  for  bone  and
cartilage regeneration after loading with BMP-2 (137) or TGF-β1 (138), where the magnetite
particles could be directed to the injury site using a magnetic field. Despite their flexibility,
liposome nanoparticles display low GF loading capacity and low stability due to enzymatic
degradation, leading to a short term release  (143). Other types of lipid NPs with different
conformations have been used in order to overcome these issues. For example,  a lecithin
anionic nanolipid core was loaded with VEGF and covered by a Pluronic F-127 shell. The
system showed increased stability in comparison to liposome systems, and a sustained release
of  VEGF  for  more  than  30  days.  The  release  period  was  extended  by  increasing  the
lecithin/Pluronic F-127 ratio,  presumably due to changes in the ionic charge that enabled
stronger interactions with VEGF (140). Recently, another SLN system has been conjugated
with heparin and loaded with NGF for neuronal differentiation. The release could be tuned by
changing the composition of the solid core, where using stearylamine resulted in a faster
release  than using esterquat,  and increasing  the  amount  of  cholesterol  resulted  in  slower
release (141).
Inorganic nanoparticles such as mesoporous silica NPs (MSNs), quantum dots (QDs) or
metallic NPs have been also applied to GF delivery. In general terms, inorganic nanoparticles
excel due to their easy handling and their physical properties. MSNs are used due to their
high surface area and porosity  (192). A good example of their application is the study by
Zhou  et  al.,  where  BMP-2  was  covalently  grafted  to  the  MSNs  surface  through  an
aminosaline linker, while dexamethasone was loaded in the nanopores to form a dual delivery
system. The combination resulted in synergistic induction of bone formation in an  in vivo
ectopic  model  (193).  It  has  also  been  shown  that  the  release  kinetics  can  be  tuned  by
controlling the porosity of the nanoparticles, where increased porosity leads to faster release
(194), or by coating them with PEG, resulting in increased release time (195). Magnetite NPs
have  been  combined  with  other  types  of  NPs,  including  MSNs  (196) and  liposomes
(137,138), to provide them with magnetic properties that enable guided targeting using an
external magnetic field. Other magnetic NPs can also be directly incorporated with GFs, such
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as superparamagnetic iron oxide nanoparticles (SPIONs), which enabled targeting specific
areas of the brain using a magnetic field after adsorption of BDNF to their surface (145). The
main  drawbacks  of  metal-based  nanoparticles  are  their  poor  degradability  and  tissue
accumulation. Thus, their long-term toxicology should be further evaluated (192). QDs have
fluorescent properties that can be used to track conjugated molecules. Conjugation of BDNF
(148) and NGF (147) with QDs enabled tracking of the GF after internalization by neurons
and  PC12  cells  respectively,  which  enabled  monitoring  of  the  receptor  internalization
dynamics. In the field of bone regeneration, calcium phosphate nanoparticles have also been
studied due to their high biocompatibility and bioactivity (197).
Overall,  NP delivery systems represent a promising approach for GF delivery. One of the
most important advantages of NP systems is the possibility of intravenous administration,
which positions them as the least invasive GF delivery method. Another unique feature of NP
systems is the ability to cross the BBB, enabling access of GFs to the central nervous system.
The specific properties of different NPs provide great advantages such as targeted delivery,
enhanced MRI contrast or tracking of the NPs. Other systems such as MSNs can be used as a
sequential  delivery system, and complex NPs can be synthesized in order to combine the
advantages of different nanostructured materials. On the other hand, aspects such as long-
term toxicity and tissue accumulation of NPs should be further investigated before advancing
to the clinical field.
2.1.3.3.1.2. Microparticles
The  use  of  microparticles (MPs)  generally  results  in  a  lower  cellular  uptake  and  tissue
penetration in comparison to NPs due to their larger sizes  (185). On the other hand, their
increased  volume  results  in  higher  drug  loading  capacity,  slower  release  and  ease  of
production.  These characteristics enable a longer-term release,  which can be extended by
increasing the particle size (198). The materials used to generate MPs for GF release include
naturally derived polymers such as gelatin (199), alginate (200) and chitosan (201), as well as
synthetic polymers such as PLGA (202). As MPs adaptability to intravenous administration is
low in  comparison  to  NPs,  most  of  the  applications  require  the  formation  of  a  scaffold
through  microsphere  fusion  (203) or  being  incorporated  in  a  solid  scaffold  (204) or  an
injectable  hydrogel  (205).  Thus,  section  2.3.3.3.  ‘Combined  approaches  in  growth factor
delivery’ will cover more of the applications of microparticles.  
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2.1.3.3.2. Scaffold Systems 
Biomaterial scaffolds can be incorporated with GFs and implanted into the damaged area to
achieve local release (91). Scaffold systems can be classified as solid scaffolds or hydrogels
depending on their composition.
Solid  scaffolds  are  typically  porous  matrices  fabricated  by  techniques  such  as  solvent
casting, gas foaming, particulate leaching, electrospinning or rapid prototyping  (90). These
systems can be classified as organic or inorganic. 
Solid organic scaffolds are  mainly polymeric,  and have been extensively studied for GF
delivery. Homo- and copolymers of lactide and glycolide (like PLGA or PLLA) have been
widely used due to their degradation into lactide and glycolide, which can enter physiological
metabolic  pathways  (206).  The  physical  properties  of  these  polymers  can  be  altered  by
varying  the  ratio  of  lactide/glycolide,  molecular  weight  or  crystallinity  (207),  which  can
directly influence the release profile of GFs. For example, PLA scaffolds have been loaded
with BDNF by entrapment for spinal cord injury applications  (149) while PLGA has been
loaded  with  BMP-2  for  bone  regeneration  (151).  Affinity-based  systems  have  also  been
generated by conjugating heparin to the surface of PLGA scaffolds. FGF was adsorbed onto
these scaffolds, resulting prolonged release and stimulation of vascularization in vivo (150).
Due  to  their  mechanical  properties  and  inherent  tissue  compatibility,  solid  inorganic
scaffolds  such  as  ceramic,  bioglass  or  titanium  play  an  important  role  in  regenerative
medicine  (208).  Calcium  phosphate-based  systems  excel  due  to  their  compositional
similarities to the native bone ECM, and they have been extensively studied for GF delivery
(197). Most commonly used calcium phosphate materials include hydroxyapatite and TCP
scaffolds with different porosities, which have been used for BMP-2 delivery resulting in
positive effects  (160–162). The incorporation of GFs within TCP to treat bone defects has
resulted  in  different  commercially  available  products.  Therapeutic  goods  administration
(TGA, Australia) and Health Canada have approved the safety of utilization of tricalcium
phosphate  (TCP)  as  scaffold  to  deliver  PDGF  (AugmentTM Bone  Graft;  Biomimetyics,
Franklin, TN). Different clinical trials have concluded that PDGF-BB (209–213) and FGF-2
(214) loaded in β-TCP resulted in improved bone regeneration in periodontal osseous defects
(70). Clinical trials using β-TCP as scaffold to deliver GDF-5 for sinus lift augmentation in
2010  (163) and for periodontal  defects  in 2012  (215) also yielded positive results.  Other
31
calcium phosphates have also been studied for GF delivery. Mesoporous bioglass scaffolds
have been fabricated to load VEGF, and the addition of pores resulted in more than 90%
loading  efficacy  and  extended  release  profile  while  retaining  VEGF  bioactivity  (165).
Sumner et al employed a titanium scaffold to deliver TGF-β1 and BMP-2 in a dog humerus
model,  resulting in improved integration  (168). In another study, VEGF and antibacterial
peptides were bound to titanium scaffolds, resulting in increased cell attachment and reduced
bacterial growth (169).
Hydrogel scaffolds are one of the most successful and versatile GF delivery approaches, and
the major proof of that are the commercially  available products  (3). A collagen hydrogel
loaded with BMP-2 (INFUSE®-BMP-2; Medtronic, Minneapolis, MN) has been approved by
the FDA for treatment of lumbar fusion. Another similar design using type I collagen matrix
to encapsulate BMP-7 (OP-1TM Putty; Olympus Biotech Corporation, Hopkinton, MA) is also
approved for  fractures  of  long bones  and lumbar  fusion procedures.  Furthermore,  PDGF
impregnated  in  a  hydrogel  (REGRANEX®, BioMimetic)  has  been approved for  diabetic
ulcer  treatment.  However,  an  increased  rate  of  mortality  secondary  to  malignancy  was
detected  in  patients  treated  with high amounts  of  REGRANEX®  (13) and other  adverse
effects such as heterotopic ossification were reported in patients treated with INFUSE (270),
which clearly shows the need for optimized controlled delivery systems. Hydrogel scaffolds
can  be  classified  according  to  the  origin  of  their  polymeric  component,  which  can  be
synthetic or naturally-derived.
Synthetic hydrogels such as poly(vinyl alcohol) (PVA) and poly(ethylene glycol) (PEG) are
biologically inert, but have well-controlled and reproducible physical and chemical properties
and no risk of disease transmission. These characteristics are of special interest for clinical
translation and mass production. A good example of their application is the study by Tong et
al.,  where  PEG has  been  crosslinked  using  thiol-ene  chemistry  (216).  This  combination
enabled high control over the mesh size and the degradation time, where decreased mesh size
and increased  degradation  time  led  to  longer-term release  for  up to  60 days.  Naturally-
derived  hydrogels  have  higher  batch-to-batch  variation,  but  they  hold  the  potential  to
interact  with  cells  and  undergo  cell-mediated  degradation.  Most  widely  used  naturally-
derived hydrogels include fibrin, collagen, gelatin, chitosan, alginate and hyaluronic acid. As
an example, tyraminated hyaluronic acid crosslinked using horseradish peroxidase (HRP) has
been studied as an injectable system for protein delivery, showing increased release time by
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increasing  the  crosslinking  density  through  changes  in  HRP  concentration  (217).  Fibrin
sealants  have  been used  for  controlled  release  of  FGF-2 and VEGF-A, enhancing  blood
reperfusion after myocardium infarction and limb ischemia (154). 
Different  strategies  have  been  designed  to  obtain  the  benefits  of  synthetic  and  natural
polymers in the same scaffold. In a comprehensive study, gelatin or heparin were crosslinked
to PEG diacrylate (PEGDA) and the composites were used for incorporation of bFGF, TGFβ,
KGF, angiopoietin-1 (Ang1) and PDGF. In general, the heparin conjugated PEGDA had a
longer  GF release  profile,  which  was  different  for  each  GFs  due  to  differences  in  their
interaction with heparin  (155,156). In another study, the GF-binding domain of fibrin was
incorporated in a PEG hydrogel. Co-delivery of FGF-2 and PlGF-2 using these gels enhanced
skin wound healing  (106). On the other hand, modification of naturally-derived polymers
with  functional  groups  that  enable  controlled  crosslinking  is  also  a  generalized  strategy.
These modifications enable tailorability of the crosslinking density and mesh size, providing
higher  control  over  the  release  profile.  As  an  example,  gelatin  undergoes  gelation  at
temperatures under 35°C. This process is not adequate for applications requiring high control
over  the  network  characteristics.  Thus,  gelatin  functionalised  with  methacryloyl  groups
(GelMA)  has  been  used  for  different  applications  that  require  high  control  over  the
crosslinking density  (218), including the generation of scaffolds for BMP-2 encapsulation
(157,158). Increasing the degree of functionalization of GelMA results in decreased mesh
sizes, increasing the release time of GFs such as BMP-2 (219). 
Both hydrogels and solid scaffolds are the most successful platforms for GF delivery,  as
shown by the amount of commercially available  products and clinical  trials  performed to
date. The ability to spatially deliver GFs at the wound site by implantation of the scaffold, or
injection followed by in situ crosslinking, is the most important advantage of these platforms.
2.1.3.3.3. Combined Approaches in Growth Factor Delivery
The  combination  of  different  materials  and  platforms  allows  several  advantages  in  GF
delivery applications. Firstly, it enables coordinated delivery of GFs by incorporating them in
different  materials  or  through  different  methods  (10).  Secondly,  combining  different
materials that can be independently modified increases the tailorability of the release profile.
Furthermore,  these  materials  can  have  other  favourable  characteristics  for  the  targeted
therapeutic application, such as high stiffness for load-bearing tissues or bioactive properties.
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Multiple incorporation strategies can be used in the same material in order to deliver different
GFs  with  independent  release  profiles.  For  example,  encapsulation  of  PDGF  in  PLGA
microspheres, followed by surface adsorption of VEGF and generation of a scaffold by gas
foaming-particulate  leaching resulted in a burst  release of VEGF and a prolonged PDGF
release  (220). In a different study, BMP-2 was covalently grafted to the surface of MSNs
through  an  aminosaline  linker  while  dexamethasone  (DEX)  was  incorporated  in  the
nanopores, obtaining short-term DEX release profile and a longer-term BMP-2 release profile
(Figure 2.3A) (193). 
MPs or NPs can be incorporated into a tissue engineering scaffold (Figure 2.3B) to further
control the GF release profile.  TGF-β1 loaded gelatin particles have been immobilized in
oligo poly(ethylene glycol) fumarate (OPF) and resulted in a reduction of the burst release.
The  release  time  can  be  further  increased  by  increasing  the  molecular  weight  and  the
crosslinking time of the OPF hydrogel  (170). Encapsulation of NT-3 in PLGA MPs, and
inclusion  of  these  MPs  in  a  ciliary-neurotrophic  factor  (CNTF)  loaded  hybrid  hydrogel
resulted  in  a  rapid  CNTF  release  and  a  more  sustained  NT-3  release.  Increasing  the
crosslinking density of the hydrogel phase resulted in increased release time from weeks to
months  (172).  Gelatin  MPs  encapsulated  in  OPF  have  been  used  for  coordinated  and
tailorable delivery of TGF-β1 and IGF-1 with the aim of cartilage regeneration  (173,174).
Further examples include BMP-2-loaded PLA microspheres incorporated in VEGF-loaded
alginate hydrogels (175) and IGF-1 encapsulated in gelatin microspheres loaded into chitosan
scaffolds containing BMP-2 (176), both resulting in enhanced bone regeneration.
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A
B
Figure 2.3.  Combined approaches in growth factor delivery.  (A) Mesoporous silica
nanoparticles  incorporated  with  two  different  bioactive  components  through  different
incorporation  strategies.  Firstly,  MSNs  were  functionalised  with  an  amino  group  by
treatment  with  APTES.  BMP-2  was  covalently  linked  to  the  amino  groups  through
carbodiimide  chemistry,  and Dexamethasone was incorporated  into  the  MSN pores  by
surface  adsorption.  Reproduced  from  (193).  (B)  Incorporation  of  microparticles  and
nanoparticles into scaffolds. Materials with different release characteristics are used to
generate MPs or NPs, enabling high control over the release profile of one or more growth
factors. These particles can be incorporated into a matrix in order to generate a scaffold
or an injectable composite material. Adapted from (10).
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2.2. Generation of In Vitro Vascularised Tissues
2.2.1. Introduction and Main Strategies
The  generation  of  engineered  constructs  of  clinically  relevant  size  is  one  of  the  biggest
challenges in tissue engineering (221). One of the main tissue engineering strategies to avoid
the  formation  of  a  necrotic  core  within  the  construct  is  to  generate  a  vessel  network
throughout the scaffold that provides a steady supply of oxygen and nutrients, mimicking the
blood vessels present in native tissues and organs. Within tissues, the main blood vessels are
arterioles, venules and capillaries, which differ in their size and general structure. Arterioles
and venules range from 5 to 100 μm in diameter and include a tunica intima (endothelial cell
monolayer), a tunica media (smooth muscle layer) and a tunica adventitia composed mainly
of collagen. Capillaries are the smallest vessels, ranging between 5 and 10 μm in diameter,
and  are  formed  by  an  endothelial  cell  layer  surrounded  by  pericytes  (222).  Efforts  to
reproduce blood vessel networks within engineered tissues have followed two main routes:
top-down strategies,  which  involve  fabrication  of  pre-designed  structures;  and bottom-up
strategies,  which aim to stimulate  endothelial  cells  to form a micro-capillary  network by
providing a suitable microenvironment (Figure 2.4). 
2.2.2. Top-down Strategies 
Top-down  strategies  use  3D  fabrication  techniques  to  generate  a  pre-designed  channel
network. Different fabrication techniques such as 3D plotting of a sacrificial ink can be used
to generate an initial template, which is then embedded in the material of interest and washed
away to leave an empty channel network. Alternatively, the materials of interest can also be
directly fabricated with a designed channel network with techniques such as lithography. The
channel network then needs to be endothelialised by perfusing seeding endothelial cells that
attach  to  the  surface  of  the  channel  and cover  it,  mimicking  the  tunica  intima  of  blood
vessels. The material of interest can contain encapsulated cells that will receive nutrients and
oxygen from the media perfused through the channel network. 
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Figure 2.4. Main strategies for the fabrication of pre-vascularised tissue analogues.
Microvessels can be fabricated within tissue engineered constructs by top-down or bottom-
up methods. Top-down approaches involve the 3D fabrication of a pre-designed channel
structure through techniques such as 3D printing or spatial laser-degradation, which are
then embedded in the scaffold material, or the direct fabrication of scaffolds with a pre-
defined channel network layer-by-layer manufacturing techniques. The channels are then
seeded with endothelial cells to form microvessels. Bottom-up approaches use chemical of
physical stimuli to promote angiogenesis or vasculogenesis by encapsulated endothelial
cells. Reproduced from (221).
2.2.2.1. Fabrication Techniques and Biomaterials
One of the most important and limiting aspects of top-down approaches is the fabrication
technique. Firstly, the resolution of the fabrication techniques used to generate the channel
network determines the diameter of the channels. Secondly, the type of fabrication technique
also limits the range of materials that can be used in the process, as some techniques such as
3D plotting require specific material viscosities and rheological behaviours.
The  most  extended  technique  to  generate  these  channel  networks  is  3D  printing  of  a
sacrificial  mould,  which is  then embedded in the material  of interest  and washed away,
leaving an empty channel  network (Figure 2.4Ai).  The sacrificial  material  needs  to have
specific rheological properties in order to be 3D plotted, including high viscosity and shear
thinning  (223).  Printable,  biocompatible  materials  such  as  water-soluble  sugars  (224),
37
agarose  (225),  alginate  (226),  gelatin  (227),  Pluronic  F-127  (228) or  polyester-based
thermoplastics (229) have been used in this step. The main advantage of this technique is its
flexibility  and  accessibility,  as  it  only  requires  the  usage  of  a  3D  printer  in  a  sterile
environment. The resolution of the channels generated using this technique is reported to be
between 150 (224) and 1000 μm (229). Additionally, the material in which the channels are
generated does not have many specific requirements, except it has to undergo a crosslinking
process. A range of hydrogels that enable cell encapsulation such as alginate  (229), gelatin
(228) or fibrin (224,227) have been used in this type of approach. One of the best examples
of this techniques is the work done by Kolesky et al., where they aimed to generate large
tissues with a perfused channel network. They printed a structure based on Pluronic F-127
and  gelatin,  where  the  Pluronic  was  the  sacrificial  material  and  gelatin  contained
mesenchymal stem cells (MSCs). This structure was then embedded in gelatin, which was
crosslinked using a fibrinogen and thrombin system. The Pluronic was removed to generate
the  channel  network,  which  was  then  endothelialised  and  used  to  provide  media  to  the
encapsulated cells (228). The co-printing of two different materials with different roles in the
construct, followed by embedding on a third cell-free material, is a good demonstration of the
flexibility of this technique.
Laser degradation is another 3D fabrication technique that enables selectively degrading
certain  regions  of  a  bulk  material  to  generate  a  channel  network  (Figure  2.4Aii).  The
limitation of this technique is that the bulk material needs to be photodegradable, restricting
the  range  of  materials  that  can  be  applied  (230,231).  Poly(ethylene  glycol)  diacrylate
(PEGDA)  crosslinked  with  1-vinyl-2-pyrrolidone  (230)  or  cyclooctyne-terminated  PEG
crosslinked using an azide crosslinker  (231) have been previously applied to selective laser
degradation. Heintz et al. fabricated channels with a resolution as small as 3 μm using this
technique. However, the minimum channel diameter that could be endothelialised was 50 μm
due to the need to perfuse cells (230). The most interesting advantage of this technique is the
possibility  of  generating  complex  three-dimensional  designs  with  intertwined  channels,
which they used to reproduce the microvascular network of a mouse brain (230).
Alternatively, the material of interest can be directly 3D fabricated in a layer-by-layer fashion
with a pore network in it using  lithography  (Figure 2.4Aiii).  This technique has allowed
materials  such as  collagen  (232,233) or  poly-(octamethylene  maleate  (anhydride)  citrate)
(POMaC) (234) to be fabricated with a controlled channel network and encapsulated cells. In
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these  studies,  separate  layers  were  crosslinked  with  the  desired  shapes  using
poly(dimethylsiloxane) (PDMS) moulds, and the layers were then bonded together to create
the channel networks (232–234). This technology has shown resolutions of around 150 μm.
However,  it  seems difficult  to  scale  up to  the  generation  of  larger  constructs  due to  the
separate fabrication process and bonding of the layers.
2.2.2.2. Endothelialisation Process
The endothelialisation step is a necessary process in top-down approaches regardless of the
fabrication technique used to generate the channel network. It is done through the perfusion
of endothelial cells together with cell culture media into the fabricated channels. HUVECs
are generally used for the endothelialisation step because they are already differentiated into
cells from the tunica intima of larger vessels  (227–229,233,234), but embryonic stem cell-
derived endothelial cells have also been reported (232). Depending on the materials used for
fabrication of the constructs, the channels can be coated with ECM-derived molecules such as
gelatin  prior  to  the  perfusion  of  endothelial  cells  to  facilitate  cell  attachment  and  the
formation of a monolayer (234). 
It has been shown that the formation of this endothelial cell monolayer changes the diffusion
characteristics of the channels, making them more similar to native vessels  (228,234,235).
Most  importantly,  it  reduces  the  attachment  of  platelets  from circulating  blood,  reducing
blood  clotting  (232) an  therefore  making  endothelialisation  an  essential  step  towards
translation of these vascularised tissues.
2.2.2.3. Encapsulated Cells
The  fabrication  of  channels  within  the  constructs  aims  to  avoid  the  lack  of  oxygen and
nutrient  diffusion  towards  the  encapsulated  cells.  These  techniques  have  allowed  the
generation of different types of tissue analogues, each of them involving different types of
encapsulated  cells.  For  example,  Kolesky  et  al.  encapsulated  MSCs  into  their  gelatin
scaffolds  and demonstrated  that  the  fabrication  of  channels  allowed diffusion of  oxygen,
nutrients  and osteogenic signals,  resulting in improved differentiation of the encapsulated
MSCs into the osteogenic  lineage  as compared to samples  without  channels  (228).  Most
importantly, the fabricated tissues were larger than 1 cm in all dimensions, demonstrating the
advantages that these techniques offer towards translation into a clinical setting. Other cell
types such as fibroblasts  (224), human brain vascular pericytes  (233) and human umbilical
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arterial smooth muscle cells  (233) have also been encapsulated in the fabricated materials,
demonstrating the ability to migrate towards the endothelialised channels and interact with
the endothelial cells in a similar way to pericytes. Encapsulating cells that show this type of
behaviour could be useful to further stabilise the endothelial cell monolayer and mimic the
vessels in native tissues. A study done by Zhang et al. demonstrated the potential of this type
of vascularised setup to provide nutrient diffusion to different  cell  types. They fabricated
collagen  scaffolds  using  lithography  and encapsulated  either  rat  primary  hepatocytes  co-
cultured  with  fibroblasts  or  human  embryonic  stem cell  (hESC)-derived  hepatocytes  co-
cultured with MSCs to generate liver tissue analogues. These constructs showed the ability to
metabolise drugs  in vitro and also secreted urea, demonstrating adequate diffusion through
the channel system. The study continued by encapsulating hESC-derived cardiomyocytes and
MSCs  in  the  construct,  which  resulted  in  cell  alignment  and  synchronous  macroscopic
contractions  after  5  days  of  culture  (234).  These  studies  show  that  the  generation  of
adequately  vascularised  tissue  analogues  could  be  applied  to  a  large  variety  of  tissue
engineering applications, enabling the fabrication of larger tissue analogues that are needed
for clinical translation.
Presently,  the  most  important  limitation  of  top-down  approaches  is  their  inability  to
reproduce blood vessels below 50 μm in diameter. More systematic measurements of oxygen
and nutrient diffusion and their impact on encapsulated cells would be key to determine the
maximum separation that should be designed between channels. Furthermore, technologies to
evaluate the quality of the endothelialised channels would be really important for adequate
comparison and optimisation of cell types, fabrication techniques and biomaterials.
2.2.3. Bottom-up Strategies
Bottom-up approaches rely on the self-organisation of encapsulated cells to form a micro-
capillary network by reproducing the natural processes of angiogenesis and vasculogenesis
Figure 2.4B). 
Angiogenesis has been reproduced in vitro by generating endothelialised channels, which are
then stimulated using fluid shear stress or gradients of growth factors to promote endothelial
cell sprouting (236,237) (Figure 2.4Bi). While these techniques are really useful as a model
of the angiogenesis process, the difficulties in scalability make them hard to translate to the
generation of large, vascularised tissues. 
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Reproducing vasculogenesis has been achieved  in vitro by encapsulating endothelial  cells
(238) or  stem  cells  (239) together  with  support  cells  such  as  fibroblasts  (240) or
mesenchymal stem cells (241) (Figure 2.4Bii). The process generally starts with clustering of
the  endothelial  cells  and  formation  of  a  lumen,  followed  by sprouting  and formation  of
interconnected  luminal  structures  (242).  Support  cells  have  shown  to  surround  these
endothelial cell structures and stabilise them, resulting in improved vessel formation (240).
2.2.3.1. Endothelial Cells
The endothelial cells in the co-cultures are the cell type that forms network structures and
develops vacuoles that fuse into a vascular lumen (243). While endothelial cells are still able
to form these structures without the need of support cells  (244), support cells are generally
co-cultured with them to accelerate self-assembly and stabilize the resulting micro-capillary
network (236,238,245). 
The  most  widely  used  endothelial  cell  types  in  pre-vascularisation  studies  are  HUVECs
(227,241,242,246,247) as  they  are  easy  to  obtain  and  have  been  extensively  studied.
However, other cell types have also been studied that could potentially result in improved
vascularisation. One of the arguments against HUVECs is that they are differentiated into
endothelial  cells  from  the  tunica  intima  of  large  vessels,  potentially  making  them  less
adequate for the formation of micro-capillaries. For example, it has been shown that Human
adipose-derived microvascular endothelial cells (HAMECs) are able to develop more mature
micro-capillary networks as compared to HUVECs in a co-culture setting (241,248), which
was  hypothesized  to  be  due  to  the  fact  that  HAMECs  originate  from  microvessels.
Furthermore,  HAMECs  could  be  obtained  from each  specific  patient  in  case  of  clinical
translation, bypassing immune rejection. Other cell types that could be readily available from
the patient before treatment are stem cells such as endothelial colony forming cells (ECFCs),
which have also shown the ability to form micro-capillaries under co-culture conditions and
are  growing  in  popularity  (249–252).  Finally  iPSC-derived  endothelial  cells  have  also
demonstrated  the  ability  to  form  micro-capillaries  (239,253).  In  fact,  Wimmer  et  al.
demonstrated  the possibility  to  obtain both endothelial  cells  and pericytes  from the same
original  iPSC culture  after  a  multi-step  maturation  process  (239).  The  obtained  vascular
organoids, which had also developed a collagen IV basement membrane, were used to model
diabetic vasculopathy. The vessels showed responses that were similar to native vessels when
exposed  to  hyperglycaemia  and  a  range  of  pharmacological  treatments  (239).  While  the
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dedifferentiation  and  differentiation  processes  seemed  long  and  convoluted  for  clinical
translation, the resulting vessel models were very similar to native vessels in ways that had
not been demonstrated previously, which is a significant step forward to understand how to
reproduce the vascular complexity in tissues and organs.
2.2.3.2. Support Cells
The support cells in the co-cultures accelerate and stabilize the assembly of endothelial cells
into micro-capillary networks, acting as pericytes. The most commonly used support cells are
fibroblasts from different origins, including human lung fibroblasts  (227,249) and dermal
fibroblasts (241,242,246,248). In a similar way to HUVECs, these cells are easy to obtain and
have been widely studied, becoming the most commonly used cell type. However, fibroblasts
are  not  fulfilling  their  native  roles  in  these  co-cultures.  Other  cell  types  that  support
vasculature in native tissues such as human aortic smooth muscle cells have also been used as
support cells, resulting in micro-capillary formation (252). In fact, it has been reported that
adipose-derived  MSCs  (aMSCs)  could  be  a  better  support  cell  type  as  compared  to
fibroblasts, as shown by the formation of a higher quality micro-capillary network when co-
encapsulated  with  HAMECs  (241).  Both  bone  marrow-derived  MSCs  (bmMSCs)
(250,251,253) and  aMSCs  (241),  which  could  also  be  obtainable  from the  patient,  have
shown the ability to differentiate into α-smooth muscle actin (α-SMA) expressing cells and
support  the  micro-capillary  network.  This  potential  has  been exploited  to  try  to  generate
models  with  both  microvessels  and  bone  formation  by  exposing  the  cells  to  specific
differentiation  factors  (250).  Klotz  et  al.  co-encapsulated  EPCs and bmMSCs in  GelMA
hydrogels and exposed them to different types of culture media. It was found that exposure of
the co-cultures to a 1:1 ratio of osteogenic and vasculogenic media resulted in formation of
microvessels with support cells expressing α-SMA and the expression of osteogenic markers
by the encapsulated cells. These results suggest that part of the MSC population differentiated
to the bone lineage, while other MSCs differentiated to support the microvessel formation
(250). This research shows the potential of using the right stromal cells to generate specific
vascularised tissue types. As discussed in the previous section, it is also possible to obtain
both endothelial cells and support cells by differentiating iPSCs (239)
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2.2.3.3. Biomaterials
To promote the self-assembly of endothelial cells into micro-capillaries, hydrogels used for
cell encapsulation need to provide very specific conditions. A key condition for a material to
be  adaptable  to  pre-vascularisation  techniques  is  that  it  needs  to  be  mechanically  soft,
generally bellow 5 kPa of compression modulus  (250,251,254). In fact, it has been shown
that  small  changes  in  the  polymer  concentration  (wt%) have  a  significant  impact  on  the
quality of the developed micro-capillary network (244,255), highlighting how specific these
conditions need to be.
The most studied materials for this application are naturally-derived ECM molecules due to
their  soft  mechanical  properties  and  bioactive  sequences,  from  which  fibrin  stands  out
(227,241,242,246,248,253). Collagen  (249), Matrigel/collagen mixtures  (239) and Gelfoam
(248) have also been used to successfully generate micro-capillaries in vitro. However, these
soft mechanical properties have also been reproduced using chemically-modified naturally-
derived polymers such as photo-crosslinked GelMA  (250,251,253), which allows tailoring
the  hydrogel  mechanical  properties  by  changing  the  degree  of  functionalisation.  Finally,
synthetic  polymers  such as  PEG have also  shown the  ability  to  promote  micro-capillary
formation when combined with RGD sequences (252) or with gelatin and laminin (256). The
fact that a range of materials that have been successful to promote micro-capillary formation
suggests that the presence of bioactive cues in the material is necessary for cell migration and
self-assembly, but these cues do not need to be very specific. However, the soft mechanical
properties are a key variable for success in bottom-up vascularisation techniques.
One  of  the  present  limitations  of  bottom-up  strategies  is  that  the  scalability  of  pre-
vascularisation techniques to generate larger tissue analogues has not been demonstrated yet.
On the other hand, the need for the materials to be very soft for the formation of micro-
capillaries would make the generation of large constructs a challenge due to the lack of shape
fidelity of soft materials.
2.2.4. Anastomosis with the Host Vasculature
A very  important  feature  of  the  vessel  networks  formed  using  top-down and bottom-up
approaches is that they have the ability to anastomose with the host vessel network after
implantation (232,238).
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Due to the larger size of the channels in top-down fabricated constructs,  the anastomosis
process  can  require  a  surgical  procedure  to  directly  connect  the  host  vessels  with  the
construct channels  (234). However, it has also been shown to happen without surgical help
(232,257,258).  Zheng  et  al.  fabricated  150  μm  diameter  endothelialised  channels  in
endothelial  cell-laden collagen hydrogels  and implanted  them in infarcted  rat  hearts.  The
presence of the channels improved the overall vascularisation of the sample 5 weeks after
implantation,  as  shown by a  6-fold  greater  vascular  density  and a  2.5-fold  higher  blood
velocity in the sample  (232). The information on how to promote this natural anastomosis
process is presently very scarce. The only variable that has been repeatedly reported to have a
significant impact in the integration of top-down fabricated constructs is the orientation of the
fabricated  channels.  Improved  integration  when  fabricating  parallel  channels  has  been
reported in a model of hind limb ischaemia (257) and in liver tissue analogues (258,259) as
compared  other  orientations.  These  results  suggest  that  there  could  be  an  optimal
arrangement for the fabricated channels.
The  formation  of  a  host-vessel  anastomosis  in  bottom-up  pre-vascularised  tissues  was
reported for the first time by Levenberg et al in 2002 (260). Since then, a number of studies
have reported similar findings and tried to study the nature of this anastomosis and variables
affecting  it.  However,  the  information  obtained  to  date  is  still  very  limited.  Chen  et  al
suggested that a high density of fibroblasts, which were used as support cells, helps accelerate
the anastomosis process (261). Sekine et al. reported that the addition of bFGF during the in
vitro culture  helped  the  tissue  integrate  once  implanted,  although  it  was  not  possible  to
distinguish between the direct effects of the presence of the GF after implantation and the
indirect effects through an improved in vitro micro-capillary formation  (262). Ben-Shaul et
al. reported improved host-vessel anastomosis when the samples had been cultured  in vitro
during  two  weeks  versus  direct  implantation  of  co-cultures  without  in  vitro maturation,
remarking the importance of the pre-vascularisation process for optimal anastomosis (263).
Techniques that allow better tracking of the host-vessel anastomosis process are needed in
order to study the optimal conditions for quick tissue integration. Furthermore, studies on the
optimal channel diameter, density and orientation of the fabricated constructs in top-down
approaches would be valuable for the field.
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2.3. Combination of Growth Factor Delivery and Vascularised Tissue Engineering
In  the  past  decade, emerging  biofabrication  approaches  that  generate  complex  scaffolds
following  a  layer-by-layer  automated  deposition  technique  have  been  studied  for
vascularisation. This automated high resolution approach offers a superior level of control
over  the  spatial  distribution  of  the  materials  in  each  single  layer,  dictating  the  scaffold
architecture. Biofabrication techniques are classified in bioprinting and bioassembly  (264).
While the number of studies using biofabrication approaches has been growing, only a very
small  number  of  studies  combine  the  delivery  of  GFs  with  cell-based  approaches  for
vascularisation purposes.
Bioprinting refers  to  the  use  of  computer-aided  transfer  processes  for  patterning  and
assembly of living and non-living materials with a prescribed 2D or 3D organization (Figure
2.5) (264). A good example of the combination of cell and GF delivery using bioprinting is
the study done by Byambaa et al., where they bioprinted a scaffold with similar architectural
features as bone using bioinks consisting of GelMA with covalently conjugated VEGF. The
GelMA-VEGF  regions  of  the  scaffold  resulted  in  increased  proliferation  and  network
formation by endothelial cell  (183). In a different study, VEGF-loaded GelMA MPs were
fabricated  with different  crosslinking densities.  The MPs showed longer  GF release  time
when  increasing  the  crosslinking  density  of  GelMA.  The  MPs  were  bioprinted  in  a
Matrigel/alginate bioink with encapsulated endothelial cells, showing that a more sustained
VEGF release resulted in increased vessel formation. Further  in vivo  implantation showed
that  the  presence  of  VEGF-releasing  MPs  resulted  in  increased  vascularization  of  the
constructs (182),  demonstrating  the  potential  of  these  combined therapies.  However,  this
approach did not include an in vitro maturation step and did not co-encapsulate support cells
for pre-vascularisation of the construct.
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Figure 2.5. Bioprinting approaches. Materials with different release characteristics are
automatically  deposited  to  generate  scaffolds  with  high  spatial  control,  enabling  the
generation  of  internal  gradients  and  controllable  3D  architectures  for  improved
biomimicry. Adapted from (268).
Bioassembly is based on the automated deposition of previously fabricated cell-containing
building blocks, such as microspheres or microtissues, within 3D scaffolds (Figure 2.6) (269).
A significant advantage of bioassembly over bioprinting is that the materials do not need to
have the specific rheological properties required for 3D printing. While this technique offers
high  potential  in  terms  of  combining  different  materials  and controlling  the  scaffold  3D
architecture, it has not been applied yet to the delivery of growth factors in combination with
cells for tissue vascularisation purposes.
Figure 2.6. Bioassembly approaches. Building blocks made of materials containing cells
or  growth  factors  with  different  release  profiles  are  assembled  into  a  solid  scaffold,
enabling  the  generation  of  internal  gradients  and  controllable  3D  architectures  for
improved biomimicry. Adapted from (269).
These examples  showcase the potential  of biofabrication to generate  complex biomimetic
scaffolds  that  include  spatially-  and  temporally-controlled  GF  release  for  both  tissue
regeneration and in vitro modelling. Furthermore, the small amount of studies dedicated to
the combination of GF delivery and cell delivery for vascularisation highlights the need for
research in this area.
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2.4. Conclusions and Future Perspectives
2.4.1 Growth Factor Delivery
Although several GFs have been identified as signalling molecules that play important roles
in developmental and regenerative processes, the use of GFs as therapeutics agents have yet
made significant progress in the clinic. One major issue that still persist is the lack of suitable
GF delivery systems to achieve optimal therapeutic effect while avoiding side effects. It was
identified that the ideal GF delivery system should meet key design criteria such as being
able to deliver the GF to a localized site, at the right concentration and following adequate
temporal  patterns.  While  there are signs that  following the natural  expression patterns  of
certain growth factors during the regenerative process may result in improved regeneration,
more research is needed in order to establish the optimal  concentrations and rates of GF
needed for each specific TERM application
A number of commercially available products based on GF delivery have been released to the
market, achieving some clinical success. However, the observation of potential side effects
highlights  the need for development  of more advanced delivery systems.  The spatial  and
temporal control over the GF release profile from these delivery systems is highly desired.
Various biomaterials, incorporation methods and fabrication techniques have been developed
and  employed  for  GF  delivery.  Although  these  delivery  platforms  often  pose  desirable
characteristics,  they  also  show important  limitations.  Additionally,  they  are  usually  only
characterised to one specific GF. In the native regenerative microenvironment, several GFs
work concurrently with different expression levels and profiles to synergistically facilitate the
desired cellular behaviour. With our current understanding of this biological phenomena and
the limitations of the current GFs delivery vehicles, it is recommended that the field should
be moving forward with combinatorial approaches.
2.4.2. Generation of In Vitro Vascularised Tissues
Top-down and bottom-up approaches have been successful at reproducing specific levels of
vascularisation.  While  top-down  approaches  can  only  fabricate  larger  endothelialised
channels (>50μm), bottom-up approaches can only generate micro-capillary networks. Thus,
both strategies fail to closely reproduce the complex vasculature in native tissues and organs.
Research is needed to try to combine both strategies, which could prove successful if the right
materials are used.
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Another aspect that requires further research is the generation of larger tissues using top-
down or bottom-up approaches. While some studies using top-down approaches have focused
on this aspect, there are no studies that use bottom-up strategies that generate tissues with
more than 1mm thickness. However, generating large tissues will be essential  for clinical
translation.
Both bottom-up and top-down approaches have shown the ability to anastomose with the host
vessel network. However, the mechanisms of this process and the variables that affect it are
not  well  known. Studies are  required to optimise the fabrication conditions  for improved
integration of vascularised tissues. 
2.4.3. Combination of Growth Factor Delivery and Vascularised Tissue Engineering
There  is  a  very  limited  number  of  studies  that  combine  GF  delivery  with  cells  for
vascularisation purposes. In fact, there are no studies up to date that combine bottom-up pre-
vascularisation techniques with growth factor delivery. Therefore, there is a wide range of
possibilities that could be explored in terms of specific GFs, release profiles, cells to deliver,
and their 3D organisation within engineered scaffolds. Biofabrication techniques show great
potential to combine GF delivery and cell delivery, making them a potentially useful tool for
tissue vascularisation purposes.
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Chapter 3. Visible Light Mediated PVA-
Tyramine Hydrogels for Covalent
Incorporation and Controlled Release of
Functional Growth Factors
3.1. Introduction
Growth factors (GFs) play critical roles in the development, function and repair of native
tissues such a skin, bone and cartilage, which has made them attractive therapeutic agents for
regenerative medicine applications.  Specifically,  GFs such as vascular  endothelial  growth
factor  (VEGF),  basic  fibroblast  growth  factor  (bFGF)  and  brain-derived  growth  factor
(BDNF) have undergone pre-clinical and clinical trials for a range of applications including
treatment of diabetic foot ulcers (1), skin burns (2), bone fractures (3) and strokes (4). Direct
injection or application of GFs into the targeted area either  results  in limited therapeutic
effects or requires very high dosage, resulting in risk of side effects such as oncogenesis (5,6)
or local  edema  (7).  This is  due to their  short  half-life  in the physiological  environment,
which can last from minutes to a few hours  (2,8). Using biomaterials as delivery vehicles
widens  the  release  time  frame  and  protects  GFs  from  the  physiological  environment,
increasing  their  half-life  (9).  Several  biomaterials  have  been investigated  as  GF delivery
vehicles, from which collagen and calcium phosphate-based scaffolds have had some clinical
success due to their biocompatibility and inherent bioactivity  (10,11). Albeit some of these
products have reached the market, there is still a need to optimise GF delivery methods to
achieve improved bioactivity and reduce the risk of side effects caused by GFs.
Achieving  controlled  delivery  of  GFs  in  a  way  that  resembles  their  natural  expression
patterns has shown potential to further improve their effectiveness  (12–15). Achieving this
level  of  control  over  the  release  profile  has,  however,  proven to  be  a  complicated  task,
especially when targeting long-term release. This is due to the current unmet limitations in
methods to incorporate GFs into biomaterials. Adsorption and entrapment are simple methods
but result in burst release profiles and inefficient incorporation  (16,17). On the other hand,
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stable  covalent  incorporation  provides  a  more  tailorable,  longer  term release  profile,  but
generally  requires prior chemical modification of the GFs, reducing their  bioactivity with
unnecessary  complications  (18).  Other  methods  relying  on  bioaffinity  are  driven  by  the
ability of specific GFs to bind molecules such as heparin to achieve longer term release, but
depend on GF specificity to binding complexes  (19). Thus, the ideal incorporation method
should be simple to lower the production costs and facilitate  clinical  translation,  but still
result in controllable long-term release for the adaptation to different regenerative therapies
without relying on highly specific interactions that limit their applicability.
With inspiration drawn from naturally-occurring di-tyrosine cross-links, different hydrogel
systems have  been developed  and used  for  tissue  engineering  and regenerative  medicine
applications  (20).  Tyraminated  hyaluronic  acid  (HA-Tyr)  cross-linked  with  horseradish
peroxidase (HRP) has been applied for rheumatoid arthritis (21) and bone regeneration (22).
Tyraminated dextran (Dex-Tyr), also cross-linked using HRP, has been studied for cartilage
regeneration  (23). A distinct characteristic of these formulations is their ability to form bi-
phenol  cross-links  with  native  tyrosine  groups  present  in  proteins,  resulting  in  enhanced
tissue adhesion (24,25). Lim et al. have previously shown that tyraminated poly-vinyl-alcohol
(PVA-Tyr) is able to covalently incorporate native gelatin and sericin during the cross-linking
process, improving cell survival, attachment and proliferation of encapsulated cells  (26,27).
The presence of ester bonds in PVA-Tyr results in a hydrolytically degradable hydrogel (28),
and a visible light initiating reaction consisting of Ruthenium (Ru) and sodium persulfate
(SPS)  enables  the  formation  of  bi-phenol  cross-links  in  a  rapid  and controllable  manner
(28,29).  It  is  therefore  hypothesised  that  this  PVA-Tyr  system  could  enable  covalent
incorporation of GFs through their native tyrosine moieties without the need of additional
chemical  modification.  GFs  will  then  be  released  through  hydrolytic  degradation  of  the
hydrogel  network  following  a  tailorable  degradation  profile.  The  combination  of  these
characteristics  result  in  a  delivery  system  that  facilitates  a  simple  and  rapid  covalent
incorporation of GFs without the need of prior chemical modification into a hydrogel system,
where the subsequent release profile can be tailored depending on the degradation profile of
the base hydrogel network. 
In  the  present  study,  the  potential  of  the  PVA-Tyr  system as  a  GF delivery  platform is
systematically  evaluated.  Mass  loss  studies  are  used to  explore  the  range of  degradation
profiles that can be obtained by changing the cross-linking conditions of PVA-Tyr. A range
of  GFs  are  then  incorporated  within  PVA-Tyr  hydrogels  and  study  their  release  profile.
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Finally, in vitro studies are used to determine the functionality of released growth factors on
endothelial cells and mesenchymal stem cells.
3.2. Materials and Methods
3.2.1. Materials
PVA  (13–23  kDa,  98%  hydrolyzed),  Dimethyl  sulfoxide,  succinic  anhydride  (SA),
triethylamine (TEA), 1,3-Dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS),
Tyramine,  sodium  persulphate  (SPS),  1,1-carbonyldiimidazole,  tris(2,2-
bipyridyl)dichlororuthenium(II) hexahydrate (Ru), molecular sieves (4 A °) and Phosphate
buffered saline (PBS),  dialysis  tubing (10 kDa molecular  weight  cutoff),  were purchased
from Sigma-Aldrich and used as received.  BSA-Texas Red conjugate was purchased from
Invitrogen. rhVEGF-165 was purchased from Gibco (PHC9394). bFGF and was purchased
from  R&D  Systems  (P09038).  BDNF  was  purchased  from  Peprotech  (540-02).  Human
umbilical  vein  endothelial  cells  (HUVEC),  vascular  cell  basal  medium,  endothelial  cell
growth kit-VEGF, trypsin for primary cells and trypsin neutralizing solution were purchased
from ATCC. Human bone marrow-derived mesenchymal stem cells (MSCs) were purchased
from  RoosterBio.  Alpha-MEM,  Fetal  bovine  serum  (FBS),  Trypsin  and
Penicillin/streptomycin were purchased from Gibco.
3.2.2. Methods
3.2.2.1. Synthesis of PVA-Tyr
PVA-Tyr  was  synthesised  according  to  a  two-step  reaction  previously  published  (26).
Briefly,  carboxyl  groups were conjugated onto the PVA backbone using SA and TEA in
DMSO. To modify the degree of carboxylation, the reaction was performed at different ratios
of SA to PVA (Figure 3.2A) while maintaining the ratio of TEA to SA at 0.73 mL/g. Tyr
moieties were then conjugated to the carboxylated PVA (PVA-COOH) using a carbodiimide-
coupling reaction. DCC, NHS and Tyramine were added to the reaction at three times the
molar  concentration  of  the  targeted  carboxyl  groups  from PVA-COOH.  The  by-product
(dicyclohexylurea)  formed during the  reaction  was removed using vacuum filtration.  The
resulting PVA-Tyr solution was further purified by dialysis against water and freeze-dried.
The resulting amounts of carboxyl groups in PVA-COOH and tyramine groups in PVA-Tyr
were quantified using 1H NMR.
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3.2.2.2. Hydrogel Fabrication
Dried PVA-Tyr was dissolved in PBS at 80 °C. Upon complete  dissolution,  the polymer
solution was cooled to room temperature (RT) and mixed with Ru and SPS stock solutions to
a final concentration of 5 to 20 PVA-Tyr wt% and 0.5/5 to 2/20 mM Ru/SPS. BSA or growth
factor solutions were mixed with the PVA-Tyr solution prior to the addition of Ru and SPS.
BSA hydrogels were obtained by mixing a 10 wt% BSA solution with Ru and SPS stock
solutions to a final concentration of 2/20 mM Ru/SPS. All samples were photo-cross-linked
using visible light (OmniCure® S1500, Excelitas Technologies with a Rosco IR/UV filter
400 – 450nm, 3min, 30 mW cm-2) in cylindrical moulds (h = 1 mm, Ø = 6 mm) in an open
environment. 
3.2.2.3. Swelling and Mass Loss Assays
After  cross-linking,  each  hydrogel  (35  μL)  was  weighed  (minitial,t0 ),  out  of  which  three
samples  per  hydrogel  composition  were  directly  freeze-dried  to  record  their  initial  dry
weights (mdry,t0) and determine the actual macromer weight fraction, which is reported as the
ratio of the initial dry weight to the initial weight. To determine the initial dry weight of the
remaining samples, the factor of the actual macromer fraction and individual initial weight
was used (Eq. 1).
Actualmacromerfraction=
mdry , t 0
minitial
(1)
The remaining samples were allowed to swell in PBS at 37 °C until up to 1d or longer time
points to determine the mass loss. Swollen hydrogel samples were collected to record wet
weight (mswollen), then freeze-dried to obtain the freeze dried weight (mdry) to calculate the
mass loss and mass swelling ratio (q) according to equations 2, 3 and 4:
mdry , t0=minitial xactualmacromerfraction (2)
Massloss=
mdry , t0−mdry
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The sol fraction of the hydrogels is defined as percent macromers that are not cross-
linked into the hydrogel network, and determined as the mass loss after equilibrium swelling
(t = 1 d).
3.2.2.4. Proteinase K Degradation Assays
PVA-Tyr hydrogels (35 µL) with or without incorporated BSA were left in a 1 mL solution
of either PBS or Proteinase K 1 mg/mL in PBS as previously described (30), then incubated
at 37 °C. The PBS or Proteinase K solutions were discarded every 48h and fresh solution was
added for continuous exposure to functional  enzyme.  Mass loss and swelling ratios  were
calculated using equations 1-4. Pure BSA hydrogel controls were generated by cross-linking
a 10wt% BSA solution in PBS with 2/20 mM Ru/SPS.
3.2.2.5. Protein and Growth Factor Retention and Release Assays
rhVEGF-165,  bFGF  and  BDNF  were  labelled  using  Alexa  Fluor  594  carboxylic  acid,
succinimidyl  ester  (ThermoFisher)  (31,32) following  the  manufacturer’s  instructions.
Unreacted dye was separated using 3 kDa MWCO centrifuge filter units. During hydrogel
fabrication,  labelled growth factors were mixed with the macromer solution before cross-
linking. Fabricated hydrogels (25 μL) were incubated in 1 mL of basal endothelial cell media
supplemented with 1% P/S.  All the media was collected at selected time points and fresh
media was added, until total hydrogel degradation. Fluorescence in the media was measured
by fluorescence  spectroscopy  (Thermo Scientific  Varioskan  Flash,  Darmstadt,  Germany).
Release  media  from  plain  PVA-Tyr  hydrogels  was  used  as  a  control  for  background
fluorescence subtraction. Release was calculated relative to the total fluorescence detected
during the degradation process. Retention was calculated as the % of growth factor left in the
hydrogel after 24h of incubation.
Table  3.1. GF  concentrations  used  for  functionality  experiments.  Concentrations  are




10, 20, 50, 250, 500 10, 20, 50, 250 50, 250, 500, 1000





3.2.2.6. Hydrogel Preparation for Bioactivity Assays
Different amounts of unlabelled rhVEGF 165, bFGF or BDNF (Table 3.1) were incorporated
in the PVA-Tyr macromere solution (5wt% PVA-7Tyr cross-linked using 0.5/5mM Ru/SPS)
before the addition of Ru/SPS and photocrosslinking following the procedure described in
section  3.2.2.2.  For  the  cell  migration  assay,  the  fabricated  GFs  incorporated  PVA-Tyr
hydrogels were incubated in assay media, where the supernatant after 1 day was collected
(initial release), and the supernatant was again collected when the samples are completely
degraded (degradation products) (Figure 1A). For the cell proliferation assay, similarly, the
GFs incorporated PVA-Tyr hydrogels were firstly incubated in assay media. The supernatant
after 1 day (initial release) was collected, followed by the samples transferred to a transwell
culture (Figure 1B). For the tube-formation assay, all samples were transferred directly to a
transwell culture after fabrication (Figure 1C). For HUVECs, the assay media composed of
vascular  endothelial  cell  basal  media  supplemented  with  1%  P/S,  2%  FBS,  50  μg/mL
ascorbic acid, 1 μg/mL hydrocortisone hemisuccinate, 0.75 units/mL heparin sulfate and 10
mM L-glutamine. For MSCs, the assay media composed of α-MEM supplemented with 2%
FBS, 20 mM ascorbic acid and 1% PS for MSC assays. 
Figure  3.1. Schematic  of  the  experimental  workflow  in  sample  preparation  for  the
migration, proliferation and tube-formation assays.
3.2.2.7. Metabolic Activity Assays
Passage 3 to 4 HUVECs or MSCs were cultured in growth media (Endothelial Basal Media
supplemented  with  ATCC  endothelial  Cell  Growth  Kit-VEGF  for  HUVEC,  or  α-MEM
supplemented with 10% FBS, Ascorbic acid 20 mM, bFGF 5 ng/mL and 1% P/S for MSC),
trypsinised, seeded in 96 well plates at a density of  500 cells/mm2 and starved for 24h in
assay media. After that, the assay media was discarded and cells were exposed during 48h to
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assay  media  with  soluble  GF  or  initial  release  from  PVA-Tyr  hydrogels  (250  μL).
Alternatively,  for  exposure  to  the degradation  products,  fresh assay media  (250 μL)  was
added to the cells  and they were exposed to  PVA-Tyr hydrogels  (from which the initial
release had been separated) through an 8 μm pore size transwell for 48h. After exposure,
AlamarBlue® was used to measure the metabolic activity of cells. Briefly, each sample was
incubated  for  5h  with  350 μL  media  containing  10% of  AlamarBlue®  solution,  diluted
according to manufacturer’s instructions. The reduction of AlamarBlue® in the solution was
determined  by  reading  absorbance  at  wavelengths  of  570  nm  and  600  nm  using  a
spectrophotometer (Thermo Scientific Varioskan Flash, Darmstadt,  Germany) followed by
data processing according to manufacturer’s instructions.
3.2.2.8. Migration Assays
Passage 3 to 4 HUVECs or MSCs were trypsinised, seeded in a 48 well-plate at a density of
1.500 cells/mm2. Cells were then starved overnight in assay media, and linear scratches were
generated using a 1mL pipette tip. Cells were then washed with PBS to discard any floating
cells or cell debris and pictures of the wound area (t0) were taken. Cells were then exposed to
250 μL of either assay media with soluble GF,  initial release or full degradation products
from PVA-Tyr or PVA-Tyr-GF hydrogels for either 8h (HUVECs) or 24h (MSCs). Pictures






3.2.2.9. 3D Endothelial Cell-Pericyte Coculture Assays
Passage 2 HUVECs and passage 3 MSCs were incubated in growth media, trypsinised and
resuspended  in  Cultrex  Stem  Cell  Qualified  RGF  Basement  Membrane  Extract  (R&D
Systems 3434-001-02) at a concentration of 5 million HUVEC and 1 million MSCs per 1 mL.
Gels were left to physically cross-link for 45 min at 37°C and 5% CO2. After that, gels were
exposed to 250 μL of growth media (positive control), assay media with soluble GF, or assay
media and PVA-Tyr hydrogels through a transwell. Media was fully changed on days 1, 3
and 5. For immunofluorescence examination, samples were collected on day 7, washed in
PBS and fixed in 4% formaldehyde for 45 minutes at RT. Samples were then blocked with
2% BSA for 1h at RT and permeabilised using a 0.2% Triton-X solution. Samples were then
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washed in PBS, and blocking buffer including mouse anti-CD-31 primary antibody at 1:100
dilution  was added for  an O/N incubation  at  4°C .  Samples  were washed three times  in
blocking buffer for 30 min each and followed by an incubation with Goat-anti-mouse (Alexa
fluor 488) secondary antibody diluted in blocking buffer (1:500) for 30 min at 37°C. Samples
were then washed 3 times in PBS during 30 min, incubated in a DAPI (1:1000) solution for 2
min and washed three times in PBS. Image stacks (100 μm thickness) were captured in 3
different areas of each sample using a Zeiss Axioimager Z1 fluorescence microscope (Carl
Zeiss Microscopy, Jena, Germany) and their  maximum intensity projection was extracted.
Total vessel length and junctions density were quantified using AngioTool software. 
3.2.2.10.Statistical Analysis
Data are presented as mean ± standard deviation. All samples were prepared in triplicates and
each  experiment  was  repeated  3  times  to  study  variability  between  experiments  (N=3).
Individual differences between groups and time points were assessed using one or two-way
ANOVA and Holm-Sidak post hoc analysis (GraphPad Prism 7). Statistical significance was
accepted at p<0.05. 
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3.3. Results and Discussion
3.3.1. Tailoring the Degradation Profile of PVA-Tyr Hydrogels
Different tissue engineering applications require specific GF release profiles. When using a
biomaterial vehicle, tailoring the release profile to specific time frames is a major challenge,
especially  for  long  term release  of  over  4  weeks.  The  initial  goal  of  this  study  was  to
demonstrate the possibility of tailoring the degradation profile of PVA-Tyr hydrogels so that
they  can  be  adaptable  to  a  range  of  applications.  Therefore,  the  effects  of  three  main
parameters on the physico-chemical properties and degradation profile of PVA-Tyr hydrogels
were  studied:  the  degree  of  tyramination,  the  macromer  concentration,  and  the  photo-
initiators (Ru/SPS) concentrations.
Figure 3.2. Synthesis of PVA-Tyr of different degrees of tyramination. (A) Ratios of SA to
hydroxyl  groups  (mol/mol)  used  during  carboxylation  of  PVA  and  quantified  degrees  of
carboxylation and tyramination of PVA.  1H NMR profiles of (B) PVA-COOH of different degrees
of  carboxylation  and  (C)  PVA-Tyr  of  different  degrees  of  tyramination.  All  experiments  were
repeated three times with three technical replicates each (N=3).
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PVA-Tyr  was  successfully  synthesised  as  previously  published  (26,33).  Firstly,  carboxyl
groups are grafted on to the hydroxyl groups of PVA, forming PVA-COOH (Figure 3.2A-B).
These carboxyl groups are subsequently substituted by tyramine groups, forming PVA-Tyr
(Figure 3.2A and 3.2C). By adjusting the SA:OH ratio during the carboxylation reaction and
then fully substituting these carboxyl groups with tyramine groups, it was possible to obtain
PVA-Tyr of average 4, 7 and 10 tyramine groups per PVA chain as confirmed by H1 NMR
(Figure 3.2A). It was hypothesised that, by varying the degree of tyramination, it is possible
to construct a library of PVA-Tyr hydrogels of different  physico-chemical  properties and
degradation rates. 
Sol fraction analysis showed that at low Ru/SPS concentration (0.5mM/5mM), higher degree
of tyramination supported higher crosslinking efficiency, where 5wt% PVA-4Tyr hydrogels
showed significantly higher sol fraction values when compared to both 5wt% PVA-7Tyr and
PVA-10Tyr gels (Figure 3.3A, Supplementary Tables 3.1-3).  This result was expected as an
increased  availability  of  tyramine  groups  would  result  in  more  efficient  cross-linking.
However,  this  phenomena  was  not  observed  when  higher  Ru/SPS  concentrations
(2mm/20mM) were utilised. Regardless, all the 5wt% PVA-Tyr hydrogels of different degree
of tyramination and Ru/SPS concentrations yielded good crosslinking efficiency evidenced
by relatively low sol fraction values (20-30%). The mass swelling ratios follow the same
trend of the sol fraction analysis, where formulations of higher sol fraction values also have
higher  mass  swelling  ratios  (Figure 3.3B,  Supplementary  Tables  S3.4-6).  This  trend was
expected, as hydrogels that retain a smaller amount of macromer after cross-linking have a
less dense network that can imbibe more water.   
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Figure 3.3. Tailoring the degradation profile of PVA-Tyr hydrogels. (A) Sol fraction and
(B) swelling ratio of hydrogels fabricated using PVA-Tyr of different degrees of tyramination and
Ru/SPS concentrations. (C) Mass loss profile and (D) Degradation time of PVA-Tyr 5wt% with
different degrees of Tyramination, cross-linked at either 0.5/5 or 2/20 mM Ru/SPS. (E) Mass loss
profile of PVA-Tyr (7Tyr, 5wt% PVA-Tyr, 0.5/5 mM Ru/SPS) and BSA (10wt%, 2/20 mM Ru/SPS)
exposed to either PBS or proteinase K (Prot K). *: Significant difference between groups (p<0.05).
#: Significant difference as compared to all other groups (p<0.05). All experiments were repeated
three times with three technical replicates each (N=3).
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The long term degradation profile of the fabricated PVA-Tyr hydrogels was further evaluated
(Figure  3.3C).  The  degradation  period  of  the  hydrogels  increased  with  the  degree  of
tyramination, where PVA-10Tyr gels take longer to degrade, followed by PVA-7Tyr then
PVA-4Tyr when cross-linked using the same Ru/SPS concentrations. A potential explanation
for  these  differences  is  that  the  increased  availability  of  tyramine  groups  resulted  in  the
formation  of  more  crosslinks,  delaying  the  degradation  of  the  network.  Our  result  is  in
agreement with previous research on tyraminated dextran (34), which showed that increasing
the degree of substitution from 5% to 10% to 15% resulted in increased crosslinking density
indicated by increase in storage modulus under the same cross-linking conditions. Similarly,
research on HA-Tyr  showed that increasing the degree of tyramination from 6 to 12.5 mol%
results  in  increased  cross-linking  density  from 3  to  5.8  mol%  (21).  Another  factor  that
possibly influenced the degradation time is the increase in hydrophobicity of the network
caused by the increased presence of tyramine moieties. 
To demonstrate  that  the physico-chemical  properties  and degradation  profile  of PVA-Tyr
hydrogels  can  be  finely  tailored,  a  library  of  degradation  profiles  was  generated  by
systematically  varying  the  photo-initiators  concentrations,  degree  of  tyramination  and
macromer  concentration  (Supplementary  Figures  S3.1-4).  Increasing  photo-initiator
concentrations  significantly  prolonged  the  total  time  required  to  achieve  complete
degradation regardless of the degree of tyramination or the macromer concentration (Figure
3.3C, Supplementary Figures S3.1-2). These results are in agreement with previous research
on degradation of PVA-Tyr hydrogels (28). Increasing the macromer concentration generally
resulted  in  shorter  degradation  times  (Supplementary  Figures S3.3-4).  This  tendency was
attributed to a reduction in the ratio of free radicals to tyramine groups, resulting in a less
efficient cross-linking. 
Another key aspect for the clinical translation of this PVA-Tyr system would be to model and
understand its potential degradation profile  in vivo.  Exposure to physiological environment
generally results in an in vitro and in vivo mismatch of degradation behaviour of biomaterials,
generally caused by the uncontrolled presence of proteases and other components that can
influence  the  swelling  behaviour  of  the  material  (35).  Theoretically,  PVA-Tyr  hydrogels
degrade exclusively through hydrolysis of the ester bonds part of the crosslinked network,
and hence should not be influenced by enzymatic degradation. As such, PVA-Tyr hydrogels
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(5wt%, 0.5/5 mM Ru/SPS) were exposed to proteinase K, a broad-spectrum protease known
to  non-specifically  degrade  a  number  of  proteins  that  has  been  widely  applied  for
investigation of enzymatic  degradation (Figure 3.3E)  (36).  It  was observed that  PVA-Tyr
hydrogels in either PBS or proteinase K had identical degradation profile, confirming that this
synthetic  hydrogel  network is  not  susceptible  to  enzymatic  degradation.  In  contrast,  pure
10wt%  BSA  hydrogels  cross-linked  using  2/20  mM  Ru/SPS  were  fully  degraded  after
overnight exposure in proteinase K due to the enzymatic proteolysis.
Overall, these results demonstrate that the degradation profiles of PVA-Tyr hydrogels can be
tailored  from  7  (short-term)  to  95  days  (long-term),  just  by  changing  the  degree  of
tyramination,  photo-initiator  and macromer concentrations,  where the primary degradation
mechanism is through hydrolysis. Furthermore, our library of degradation profiles shows that
the exact degradation time that is needed for any application can be achieved by tuning these
cross-linking  parameters  (Supplementary  Figure  S3.1-4).  These  results  highlight  that  the
PVA-Tyr platform could be adapted to tissue engineering applications that require short term
or long term release, such as tissue vascularisation or bone and cartilage regeneration.
3.3.2. Tailoring the Incorporation and Release of Proteins in PVA-Tyr Hydrogels
PVA-Tyr  has  pendant  tyramine  moieties  that  can  form  covalent  bi-phenol  bonds  with
naturally  occurring  tyrosine  groups  of  proteins  when  using  the  photo-initiating  system
employed in this study. It was sought to evaluate the efficiency of protein incorporation into
PVA-Tyr hydrogels using BSA as a model protein. PVA-Tyr hydrogels with incorporated
BSA  fabricated  under  different  cross-linking  conditions  were  subjected  to  a  mass  loss,
swelling and release study. Our initial results indicated that the BSA incorporated into 5wt%
PVA-7Tyr hydrogels crosslinked using 0.5/5 mM Ru/SPS had low retention (<20%, Figure
3.4A). Increasing the degree of tyramination did not affect the BSA retention, where both 5wt
% PVA-7Tyr and PVA-10Tyr hydrogels crosslinked at the same Ru/SPS concentration had
equally  low  BSA  retention.  However,  it  was  observed  that  increasing  the  Ru/SPS
concentration significantly enhanced the retention of BSA within the hydrogel to 50% and
80%  in  5wt%  PVA-7Tyr  crosslinked  using  1/10  and  2/20  mM  Ru/SPS,  respectively.
Interestingly, when using a similar Ru/SPS concentration (2/20 mM Ru/SPS), it was observed
that  the  BSA  retention  was  significantly  lower  in  hydrogels  of  higher  macromer
concentration, where 20wt% PVA-Tyr hydrogel resulted in 65% BSA retention as compared
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to 5wt% PVA-Tyr gels (80% retention). These results were attributed to the higher cross-
linking efficiency caused by the higher ratio of free radical to tyrosine group in hydrogels
with  lower  macromer  concentration,  which  also  results  in  longer  degradation  times
(Supplementary  Figure S3.1-2).  Interestingly,  the  differences  between groups in  terms of
BSA retention were more marked than the differences in sol fraction, which was 10-20% in
all groups, or swelling ratio, which did not show significant changes when increasing the Ru/
SPS concentrations from 1/10 to 2/20 mM (Supplementary Figures S3.5A-B). These results
demonstrate  that  modifying  the  cross-linking  conditions  allows  us  to  control  the
incorporation efficiency of proteins into our PVA-Tyr hydrogels.
Incorporating covalently bound proteins in the polymer network could potentially alter the
rate  of  hydrolytic  degradation  of  the  hydrogels  or  make  them  sensitive  to  proteolytic
degradation, modifying their degradation and release profiles in an unwanted manner. These
hypotheses  were  tested  by  exposing  PVA-Tyr  hydrogels  (5wt%,  0.5/5  mM  Ru/SPS)
incorporated with BSA 10 ng/mL to PBS or Proteinase K. In PBS, it was found that the
addition of 0.05 mg/mL BSA did not change the degradation time of the hydrogels. However,
increasing the BSA concentration to 10 mg/mL resulted in increased degradation time from 8
to 12 days (Supplementary Figure S3.6A-B). At this concentration, it is possible that the large
size  and increased  presence  of  BSA results  in  molecular  entanglements  that  cause  steric
hindrance to the hydrolysis of the ester bonds. Exposure to proteinase K did not result in
significant  differences in the mass loss or swelling profile of PVA-Tyr with incorporated
BSA (Figure 3.4B and Supplementary Figure S3.6C), whereas plain 10wt% BSA hydrogels
were fully degraded after overnight exposure. In addition, the release profile of fluorescently-
labelled BSA (0.05mg/ml) from the hydrogels was measured, showing that the release profile
was not significantly affected when incubated in proteinase K (Supplementary Figure S3.6D).
These results suggest that the PVA-Tyr network can protect the incorporated proteins from
the action of proteases, which is very important not only to maintain the degradation and
release processes driven exclusively by hydrolysis, but also to protect incorporated GFs from
degradation in the physiological environment. 
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Figure 3.4. Controllable incorporation and release of BSA from PVA-Tyr hydrogels.
(A) Effects of proteinase K exposure on the mass loss profile of PVA-Tyr with incorporated
BSA hydrogels. (B)  BSA retention  and  (C)  BSA  release  profile  of  PVA-Tyr  hydrogels
generated with different degrees of tyramination, macromer and Ru/SPS concentrations. *:
Significant  difference  between  groups  (p<0.05).  #:  Significant  difference  to  all  other
groups (p<0.05). N/S: no significant differences between groups (p>0.05).  Experiments
were repeated 3 times with 3 technical repeats each (N=3).
Long-term BSA release measurements revealed that the release time matched the hydrogel
degradation  time for  all  cross-linking  conditions  (Figure  3.4C and Supplementary  Figure
S3.7A-B).  These  results  demonstrate  that  the  timespan  of  the  release  profile  by  can  be
tailored modifying the formulation and cross-linking conditions of our PVA-Tyr hydrogels.
Furthermore, after the initial 24h of release of non-incorporated proteins, all release profiles
displayed linear tendencies up until total degradation of the hydrogel (Supplementary Figure
S3.8), with a minimum R2 of 0.936 in 20wt% PVA-Tyr hydrogels (crosslinked with 2/20 mM
Ru/SPS) to a maximum of 0.986 in 5wt% PVA-Tyr hydrogels (crosslinked with 0.5/5 mM
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Ru/SPS) (Supplementary Table S3.7). This indicates that the released protein concentration is
consistent during the degradation process, which would result in constant promotion of the
desired changes in cell behaviour.
3.3.3. Covalent Incorporation and Release of  Different Growth Factors in PVA-Tyr
Hydrogels
 After studying the general incorporation and release dynamics of the system using BSA as a
model protein, this system was further evaluated using clinically relevant GFs, specifically
VEGF, bFGF and BDNF. Properties like the isoelectric point  (37), the hydrodynamic size
(38) or the presence of certain amino acid sequences  (39) in GFs heavily influence their
release  profile  when  they  are  directly  adsorbed  or  incorporated  into  biomaterials.  Using
covalent incorporation,  the major factors determining the release are the efficiency of the
covalent incorporation and the rate of hydrolytic degradation of the PVA-GF bonds, and thus
different  GFs  would  be  released  at  the  same rates.  It  was  hypothesized  that  the  release
profiles of different GFs could then potentially be determined by the presence and availability
of tyrosine groups in the GFs, which would dictate the amount of bi-phenol bonds formed
between GFs and PVA-Tyr during the cross-linking process.
Figure 3.5. Incorporation and release of growth factors in PVA-Tyr hydrogels. (A)
Growth factor  retention and (B) release profile  from PVA-7Tyr 5wt% hydrogels cross-
linked  at  a  range  of  Ru/SPS  concentrations.*:  significant  difference  between  groups
(p<0.05). Experiments were repeated 3 times with 3 technical repeats each (N=3).
Initial mass loss and swelling studies showed that the incorporation of different GFs (VEGF,
bFGF or BDNF) at a range of different concentrations did not result in changes in the sol
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fraction values or swelling ratio of the resultant hydrogels (Supplementary Figures S3.9-10).
The retention of GFs on day 1 was then studied (Figure 3.5A). When incorporated in PVA-
Tyr crosslinked with 0.5/5 mM Ru/SPS, the retention values were between 25% and 35% for
those three GFs. A potential explanation for the lower retention of GFs as compared to the
cross-linking efficiency of PVA-Tyr is an overall lower availability of tyrosine groups per GF
molecule. For example, PVA-7Tyr macromers contain an average of 7 tyramines per polymer
chain  with a  linear  conformation,  which results  in  the tyramines  being accessible  for bi-
phenol  bond  formation.  On  the  other  hand,  the  availability  of  tyrosine  moieties  in  the
incorporated GFs depends on their different structural conformation, which results in only a
fraction of the tyrosine groups being available  to participate  in the cross-linking reaction
(Supplementary Table S3.8)  (40–43). This lower availability results in decreased formation
of bi-phenol bonds between PVA-Tyr and GFs, resulting in lower retention. In a similar way
to BSA, increasing the Ru/SPS concentration improved GF retention, reaching 75-85% for
samples crosslinked using 2/20 mM Ru/SPS with no significant differences between GFs.
Interestingly,  VEGF  showed  small  but  significant  differences  in  the  retention  rate  as
compared to BDNF when incorporated using 0.5/5 and 1/10 mM Ru/SPS, demonstrating the
possibility of GF-dependent incorporation efficiency. As both VEGF and BDNF have similar
number  of  tyrosine  residues  in  their  sequence  (Supplementary  Table  S3.8),  this  result
suggests  that  the  availability  of  tyrosine  groups  is  not  the  only  factor  determining  the
incorporation efficiency and release profiles.  
In a similar way to the incorporation efficiency, the release profile of encapsulated GFs could
change  depending  on their  tyrosine  content  and other  characteristics  of  the  proteins  that
determine surface interactions  and diffusion rates.  Results  showed that  VEGF, bFGF and
BDNF had a release time matching the degradation time of the hydrogels (Figure 3.5B),
similarly to BSA. Interestingly, the release profiles were comparable between VEGF, bFGF
and BDNF under  all  cross-linking  conditions.  Furthermore,  the  release  profiles  fit  linear
trends when PVA-Tyr was cross-linked at 1/10 and 2/20 mM Ru/SPS, with R2 values around
0.9 for all GFs (Supplementary Table S3.9). Overall, these results demonstrate that PVA-Tyr
can  incorporate  and  release  a  range  of  different  GFs,  that  the  release  time  span  and
incorporation rate can be modulated by changing the hydrogel cross-linking conditions and
that the differences between GFs in terms of retention and release are small. These aspects
101
are  key  for  the  adaptation  of  PVA-Tyr  hydrogels  to  different  regenerative  medicine
applications that require any protein to be delivered in a specific time frame. 
3.3.4. Evaluating the Bioactivity of Growth Factors Released from PVA-Tyr Hydrogels
 
During photo-crosslinking, GFs in the system are exposed to oxidative damage. Although
previous studies showed that gelatin is able to retain its ability to promote cell attachment and
proliferation after cross-linking (26), these properties come mostly from the presence of short
amino acid sequences like RGD, which do not rely so much on the 3D conformation of the
protein.  Receptor-binding domains  in  GFs have  a  higher  specificity  and complexity,  and
therefore their binding affinity is more sensitive to oxidative damage, modification of certain
amino acid residues or changes  in tertiary structure.  Previous studies showed that  photo-
crosslinking and exposure to UV light can reduce the bioactivity of GFs and enzymes in a
dose-dependent manner  (44,45). For example,  Gu  et al. showed that VEGF bioactivity is
reduced after exposure to UV alone or to UV-activated photoinitiator (DMPA) in a dose-
dependent manner, and this reduction is affected by other factors such as the presence of
albumin  or  the  macromer  molecular  weight  (44).  It  has  also  been  shown  that  the
photoinitiator system used can also influence these changes in functionality  (45). Although
the  activation  of  our  system  through  the  more  clinically  friendly  visible  light  (450  nm
wavelength) could be a potential advantage to maintain GF bioactivity during this process, it
remains  inevitable  that  the  GFs  are  subjected  to  radical-based  oxidative  damage.
Additionally, the chemical modification that remains in some tyrosine groups after release
could further affect their receptor-binding affinity, especially if those tyrosine residues are
localised in the receptor-binding domain. During our initial bioactivity studies, the aim was
trying  to  determine  that  GFs retain  bioactivity  even after  covalent  incorporation  into  the
network and formation of bi-phenol  groups.  To do that,  the initial  24h of release (initial
release)  was separated from the rest  of  the release profile  (degradation products).  It  was
assumed that the initial release contains mostly GFs that were not incorporated in the matrix,
and therefore would be mostly affected by oxidative damage. In the degradation products
group, most of the GF has been incorporated in the network and posteriorly released, and
therefore it was exposed to both oxidative damage and the chemical modifications associated
to covalent incorporation. 
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In a similar way to the retention and release dynamics, the effects of covalent incorporation
on GF bioactivity could differ between GFs depending on their susceptibility to oxidative
damage or the stability of their receptor-binding domains. VEGF (46), bFGF (47) and BDNF
(48) have  been  widely  studied  as  vascularisation  promoters.  Based  on  that  information,
vascularisation in vitro models were chosen to study their bioactivity, which allowed a more
reliable comparison of how the incorporation and release processes affect the bioactivity of
these  three  GFs.  5wt%  PVA-7Tyr  cross-linked  using  0.5/5mM  Ru/SPS,  a  short-term
degradation formulation (7-9 days), was chosen for the bioactivity studies as vascularisation
happens  during  the  first  1-2  weeks  of  tissue  regeneration  (49).  Metabolic  activity  and
migration assays were performed to evaluate the bioactivity of GFs right after being released
from PVA-Tyr, whereas 3D vascularisation assays were performed to evaluate the bioactivity
of the overall release profile in a longer term assay.
3.3.4.1.Effects of Released Growth Factors on the Metabolic Activity of HUVECs and
MSCs
VEGF, bFGF and BDNF were incorporated into PVA-Tyr and both HUVECs and MSCs
were  exposed  to  the  resulting  initial  release  and  degradation  products  (Figure  3.6A-F).
Released  VEGF  from  both  the  initial  release  and  the  degradation  products  induced  an
increase  in  metabolic  activity  in  HUVECs (Figure 3.6A) and MSCs (Figure  3.6B).When
comparing  free  VEGF to  VEGF released  from hydrogels  that  were  initially  loaded  with
equivalent VEGF concentrations, the free control resulted in higher metabolic activity in both
HUVECs and MSCs. Part  of these differences  could be explained by the lower effective
concentration caused by the separation of the release in two phases. However, we attribute
most of the differences to the effects of oxidative stress of VEGF. Similar tendencies were
found with bFGF, where both the initial release and the degradation products were able to
induce an increase in metabolic activity in both cell types (Figures 3.6C-D). At the highest
concentration tested, the released bFGF was able to induce an increase in metabolic activity
in HUVECs at rates that were equivalent to its free bFGF control. BDNF did not increase
HUVEC metabolic activity in its free form (Figure 3.6E), which is in accordance to previous
reports where BDNF pose no effect on the proliferative capacity of HUVECs  (50). It did,
however,  induce  an  increase  in  metabolic  activity  in  MSCs  (Figure  3.6F).  Interestingly,
exposure  to  both  the  initial  release  and  the  degradation  products  of  BDNF  resulted  in
increased MSC metabolic activity at rates that were comparable to their free BDNF controls. 
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Figure 3.6. Effects of released growth factors on the metabolic activity of HUVECs
and MSCs. Stimulation of HUVEC (A, C, E) and MSCs (B, D, F) by VEGF (A, B), bFGF
(C,  D)  and  BDNF  (E,  F)  released  from  PVA-Tyr  hydrogels  (7Tyr,  5wt%,  0.5/5  mM
Ru/SPS) during 48h. *: Significant difference (p<0.05) as compared to its corresponding
negative control (0 ng/mL). Experiments were repeated 3 times with 3 technical repeats
each (N=3).
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Overall, these results show that the tested GFs are able to withstand the oxidative stress and
the chemical modifications associated to covalent incorporation, maintaining at least part of
their ability to promote HUVEC and MSC metabolic activity. Furthermore, they show that
the sensitivity to changes in their receptor-binding domains can differ between specific GFs.
Specifically, bFGF and BDNF are potentially more resistant to these changes as compared to
VEGF. Therefore, any new GF that is to be incorporated into PVA-Tyr will need to be tested
in a similar way.
3.3.5. Effects of released growth factors on the migration of HUVECs and MSCs 
The  overall  functionality  of  GFs  is  the  result  of  binding  to  a  combination  of  different
receptors.  Therefore,  it  is  important  to  evaluate  GF bioactivity  with  multiple  assays  that
recapitulate  their  different  effects.  In  a  regenerative  medicine  context,  a  migration  assay
provides  information  about  the  ability  of  the  GF  to  recruit  cells  from  the  surrounding
environment  to  promote  tissue  regeneration.  Scratch  assays  were  performed  on  both
HUVECs and MSCs by exposing them to the separated initial release or degradation products
(fully degraded hydrogel) (Figure 3.7A-D). Results showed that VEGF, bFGF and BDNF
were able to induce cell migration regardless of the cell type, the exposure to oxidative stress
or the presence of bi-phenol groups. . These findings are consistent with previous reports
where VEGF, bFGF and BDNF induced migration of HUVECs (50–53) and MSCs (54–56).
Interestingly, the rates of migration induced by both the initial release and the degradation
products were similar to their free GF counterparts, which is in contrast with the results seen
in metabolic activity assays for VEGF and bFGF. This disparity between results could be
caused  by  changes  in  the  GF  that  only  affect  the  binding  affinity  with  some  of  these
receptors.
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Figure 3.7. Effects of released growth factors on the migration HUVECs and MSCs.
(A)  Representative  pictures  of  HUVEC  migration,  (B)  HUVEC  wound  closure  assay
quantification after 8h of exposure, (C) Representative pictures of MSC migration and (D)
MSC wound closure quantification after 24h of exposure. PVA-7Tyr was cross-linked at
5wt%,  0.5/5  mM  Ru/SPS.  Scale  bar:  200  μm.  *:  Significant  difference  (p<0.05)  as
compared to its respective negative (-) control. Experiments were repeated 3 times with 3
technical repeats each (N=3).
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3.3.4.3. Effects of released growth factors on 3D network formation by HUVEC/MSC
co-cultures
To demonstrate the capability of the PVA-Tyr-GF system to stimulate cell response in a more
complex setup and during a longer time span, an established 3D HUVEC/MSC co-culture
system  (57–59) was  exposed  to  PVA-Tyr  hydrogels  with  incorporated  GFs  through  a
transwell system. Immunofluorescence at day 7 (Figure 3.8A) showed that VEGF, bFGF and
BDNF were able to promote an increase in junctions density (Figure 3.8B) both as free GF in
media or released from PVA-Tyr. VEGF and bFGF also induced an increase in total vessel
length  (Figure  3.8C).  These  results  agree  with HUVEC metabolic  activity  and migration
results,  demonstrating  that  the  GFs  still  retain  bioactivity  after  covalent  incorporation.
Moreover,  released  GFs  displayed  an  ability  to  promote  network  formation  that  was
comparable to the free GF controls despite the fact that fresh GFs were added in every media
change in the latter groups. This result suggests that the hydrogel system protects the GFs
from the microenvironment,  which agrees with previous reports  on biomaterial-based GF
delivery  (Kempen et al., 2008; Tong, Lee, Bararpour, & Yang, 2015). Another interesting
observation is that BDNF was able to promote 3D vessel formation despite not promoting
HUVEC metabolic activity. These results are also supported by previous literature  (48,50),
and suggest that the effects of BDNF on angiogenesis are triggered mostly by the interaction
with MSCs.
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Figure 3.8. Effects of released growth factors on 3D network formation by HUVEC/MSC co-
cultures. (A) Representative images of the CD-31 immunostaining (green) showing the 3D network
formation in ECM hydrogels after continuous exposure to either soluble GF or release from PVA-
Tyr hydrogels (5wt%, 0.5/5 mM Ru/SPS) after 7 days. (B) Junctions density and (C) total vessel
length extracted from Angiotool network analysis. Scale bars: 200 μm. *: Significant difference
(p<0.05) as compared to assay media. #: Significant difference (p<0.05) as compared to PVA-Tyr.
Experiments were repeated 3 times with 3 technical repeats each (N=3).
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Overall, bioactivity studies show that it is possible to incorporate GFs in PVA-Tyr hydrogels
while retaining their  functionality.  Results suggest that different GFs could have different
sensitivities to the effects of oxidative stress and the chemical modifications associated to
covalent  incorporation,  as shown by metabolic  activity studies when comparing VEGF to
bFGF or BDNF. Furthermore, these effects could potentially modify the binding affinities of
GFs to each of their receptors in different ways. A question remaining to be answered is how
increasing the Ru/SPS concentrations will  affect  GF bioactivity,  as previous studies have
shown that the loss of functionality depends on the photoinitiator concentration  (44,45). A
potential strategy to reduce oxidative stress could be the addition of albumin or other proteins
with radical-quenching properties  to  the hydrogels  (44).  Our results  have shown that  the
protein concentration in the hydrogels can be increased without inducing changes in their
degradation profile, which makes this strategy feasible for future research.
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3.4. Conclusions
In the present study, the potential of PVA-Tyr/Ru/SPS as a growth factor delivery system has
been investigated.  It has been demonstrated that, by changing the degree of tyramination,
macromer  concentration  and  Ru/SPS  concentration,  hydrogels  with  highly  tailorable
degradation profiles from seven days to up to three months can be obtained. The release of
covalently  incorporated  BSA and  GFs  from different  PVA-Tyr  formulations  consistently
showed a linear tendency that lasted until total degradation of the hydrogel, demonstrating
potential  for  long  term  continuous  release  applications.  It  has  been  shown  that  the
encapsulation of VEGF, bFGF or BDNF in PVA-Tyr does not result in relevant differences
in the incorporation rate or release profile of the system, which facilitates its translation to the
delivery of different GFs and even coordinated delivery. Furthermore, proteinase K has been
used as a model to show that the degradation of PVA-Tyr hydrogels is driven by hydrolysis
even after the covalent incorporation of a high protein concentration. Finally, 2D and 3D in
vitro models were used to prove that VEGF, bFGF and BDNF still retain functionality after
exposure  to  oxidative  stress  and  to  the  chemical  modifications  associated  with  covalent
incorporation. To our knowledge, no other GF delivery system has shown to provide such
level  of  control  over  the  release  profiles  in  combination  with  the  ability  to  covalently
incorporate a wide range of native proteins.
There are some aspects of the system that still need to be further investigated. Studies on the
effects of increased Ru/SPS concentration in GF bioactivity should be performed, together
with potential strategies to reduce oxidative stress such as the addition of protective proteins
in the hydrogel. However, evidence has been provided showing that the process of covalent
incorporation  does  not  inactivate  the  studied  GFs and,  therefore,  that  this  type  of  cross-
linking is a viable strategy for long term GF delivery. Another key aspect for future study is
the degradation profile of PVA-Tyr hydrogels in an in vivo environment. 
Overall, the present study provides sufficient evidence to demonstrate the potential of PVA-
Tyr as a highly tailorable GF delivery system due to its controllable degradation profiles, its
long-term linear  release and its  ability  to  incorporate  and release a  wide range of native
proteins in a simple manner while retaining functionality.
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3.5. Supplementary information
Supplementary Table S3.1. Sol fraction values for PVA-4Tyr hydrogels cross-linked at
different macromer and Ru/SPS concentration. 




34.1 ± 11.0 53.6 ± 5.9
1.5/15 mM Ru/SPS
34.2 ± 4.8 44.8 ± 1.7 73.0 ± 2.9
2/20 mM Ru/SPS
25.2 ± 9.9 45.3 ± 3.6 63.9 ± 1.4 73.5 ± 5.5
Supplementary Table S3.2. Sol fraction values for PVA-7Tyr hydrogels cross-linked at
different macromer and Ru/SPS concentration. 




14.0 ± 8.0 18.2 ± 2.7
1.5/15 mM Ru/SPS
11.8 ± 2.7 18.6 ± 5.2 20.5 ± 2.3
2/20 mM Ru/SPS
13.9 ± 5.9 14.2 ± 6.9 24.5 ± 5.2 26.4 ± 9.7
Supplementary Table S3.3. Sol fraction values for PVA-10Tyr hydrogels cross-linked at
different macromer and Ru/SPS concentration. 




9.2 ± 5.2 19.3 ± 6.2
1.5/15 mM Ru/SPS
7.8 ± 3.0 14.1 ± 5.4 17.6 ± 2.8
2/20 mM Ru/SPS
22.6 ± 6.7 17.4 ± 2.6 20.6 ± 6.7 32.6 ± 9.7
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Supplementary Table S3.4. Swelling ratio values for PVA-4Tyr hydrogels cross-linked at
different macromer and Ru/SPS concentration. 




26.4 ± 3.9 31.0 ± 1.0
1.5/15 mM Ru/SPS
21.6 ± 1.6 18.7 ± 1.5 29.0 ± 5.5
2/20 mM Ru/SPS
19.5 ± 6.4 16.7 ± 1.3 21.2 ± 2.3 22.25 ± 5.3
Supplementary Table S3.5. Swelling ratio values for PVA-7Tyr hydrogels cross-linked at
different macromer and Ru/SPS concentration. 




12.9 ± 1.6 12.3 ± 1.1
1.5/15 mM Ru/SPS
11.8 ± 0.5 10.9 ± 1.0 11.0 ± 0.8
2/20 mM Ru/SPS
11.9 ± 0.4 10.1 ± 0.8 10.5 ± 0.8 11.0 ± 0.8
Supplementary Table S3.6. Swelling ratio values for PVA-10Tyr hydrogels cross-linked
at different macromer and Ru/SPS concentration. 




15.0 ± 1.8 14.0 ± 1.2
1.5/15 mM Ru/SPS
13.0 ± 2.0 9.7 ± 0.2 11.3 ± 0.8
2/20 mM Ru/SPS
12.3 ± 1.6 10.9 ± 1.0 10.5 ± 1.2 10.2 ± 2.0
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Supplementary  Figure  S3.1.  Degradation  of  PVA-7Tyr  hydrogels  with  varying
Ru/SPS concentrations. (A-C) Mass loss and (D-F) swelling ratio of PVA-7Tyr hydrogels





Supplementary  Figure  S3.2.  Degradation  of  PVA-10Tyr  hydrogels  with  varying
Ru/SPS  concentrations.  (A-C)  Mass  loss  and  (D-F)  swelling  ratio  of  PVA-10Tyr
hydrogels  cross-linked  using  increasing  Ru/SPS  concentrations  (0.5/5-2/20  mM)  at
different macromer concentrations (5-15wt%).
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Supplementary Figure S3.3. Degradation of PVA-7Tyr hydrogels with varying 
macromer concentration. (A-C) Mass loss and (D-F) swelling ratio of PVA-7Tyr 
hydrogels cross-linked using increasing macromer concentrations (5-20wt%) and a range 




Supplementary  Figure  S3.4.  Degradation  of  PVA-10Tyr  hydrogels  with  varying
macromer  concentration.  (A-C)  Mass  loss  and  (D-F)  swelling  ratio  of  PVA-10Tyr
hydrogels cross-linked using increasing macromer concentrations (5-15wt%) and a range
photoinitiator concentrations (1/10-2/20 mM).
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Supplementary Figure S3.5. Physico-chemical properties of PVA-Tyr hydrogels with
incorporated BSA.  (A) Sol fraction and (B) day 1 swelling ratio, of PVA-Tyr hydrogels
with incorporated BSA cross-linked at different conditions.
A B
C D
Supplementary Figure S3.6.  Degradation of PVA-Tyr hydrogels  with incorporated
BSA under proteinase K exposure.  (A) Mass loss and (B) Swelling ratio of PVA-Tyr
hydrogels  with  incorporated BSA.  (C) Swelling  ratio  and (D) BSA release of PVA-Tyr




Supplementary  figure  S3.7.  Degradation  profile  of  PVA-Tyr  hydrogels  with
incorporated  BSA  crosslinked  using  different  photoinitiator  and  macromer
concentrations. (A) Mass loss profile and (B) swelling ratio profile of PVA-Tyr hydrogels
with incorporated BSA cross-linked under different conditions.
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Supplementary Figure S3.8. Linear regression of BSA release profiles from PVA-Tyr
hydrogels crosslinked using different photoinitiator and macromer concentrations.
Supplementary Table S3.7. R2 of the BSA release linear regression for different PVA-Tyr 





























Supplementary Figure S3.9.  Sol  fraction of  PVA-Tyr hydrogels  with incorproated
growth factors.  Sol  fraction  of  PVA-7Tyr hydrogels  cross-linked  at  5  wt%,  0.5/5  mM
Ru/SPS incorporated with different concentrations of (A) BSA, (B) VEGF, (C) bFGF and
(D) BDNF.  Protein  concentrations  are  expressed  as  protein  weight  per  volume of  the
macromer solution  before  cross-linking.  No significant  differences  were found between
groups (p>0.05)
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A B C
D
Supplementary Figure S3.10. Swelling ratio of PVA-Tyr hydrogels with incorproated
growth factors.  Swelling ratio of PVA-7Tyr hydrogels cross-linked at 5 wt%, 0.5/5 mM
Ru/SPS incorporated with different concentrations of (A) BSA, (B) VEGF, (C) bFGF and
(D) BDNF.  Protein  concentrations  are  expressed  as  protein  weight  per  volume of  the
macromer solution  before  cross-linking.  No significant  differences  were found between
groups (p>0.05)
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Supplementary Table S3.8. Tyrosine and tyramine residues present and surface available
in the incorporated growth factors. Available residues were extracted from Protein Data









10 kDa 7 (Tyramine) 7 (Tyramine)
Albumin 66 kDa 18 3 (40)
VEGF 19 kDa 4 3 (41)
bFGF 9.9 kDa 10 1 (42)
BDNF 13.6 kDa 4 3 (43) 
Supplementary Table S3.9. R2 of the linear regression of the VEGF, bFGF and BDNF 




























R2 0.696 0.7552 0.6492 0.9148 0.9116 0.8467 0.9084 0.9194 0.9172
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Factor Delivery System for the Treatment of
Perthes Disease
4.1. Introduction
Legg-Calve-Perthes  disease  (Also  known  as  LCPD  or  Perthes  disease)  is  an  idiopathic
avascular necrosis of the femoral head (Figure 4.1) (1). It is considered a rare disease, with an
incidence ranging from 0.4/100,000 to 29/100,000 children below 15 years of age according
to epidemiological studies in different countries (2). The causes of the ischaemic episodes in
the femoral head are not well known, and it has been hypothesized that instances of micro-
trauma  (3) and  environmental  factors  such  as  low-socioeconomic  status  (4) and  passive
smoking (5) could be involved. 
Figure 4.1. Schematic view of avascular necrosis of the femoral head. (A) Blood supply
to  the  femoral  head  mainly  comes  from the  retinacular  arteries  and  a  branch  of  the
obturator artery. (B) Disruption of the blood vessel supply results in necrosis and collapse
of the femoral head. Adapted from (6).
In Perthes disease, tissue necrosis causes the femoral head to deform under the physiological
loading forces across the hip joint. The resulting symptoms include pain, restricted range of
movement  and  reduced  functional  ability  (7).  Early  intervention  is  often  performed  in
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children to allow regrowth of healthy bone tissue. The most common intervention is core
decompression, which consists in drilling a small hole in the necrotic bone to decrease the
intraosseous pressure (8). Despite early intervention, the progression of the disease results in
collapse of the femoral head (Figure 4.1B). If collapse happens, the long-term prognosis is
poor (9–12), resulting in pain, joint stiffness, leg length inequality, limping and osteoarthritis
(13). At this stage, early hip arthroplasty is necessary for pain relief and improvement in daily
function (14). However, this procedure has increased complications in patients with Perthes
disease (15). It therefore seems imperative to treat this condition accurately and successfully
at its onset.
The underlying pathological condition in Perthes disease is the lack of blood supply in the
femoral head. Therefore, a rational early treatment could aim to restore this blood supply,
thus providing oxygen and nutrients to the area and promoting the formation of new, healthy
bone. Delivering growth factors (GFs) is one of the most promising approaches to promote
angiogenesis  (16). VEGF is one of the most studied angiogenesis-promoting GFs  (17–20)
and plays an important role in bone repair and regeneration (21), which has inspired several
research studies on the use of VEGF to promote bone vascularisation and regeneration (22–
25). For example, Kaigler et al. delivered VEGF into rat critical-sized bone defects either by
bolus administration or loaded into an alginate hydrogel. Their study showed that delivering
VEGF using the alginate hydrogel resulted in improved blood vessel density 4 weeks after
implantation and improved bone density 8 weeks after implantation as compared to negative
controls without delivered VEGF and the bolus delivery group (25). These results show not
only that VEGF could be a promising treatment for the promotion of revascularisation of the
femoral head and the subsequent formation of new bone, but also that its release needs to be
controlled using vehicles such as biomaterials. In fact, VEGF has also been used specifically
for cases of avascular necrosis of the femoral head (54), but these studies did not focus on
controlling the GF release and the degradation of the materials in a way that coordinates with
tissue regeneration.  In order to deliver VEGF to promote revascularisation of the femoral
head,  it  is  crucial  to  use a  delivery  system that  can  be adapted  to  releasing  VEGF in a
controlled manner during the vascularisation process. In Chapter 3, PVA-Tyr was studied as
a GF delivery system that excelled due to its  highly controllable  degradation and release
kinetics.  Furthermore,  the feasibility  of the system was tested  in vitro,  demonstrating the
bioactivity of released VEGF, which was evidenced by its ability to promote endothelial cell
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proliferation,  migration  and  network  formation.  These  characteristics  make  the  PVA-Tyr
system a solid candidate for its application in Perthes disease.
Another important aspect to consider when designing a delivery system that aims to promote
vascularisation is its interaction with cells. Newly formed vessels branching from the host
vasculature need to penetrate into the necrotic area during the early stages of regeneration
(26), making materials with cell-adhesive properties that facilitate cell migration and ECM
remodelling highly desirable for this application. However, one of the limitations of PVA as a
delivery system is its lack of biological recognition sites for interaction with cells (27). es.
In this chapter, a potential application of the PVA-Tyr system is demonstrated by tailoring it
to deliver VEGF for the treatment of Perthes disease. The first aim of the chapter was to
study the possibility of combining PVA-Tyr hydrogels with gelatin and investigate the effects
of this combination on the interaction of the gels with endothelial  cells, their degradation
properties  and their  GF release profile.  The second aim of the chapter  was to develop a
strategy to inject  these hydrogels into the femoral  head, specifically  in a piglet  model of
avascular necrosis. While my personal involvement was exclusively in the materials related
aspects of the study, preliminary results of the in vivo experiment to evaluate the potential of
these VEGF loaded PVA-Tyr hydrogels are also provided in the chapter. 
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4.2. Materials and Methods
4.2.1. Hydrogel Fabrication
Dried PVA-Tyr was dissolved in PBS at 80 °C. Upon complete  dissolution,  the polymer
solution was cooled to room temperature (RT) and mixed with Ru and SPS stock solutions to
a final concentration of 5wt% PVA-Tyr and 0.5/5 mM Ru/SPS. Gelatin  or growth factor
stock solutions were mixed with the PVA-Tyr solution prior to the addition of Ru and SPS.
BSA hydrogels were obtained by mixing a 10wt% BSA solution with Ru and SPS stock
solutions to a final concentration of 2/20 mM Ru/SPS. All samples were photo-crosslinked
using visible light (OmniCure® S1500, Excelitas Technologies with a Rosco IR/UV filter
400 – 450nm, 3min, 300 mW cm-2) in cylindrical moulds (h = 2 mm, Ø = 6 mm) in an open
environment. 
4.2.2. Swelling and Mass Loss Assays
After crosslinking, each hydrogel (35 μL) was weighed (minitial,t0 ), out of which three samples
per hydrogel composition were directly freeze-dried to record their initial dry weights (mdry,t0)
and determine the actual  macromer weight fraction,  which is  reported as the ratio of the
initial dry weight to the initial weight. To determine the initial dry weight of the remaining
samples, the factor of the actual macromer fraction and individual initial weight was used
(Eq. 1).
Actualmacromerfraction=
mdry , t 0
minitial
(1)
The remaining samples were allowed to swell in PBS at 37 °C until up to 1d or longer time
points to determine the mass loss. Swollen hydrogel samples were collected to record wet
weight (mswollen),  then  freeze-dried to obtain the freeze dried weight (mdry) to calculate the
mass loss and mass swelling ratio (q) according to equations 2 and 3:
mdry , t0=minitial xactualmacromerfrac t ion (2)
Massloss=
mdry , t0−mdry
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The sol fraction of the hydrogels is defined as percent macromers that are not crosslinked into
the hydrogel network, and determined as the mass loss after equilibrium swelling (t = 1 d).
4.2.3. Cell Attachment Assays
PVA-Tyr hydrogels were fabricated directly in the cell culture wells of a 24 well-plate using
a silicon mould (6mm diameter,  1mm depth) and allowed to swell  overnight in Vascular
Basal Media (ATCC) supplemented with Endothelial Cell Growth Kit-VEGF (ATCC) and
Penicillin/Streptomycin (Referred to as endothelial growth media, EGM). Green fluorescent
protein-labelled  human  umbilical  vein  endothelial  cells  (GFP-HUVECs,  obtained  from
Cellworks)  were  cultured  in  EGM up to  passage  3  to  4,  trypsinized  and  seeded  on the
hydrogels at a density of 1.000 cells/mm2. After 6h, hydrogels were washed two times using
EGM  and  imaged  using  a  Zeiss  Axioimager  Z1  fluorescence  microscope  (Carl  Zeiss
Microscopy, Jena, Germany).
4.2.4. Effect of Proteinase Exposure on Degradation Profile
PVA-Tyr  and hydrogels  were  left  in  either  PBS or  PBS with  additional  Proteinase  K 1
mg/mL  as previously described  (38), then incubated at 37°C. The PBS solutions with our
without Proteinase K were discarded every 48h and fresh solution was added for continuous
exposure to functional enzyme. Mass loss and swelling ratios were calculated using equations
1-4.
4.2.5. Preparation of PVA-Gelatin-VEGF Hydrogels for the In Vivo Study
For each individual sample, 500 μL of a PVA-Tyr (5wt%, functionalised with 7 tyramines
per chain) and Gelatin (1wt%) solution with or without 250 ng of VEGF-165 were mixed
with Ru/SPS (1/10 mM final concentration) and crosslinked using visible light (OmniCure®
S1500, Excelitas Technologies with a Rosco IR/UV filter 400 – 450nm, 3min, 300 mW cm -2)
in a transparent syringe.
4.2.6. In Vivo Surgical Procedure
To perform a pilot study to evaluate the effectiveness and feasibility of the system in an in
vivo setting,  a  previously  validated  piglet  model  of  avascular  necrosis  was used  (39–41)
under ethics approval from the University of Otago Animal Ethics Committee (AEC 2017-
43). Briefly, large white/landrace cross piglets were anesthetised using 2% isoflurane. The
limbs and pelvic area were sterilised using 2% chlorhexidine/70%isopropyl alcohol and a
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longitudinal incision was made over the hip. Gluteus and hip abductor muscles overlying the
hip joint were identified and separated using retractors. The hip joint capsule was partially
incised to expose the lateral aspect of the femoral head and neck. The ligamentum teres was
visualized by subluxing the femoral head and resected using a curved scissor. A 1.0 nylon
suture was then passed around the femoral neck and tied tightly to ensure obstruction of the
retinacular  vessels.  After vessel disruption,  a hole was drilled with the entry point at  the
anterolateral proximal femur, penetrating across the centre of the growth plate into the core of
the femoral head. PVA-Tyr hydrogels (500 µL, 5% PVA-Tyr, 1% Gelatin, 0.5/5 Ru/SPS)
with or without VEGF (500 ng/mL) were then delivered through this hole using a Jamshidi
needle.  Experimental  groups  included  a  group  where  no  vessels  were  disrupted  (No
operation,  n=2),  a group with disrupted vessels  (Vessels  disrupted,  n=4),  a  group with a
drilled  hole  but  no  material  delivered  (Sham,  n=4),  a  group  where  PVA-Gelatin  was
delivered (PVA-Gel,  n=8) and a group where PVA-Gelatin  with incorporated VEGF was
delivered (PVA-Gel-VEGF, n=8). The treatments were randomly distributed between piglets.
4.2.7. Histological Analysis and Imaging
Animals were sacrificed 15 weeks after the surgical procedure and the proximal part of the
femur  was  harvested.  Samples  were  examined  grossly,  dissected  and  CT  imaged.  The
samples were then fixed in 10% buffered formalin, decalcified,  embedded in paraffin and
sectioned. For general histological analysis, the sections were stained with hematoxylin and
eosin staining.
4.2.8. Statistical Analysis
All samples were prepared in triplicates and each experiment was repeated three times to
study  variability  between  experiments  (N=3)  except  for  the  in  vivo study.  Individual
differences between groups and time points were assessed using one or two-way ANOVA
and Holm-Sidak post hoc analysis (GraphPad Prism 7). Statistical significance was accepted
at p<0.05. 
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4.3. Results and Discussion
There has been extensive research on imparting synthetic polymers such as PVA with the
ability  to directly  interact  with cells  through different  strategies  (28).  The most extended
strategy to improve cell interaction with the material is to directly bind or incorporate either
natural ECM molecules or their bioactive sequences to the material. A good example of this
strategy  is  the  extensive  study  by  Anderson  et  al.,  where  the  effects  of  surface
functionalisation  of  PVA  with  collagen,  laminin,  fibronectin  or  peptides  formed  by  the
bioactive  sequences  of  these  ECM molecules  (GFPGER, YIGSR and RGD respectively)
were  evaluated.  Their  study  demonstrated  that  all  of  these  modifications  promoted  the
attachment of endothelial colony forming cells to the material (29). While most strategies to
improve  the  cell-adhesive  properties  of  synthetic  materials  require  additional  fabrication
techniques  (30) or chemical modification of the material  (29,31–33), PVA-Tyr allows the
incorporation of functional proteins without these additional steps (34,35). Gelatin has been
widely used in tissue engineering as it  allows and promotes cell  adhesion,  migration and
proliferation  while  being  a  cheap,  easy to  handle,  non-immunogenic  biopolymer  (36,37).
These characteristics make it a reasonable candidate to be incorporated into the PVA-Tyr GF
delivery system to improve its cell-adhesive capabilities.
It was hypothesized that it would be possible to determine a concentration of gelatin that
promotes endothelial cell attachment while not having a significant impact on the degradation
of PVA-Tyr hydrogels and GF release profiles from the resulting hydrogels. Other aspects
such as the mechanical properties of the hydrogels could be altered by the encapsulation of
gelatin. However, these were not analysed in this chapteer as we focused in the material’s
capabilities as a delivery vehicle.
4.3.1. Effects of Gelatin Incorporation on Endothelial Cell Attachment
The initial  hypothesis  to prove was that incorporation of gelatin  would improve the cell-
attachment  properties  of  PVA-Tyr  hydrogels.  Human  umbilical  vein  endothelial  cells
(HUVECs)  were  chosen  as  a  model  for  cell  attachment  studies,  as  the  aim  of  the
incorporation  of  gelatin  was  to  improve  the  interactions  of  the  material  with  cells  from
invading blood vessels after implantation. To evaluate these interactions, PVA-Tyr hydrogels
with different concentrations of incorporated gelatin (0 to 5wt%) were fabricated, followed
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by seeding endothelial cells onto the hydrogel surface (Figure 4.2A), and the amount of cells
able to attach to it were quantified (Figure 4.2B). 
As expected, plain PVA-Tyr hydrogels resulted in low cell attachment due to the lack of cell-
interactive  features,  where  only  an  average  of  3  cells/mm2 remained  in  the  surface  after
incubation. The incorporation of gelatin at 0.01 or 0.1wt% resulted in a tendency towards
increasing  endothelial  cell  attachment  (9  and  22  cells/mm2 respectively)  but  showed  no
significant differences as compared to plain PVA-Tyr hydrogels. When the concentration of
incorporated  gelatin  was  increased  to  1wt%,  there  was  a  significant  increase  in  cell
attachment to an average of 125 cells/mm2. Further increasing the gelatin concentration to
5wt% resulted in an increase in cell attachment up to 560 cells/mm2. These results differ from
previous research, where the incorporation of 0.01wt% gelatin already resulted in significant
increases  in  fibroblast  attachment  (35).  The  morphology  of  attached  endothelial  cells
remained round regardless of the incorporated gelatin concentrations (Figure 4.2A), which is
another  difference  as  compared  to  previous  work  (35).  A  potential  explanation  of  these
differences in cell attachment is the cell type used, as Lim et al. used L929 fibroblasts instead
of  HUVECs  (35).  Previous  studies  have  reported  that  endothelial  cells  have  lower  cell
attachment  on  various  biomaterial  surfaces  as  compared  to  fibroblasts  (42,43),  which
supports  these  observations.  Another  potential  explanation  is  differences  in  the  physico-
chemical properties between the PVA-Tyr hydrogels used in both studies. While Lim et al.
used 20wt% PVA-Tyr, 2/20 mM Ru/SPS, the present study used 5wt% PVA-Tyr, 0.5/5mM
Ru/SPS, where both formulations resulted in different swelling ratios and sol fraction values
(35).  Several  studies  have  shown  that  the  physico-chemical  properties  of  the  material
determine  the  attachment  and  morphology  of  endothelial  cells,  making  it  a  potential
explanation of the diverging results (44,45).
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Figure  4.2. Effects  of  gelatin  incorporation  on  the  attachment  of  endothelial  cells
seeded  on  PVA-Tyr  hydrogels. (A)  Representative  fluorescence  pictures  and  (B)
quantification of GFP-labelled human umbilical vein endothelial cells (HUVECs) attached
on PVA-Tyr hydrogels with incorporated gelatin (Gel) 6h after cell seeding.*: Significantly
higher  (p<0.05)  as  compared to  groups with lower gelatin  concentrations.  Experiments
were repeated 3 times with 3 technical repeats each (N=3).
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4.3.2.  Effects  of  Gelatin  Incorporation  on  the  Physico-Chemical  Properties  and
Degradation Profile of PVA-Tyr Hydrogels
The  covalent  incorporation  of  gelatin  into  PVA-Tyr  hydrogels  could  alter  the  physico-
chemical  properties  of  the  base  PVA-Tyr  network  which  further  affects  the  degradation
profile.  These changes  are  not  desirable  for the clinical  translation  of PVA-Tyr as  a GF
delivery system, since they would potentially result in changes in the GF release kinetics as
compared to previous testing that was done in pure PVA-Tyr hydrogels. To systematically
evaluate the effects of gelatin incorporation on the degradation properties of PVA-Tyr gels, a
range  of  gelatin  concentrations  from  0.01  to  5wt%  were  incorporated  into  PVA-Tyr
hydrogels and mass loss studies were performed. Mass loss studies revealed that the initial
sol fraction (Figure 4.3A) and day 1 swelling ratio (Figure 4.3B) of the hydrogels was not
altered by the incorporation of 0.01 to 1wt% of gelatin, yielding sol fraction values around
20% in all cases. However, when a gelatin concentration of 5wt% was incorporated, the sol
fraction increased from 20 to 80% and the swelling ratio was doubled from 20 to 40. 
Longer-term mass loss and swelling profiles (Figure 4.3C-D) revealed similar tendencies,
where the incorporation of gelatin concentrations between 0.01 and 1wt% did not alter the
degradation time (8 days) or the mass loss and swelling values at any time point. On the other
hand,  further  increasing  gelatin  concentration  to  5  wt%  significantly  enhanced  the
degradation rate of the PVA-Tyr hydrogels to2 or 3 days after fabrication. These results agree
with previous research, where the incorporation of gelatin into 20wt% PVA-Tyr hydrogels at
concentrations up to 1wt% resulted in no differences in the physico-chemical properties of
the hydrogels or their degradation profile  (35). A remarkable aspect of these results is how
they differ from the effects  of albumin incorporation  into PVA-Tyr hydrogels  in  Section
3.3.2, where the incorporation of 1wt% albumin resulted in longer degradation time of the
gels. A potential explanation of these differences is the disparity between the properties of
gelatin and albumin. While albumin is a 66 kDa protein containing 18 tyrosine residues per
molecule  (46),  gelatin  is  a  polydisperse  solution  of  polypeptides  with  a  highly  variable
molecular weight and number of tyrosine residues per molecule (47). These differences could
result  in  a  less  homogeneous  crosslinking,  where  the  incorporation  of  a  high  enough
concentration of gelatin destabilizes the network and results in lower crosslinking efficiency
and faster degradation. In contrast, the incorporation of albumin results in higher crosslinking
144
Chapter 4. Adaptation the PVA-Tyr Growth Factor Delivery System for the Treatment of Perthes
Disease
density  and lower swelling  ratio,  making di-tyrosine bonds less  accessible  for  hydrolytic
degradation and extending the degradation time of the hydrogels.
Figure 4.3. Effects of gelatin incorporation on the physico-chemical properties of PVA-
Tyr hydrogels. (A) Sol fraction, (B) swelling ratio, (C) Mass loss profile and (D) Swelling
profile  of  PVA-Tyr  hydrogels  crosslinked  at  5wt%,  0.5/5  mM Ru/SPS  with  a  range  of
incorporated gelatin (Gel) concentrations. *: Significant difference (p<0.05) as compared
to  PVA-Tyr  control.  Experiments  were  repeated  3  times  with  3  technical  repeats  each
(N=3).
These  initial  results  show  that  a  minimum  of  1wt%  incorporated  gelatin  is  required  to
enhance endothelial  cell  attachment.  On the other hand, the incorporation of up to 1wt%
gelatin into PVA-Tyr hydrogels results in no changes in its swelling and degradation profile,
while the incorporation of higher concentrations of gelatin drastically altered these properties.
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Therefore,  1wt%  gelatin  was  selected  as  the  most  adequate  concentration  for  further
experiments. 
4.3.3. Effects of Gelatin Incorporation on Protease-Catalysed Degradation of PVA-Tyr 
Hydrogels
In Chapter 3, it was demonstrated that PVA-Tyr hydrogels are not susceptible to Proteinase K
degradation. Furthermore, the incorporation of up to 1wt% albumin into PVA-Tyr hydrogels
did not change these properties, demonstrating that PVA-Tyr was protecting the incorporated
albumin from protease  degradation.  Thus,  it  would be expected  that  the incorporation  of
gelatin  at  1wt%  would  not  alter  the  sensitivity  of  PVA-Tyr  hydrogels  to  protease  K
degradation. However, it is possible that the different properties of albumin and gelatin result
in  diverging  sensitivities  to  protease  degradation.  In  section  4.3.2,  it  was  observed  that
incorporating  1wt%  gelatin  did  not  alter  the  physico-chemical  properties  of  PVA-Tyr
hydrogels, while incorporating 1wt% albumin into PVA-Tyr hydrogels significantly impacted
the  swelling  and  degradation  behaviour  of  the  gels  (Section  3.3.2).  Knowing  that  the
incorporation of gelatin and albumin can result in diverging tendencies in the degradation and
swelling profiles of PVA-Tyr hydrogels, it was hypothesized that incorporating gelatin into
PVA-Tyr hydrogels could alter their susceptibility to protease degradation. 
To confirm this, mass loss studies were performed on PVA-Tyr hydrogels with or without
1wt% gelatin in proteinase K (Figure 4.4). Initial mass loss (Figure 4.4A) and swelling ratio
(Figure  4.4B)  measurements  revealed  that  exposure  to  proteinase  K  did  not  result  in
significant differences in sol fraction or day 1 swelling ratio, which agrees with our previous
results using albumin. As seen in Chapter 3, pure BSA hydrogel controls were susceptible to
degradation by proteinase K and were completely degraded after 24h. 
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Figure 4.4. Effects of gelatin incorporation on protease-catalysed degradation of PVA-
Tyr hydrogels. (A) Sol fraction, (B) Swelling ratio at day 1, (C) Mass loss profile and (D)
swelling ratio profile of 5wt% PVA-Tyr or 5wt% PVA-Tyr with incorporated 1wt% gelatin,
crosslinked at 0.5/5 mM Ru/SPS. BSA controls were crosslinked at 10wt% BSA, 2/20 mM
Ru/SPS. Hydrogels were exposed to either PBS or proteinase K 1mg/mL dissolved in PBS.
*:  Significant  difference  (p<0.05) between groups.  #:  Significant  difference  (p<0.05) as
compared to plain PVA-Tyr hydrogels in PBS. Experiments were repeated 3 times with 3
technical repeats each (N=3).
Longer-term mass loss (Figure 4.C) and swelling studies (Figure 4.4D) further confirmed that
proteinase K did not have an effect on the degradation and swelling ratio profiles of PVA-Tyr
hydrogels regardless of the incorporation of 1wt% gelatin. All PVA-Tyr hydrogels showed
comparable mass loss and swelling values in all time points, and their degradation time was
between 8 and 9 days in all groups. BSA controls exposed to PBS showed stable mass loss
and  swelling  ratio  throughout  the  whole  experiment.  These  results  provide  further
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information about the changes in physico-chemical properties of PVA-Tyr hydrogels after the
incorporation  different  types  of  proteins.  The  incorporation  of  1wt%  albumin  initially
resulted in longer hydrolytic degradation times of PVA-Tyr hydrogels when exposed to PBS,
but did not alter the sensitivity of the hydrogels to proteinase K degradation (Section 3.3.2).
On the other hand, the incorporation of 1wt% gelatin into PVA-Tyr hydrogels did not result
in  changes  in  degradation  or  swelling  profiles  of  the  gels,  and  also  did  not  alter  their
sensitivity to proteinase K degradation (Figures 4.3 and 4.4). This suggests that the ability of
PVA-Tyr hydrogels to protect incorporated proteins from protease degradation is not likely to
be affected by the incorporation of different types of proteins, while the rate of hydrolytic
degradation  of  the  gels  could  vary  depending  on  the  incorporated  proteins  and  their
concentrations. Overall, these results further confirm that the incorporation of 1wt% gelatin
into PVA-Tyr hydrogels does not have a significant effect on their degradation profile.
4.3.4. Effects of Gelatin Incorporation on Growth Factor Retention and Release
Mass loss assays have confirmed that the incorporation of gelatin does not alter the physico-
chemical properties of PVA-Tyr hydrogels (Section 4.3.3). Therefore, it would be expected
that  the  incorporation  and  release  of  GFs  will  not  be  altered  either.  To  confirm  that,
fluorescently  tagged  VEGF,  bFGF  and  BDNF  were  incorporated  into  PVA-Tyr  and
hydrogels  with  and  without  1wt% incorporated  gelatin.  Release  assays  revealed  that  the
retention values remain between 25 and 30% regardless of the incorporation of gelatin and
independently of which GF was incorporated, with no significant differences between groups
(Figure 4.5A). These results show that the incorporation of 1wt% gelatin does not alter GF
retention in the studied conditions. The release profiles (Figure 4.5B) were also comparable
in all groups and showed no significant differences in any of the time points.
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Figure 4.5. Effects of gelatin incorporation on growth factor retention and release. (A)
Retention  and  (B)  release  of  VEGF,  bFGF  and  BDNF  in  PVA-Tyr  (5wt%,  0.5/5mM
Ru/SPS)  or  PVA-Gel  (5wt%  PVA-Tyr,  1wt%  gelatin,  0.5/5mM  Ru/SPS)  hydrogels.
Experiments were repeated 3 times with 3 technical repeats each (N=3).
These results further confirm that the incorporation of gelatin does not alter the properties of
the hydrogel in terms of its GF retention and release,  further demonstrating that this  is a
viable strategy to improve the bioactivity of the PVA-GF platform. 
4.3.5. Adaptation of the PVA-Tyr Delivery System to Injection Using Surgical Tools
In sections 4.3.1-4, gelatin was covalently incorporated into PVA-Tyr hydrogels to improve
their  interaction  with  endothelial  cells.  It  was  shown  that  the  incorporation  of  gelatin
improves endothelial cell attachment on PVA-Tyr hydrogels while not altering the hydrolytic
degradation of the hydrogels, their susceptibility to protease degradation or the release profile
of  encapsulated  GFs.  Therefore,  the  incorporation  of  gelatin  was  considered  to  be  a
successful step towards the adaptation of the PVA-Tyr GF delivery system for the treatment
of  Perthes  disease.  The  GF chosen  for  the  delivery  is  VEGF,  as  it  is  a  widely  studied
angiogenesis-promoting GF (17–20) that has also shown positive results in bone regeneration
settings  (21). The next aspect to consider for the adaptation of the system was the delivery
method.
The  surgical  intervention  to  which  the  PVA-Tyr  system needed  to  be  adapted  aimed  to
connect  the  arterial  network  in  the  body of  the  femur  with  the  femoral  head,  providing
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vascular supply to the femoral head when it is not receiving enough nutrients and oxygen.
The process involved drilling a hole in the lateral side of the femur, reaching the core of the
femoral  head (Figure 4.6).  The VEGF-loaded PVA-Tyr hydrogel  was then delivered  and
fixated into the core of the femoral head through the drilled hole, where it would release
VEGF to attract angiogenic sprouts towards it from the arterial network in the femoral body. 
Figure 4.6. Schematic view of the vascular supply in the femoral head and important
areas for the surgical  intervention. The branch of  the obturator  artery that  provides
blood supply to the medial side of the femoral head was disrupted and the retinacular
arteries were blocked during the surgical  procedure to generate a model  of  avascular
necrosis. The dashed arrow indicates the point of entrance and direction of the drilled hole
through which the hydrogel was delivered. 
The ideal method of delivery would then be to inject the hydrogel through the drilled hole.
The  approach  that  is  generally  envisioned  for  this  type  of  delivery  is  to  first  inject  the
precursor solution into the area of need and then irradiate it with a light source for in situ
crosslinking (48). However, this was not the most ideal setup for a series of reasons. Firstly,
the internal  environment  of the bone would contain blood that  cannot be easily removed
during the surgical intervention,  which is a significant difference compared to other areas
such as cartilage  (48) and could result in diffusion of the precursor solution. This diffusion
would influence the crosslinking process and release GFs, macromer and photoinitiators into
the body in an unwanted manner. Secondly, the PVA-Tyr and gelatin precursor solution is
not highly viscous, making it more susceptible to this unwanted diffusion. Thirdly, the depth
of the hole could result in uneven crosslinking of the scaffold in the deeper areas due to the
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limitations in light penetration (49). Therefore, the possibility to crosslink the hydrogel before
injecting it into the area of interest was explored. The precursor solution was successfully
crosslinked inside a syringe and then injected into a Jamshidi needle, which enabled pushing
it out into the area of interest using the internal cannula of the needle (Figure 4.7). 
Figure  4.7.  Crosslinking  and  injection  of  PVA-Tyr  with  gelatin  and  VEGF using
standard surgical tools for its evaluation in a model of avascular necrosis. The first
step was to crosslink the precursor solution inside a syringe, followed by loading of the
crosslinked hydrogel into a Jamshidi needle. The needle is then inserted into the area of
interest and the hydrogel is pushed out using the inner cannula. 
This procedure avoids the risk of unwanted diffusion and uneven crosslinking during the
surgical  procedure.  Furthermore,  it  facilitated  the  preparation  of  the  samples  before  the
intervention, as sterile syringes loaded with the crosslinked polymer could be brought to the
intervention site fully prepared to load into the Jamshidi needle. This is the first instance of
PVA-Tyr  hydrogels  being  evaluated  as  an  injectable  system,  which  opens  the  door  to
potential clinical translation. 
4.3.6. Preliminary Results of the In Vivo Study
After  the  system  was  fully  adapted  for  its  delivery  into  the  femoral  head,  the  surgical
procedure for a pilot in vivo study on the effectiveness of the PVA-Tyr GF delivery system to
promote revascularisation of the femoral head was performed. The proximal part of the femur
was harvested 15 weeks after the surgery, samples were imaged and CT scans were taken.
Figure 4.8 includes a reduced version of the results including an image for each of these
groups and levels of deformity, and supplementary figures S4.1-5 include the images of all
the samples in the experiment for extended information. Both types of imaging revealed that,
in a high percentage of the samples where the blood flow had been disrupted, the spherical
morphology of the femoral head was completely altered and in some samples the femoral
head had fallen apart from the femoral body due to tissue necrosis. This level of deformation
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has not been reported in previous instances of this model  (39–41). An explanation for that
could be the fact that both legs were operated for each piglet, which could have resulted in an
unwanted  weight  overload  of  the  avascular  femoral  heads  and  increased  deformities  as
compared to other studies. 
In accordance with these observations,  samples were classified in  three categories  (Table
4.1). When the femoral head showed normal external morphology and size and its general
features could be identified in the CT scans, it was classified as a ‘healthy femoral head’.
When the femoral head presented alterations in shape and/or size but was still identifiable in
the general images or CT scans, it was classified as ‘deformed femoral head’. Finally, when
no structures could be identified as the femoral head through neither general imaging nor CT,
the sample was classified as ‘femoral head cannot be identified’. The classification revealed
that 100% of the non-operated femoral heads had a healthy morphology, whereas 0% of the
femoral heads in the ‘vessels disrupted’ group could be identified. This result demonstrates
that the blood flow was successfully disrupted in the ‘vessels disrupted’ group and the model
was executed successfully. Samples in the sham group lost the femoral head in 75% of the
cases,  which could be a sign that  the blood vessels  from the femoral  body were able to
migrate towards the femoral head thanks to the drilled hole. Injecting PVA-Tyr hydrogels
with incorporated 1wt% gelatin (PVA-Gel) hydrogels with or without VEGF into the drilled
hole further reduced the loss of femoral head to 62.5% regardless of the presence of VEGF.
While there appears to be an increasing trend in the maintenance of the femoral head when
drilling the hole and delivering the hydrogel, the number of samples was not high enough to
provide  statistical  significance  and  the  imaging  should  be  followed  up  with  quantitative
analysis. It is possible that the excessive deformation of the femoral heads interfered with the
results, making them harder to interpret. 
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Figure 4.8. Example images of the femoral heads after the surgical intervention and treatment with
PVA-Tyr hydrogels. General images (Left row), CT images (Middle row) and hematoxylin-eosin staining of
the histological sections (Right row). No operation: positive control  with no surgical procedure.  Vessels
disrupted: The blood supply to the femoral head was disrupted. Sham: The blood supply to the femoral head
was disrupted and a hole was drilled from the body to the centre of the femoral head. PVA-Gel: The blood
supply was disrupted, the hole was drilled and a 5wt% PVA-Tyr + 1wt% Gelatin (PVA-Gel) hydrogel was
delivered. PVA-Gel + VEGF: The blood supply was disrupted, the hole was drilled and a 5wt% PVA-Tyr +
1wt% Gelatin (PVA-Gel) + VEGF hydrogel was delivered. White and black arrows indicate the spot where
the femoral head should be and the fallen necrotic femoral head. The white dashed arrow indicates the
surface on which the sample was imaged.
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No operation 2 2 0 0 0
Vessels disrupted 4 0 0 4 100
Sham 4 0 1 3 75
PVA-Gel 8 0 3 5 62.5
PVA-Gel-VEGF 8 0 3 5 62.5
Overall, while these results do not demonstrate that delivery of PVA-Tyr with encapsulated
VEGF  improved  the  vascularisation  in  the  femoral  head,  the  delivery  of  the  hydrogels
resulted in an increasing  trend to  maintain  the femoral  head as  compared to  its  negative
controls. To provide detailed information on the effects of the treatments, further analysis of
the  vessel  density  and  diameter  will  be  performed  in  the  histological  images.  Other
characteristics of the tissue such as the quality of the cartilage in the joint and in the growth
plate will also be evaluated using Safranin O staining  (53), together with the presence of
necrotic and fibrotic tissue in the area. If these quantifications provide evidence indicating
positive  effects,  it  will  be necessary to  perform follow-up experiments  with an improved
setup  and  increased  number  of  samples  to  generate  statistically  relevant  numbers.
Furthermore,  it  will  be  important  to  determine  the  adequate  concentration  of  VEGF  to
promoter angiogenesis while avoiding side effects such as edema.
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4.4. Conclusions
In  this  chapter,  the  PVA-Tyr  system  was  adapted  to  promote  vascularisation  in  a  very
specific clinical setting, to revascularise the femoral head in cases of Perthes disease. 
Firstly, the ability of the system to directly interact with cells in the surrounding environment
was improved. The ability of PVA-Tyr to bind to any tyrosine-containing protein allowed
incorporation of gelatin into the hydrogels, which promoted the attachment of endothelial
cells when incorporated at a concentration of 1wt% or higher. It was demonstrated that the
incorporation of 1wt% gelatin didn’t affect any of the key attributes of PVA-Tyr hydrogels
(degradation time, resistance to protease degradation and controlled release time frame of
GFs), which shows the ability of the system to incorporate multiple proteins at the same time
while still controlling the release of loaded GFs. 
Secondly,  the  system  was  adapted  to  the  specific  surgical  procedure  and  tools  used  by
performing the photo-crosslinking prior to the injection into the site of injury, which avoided
unnecessary  risks  such  as  uneven  crosslinking  or  burst  release  into  the  body.  It  was
demonstrated  that  the  PVA-Tyr  system  can  be  utilised  as  an  injectable  system,  easily
moulded into various shapes and further administered to designated locations in the body.  
Finally,  PVA-Tyr hydrogels with incorporated gelatin and VEGF were applied in a large
mammalian  in vivo model of avascular necrosis. While the data is still not conclusive and
needs to be further analysed, there seems to be a tendency to improve the maintenance of the
femoral head after injection of the PVA-Tyr hydrogels.
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4.5. Supplementary Information
Supplementary Figure S4.1. Images of the femoral heads at the end of the experiment
in the “No Operation” group. General images (Left row) and CT images (Right row) 15
weeks after interventions. This group was the  positive control with no surgical procedure. 
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Supplementary Figure S4.2. Images of the femoral heads at the end of the experiment
in the “Vessels Cut” group. General images (Left and middle right rows) and CT images
(Middle left and right rows) 15 weeks after interventions. In this group, the blood supply to
the femoral head was disrupted.
Supplementary Figure S4.3. Images of the femoral heads at the end of the experiment
in the “Sham” group. General images (Left and middle right rows) and CT images (Middle
left  and right rows) 15 weeks after interventions.  In this group, the blood supply to the
femoral  head was disrupted and a hole was drilled  from the body to  the  centre  of  the
femoral head.
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Supplementary Figure S4.4. Images of the femoral heads at the end of the experiment
in the “PVA-Gel” group. General images (Left and middle right rows) and CT images
(Middle left and right rows) 15 weeks after interventions. PVA-Gel: The blood supply was
disrupted, the hole was drilled and a 5wt% PVA-Tyr + 1wt% Gelatin (PVA-Gel) hydrogel
was delivered.
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Supplementary Figure S4.5. Images of the femoral heads at the end of the experiment
in the “PVA-Gel-VEGF” group. General images (Left  and middle right rows) and CT
images (Middle left and right rows) 15 weeks after interventions. PVA-Gel + VEGF: The
blood supply was disrupted, the hole was drilled and a 5wt% PVA-Tyr + 1wt% Gelatin
(PVA-Gel) + VEGF hydrogel was delivered.
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Chapter 5. Biofabrication of Multi-Scale
Vascularised Tissues with Controllable 3D
Architecture
5.1. Introduction
o  avoid  the  formation  of  a  necrotic  core  within  the  tissue  engineered  constructs,  it  is
necessary to generate a blood vessel network throughout the scaffold that provides a steady
supply of oxygen and nutrients.Efforts to reproduce blood vessel networks within engineered
tissues have followed two main routes: top-down strategies, which involve fabrication of pre-
designed structures;  and bottom-up strategies,  which aim to stimulate  endothelial  cells  to
form a micro-capillary network by providing a suitable microenvironment (1). 
Top-down strategies have been successful in reproducing vessel-like structures at a larger
scale, generally between 100 and 800 μm in diameter (3–5). The fabrication procedure often
starts by generating an initial 3D channel network using a sacrificial material, which is then
embedded in  the material  of  interest.  The channel  network is  then  perfused with  culture
media  to  remove  the  sacrificial  material  (4).  Other  fabrication  technologies  such  as
lithography can also be used to generate this initial channel network  (5). Regardless of the
fabrication method, the channels need then to be perfused with endothelial cells to form a cell
monolayer covering its internal surface (4–7). This process, called endothelialisation, reduces
the  permeability  of  the  channels  (4) and  inhibits  platelet  attachment  (5) in  a  way  that
resembles native vessels. For example, Kolesky et al. successfully generated large engineered
constructs with vascularised channels by co-printing Pluronic F127 as a sacrificial ink and a
gelatin-based  MSC-laden  bioink  (4).  After  removal  of  the  sacrificial  structure  and
endothelialisation of the channels by perfusing HUVECs, the encapsulated MSCs were able
to receive oxygen, nutrients and osteogenic differentiation factors in the media that allowed
for  improved  osteogenic  differentiation  as  compared  to  a  control  without  the  fabricated
microchannels.  However,  this  type  of  techniques  fail  to  reproduce  the  density  and small
diameter of capillaries in native tissues due to lack of resolution in the fabrication techniques
and limitations in the diameter needed for perfusion of endothelial  cells  (1). Furthermore,
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they generally do not provide measurements demonstrating that the oxygen and nutrients are
reaching the entirety of the construct, which is the main problem targeted by vascularised
tissue engineering.
Bottom-up strategies have been able to generate vessels that are more similar to capillaries in
size and structure. The process involves encapsulating endothelial cells and pericyte-acting
support cells in a hydrogel matrix (generally fibrin or collagen) and then stimulating them
with the right combination of growth factors so that they self-assemble into micro-capillary
networks  (8).  The  resulting  networks  are  lumenised  and  have  a  high  density  of  micro-
capillaries that present a tunica intima, pericytes and a basal membrane, mimicking native
capillary networks (9,10). These networks have shown the ability to anastomose with the host
vessel network post-implantation  (11–13), which is promoted by  in vitro maturation  pre-
implantation  (14). However, the majority of studies on pre-vascularisation focus on small
tissue analogues, missing a key step towards the translation to a clinical setting (10,14–17).
For  example,  Ben-Shaul  et  al.  studied  the  invasion  of  host  vessels  into  fibrin  hydrogels
containing  encapsulated  endothelial  cells  and  fibroblasts  after  implantation  in  mice  (14).
When comparing samples that had undergone different time periods of in vitro maturation (1
day or 14 days, which were considered not pre-vascularised or pre-vascularised respectively),
they found that the implantation of pre-vascularised samples resulted in improved host vessel
penetration  and  decreased  clot  formation  as  compared  to  samples  that  were  not  pre-
vascularised.  While  this  study generated  very valuable  information  and demonstrated  the
potential of this type of approaches, the samples were discs of 1mm thickness and 6 mm
diameter that only contained 7 μL of fibrin with encapsulated cells, which is very far from the
size needed for translation to larger mammals. It is also worth noting that the invasion of host
vessels starts at the external areas of the constructs and progresses towards the centre  (14),
making  size  and surface-volume ratio  key parameters  to  consider  when scaling  up  these
techniques. It has been shown that the implantation and anastomosis of vascularised small
tissues improves oxygen diffusion in vivo (13), but this advantage remains to be demonstrated
for larger tissue analogues.
Thus, the translation of present technologies to the generation of large, vascularised tissues
still  remains  a  challenge.  While  top-down strategies  are  limited  by  the  resolution  of  the
fabrication  technique  and  thus  struggle  to  generate  capillary-like  networks,  bottom-up
strategies have not been demonstrated to enable the generation of larger channels and larger
tissues.  To  generate  large  tissue  analogues  that  recapitulate  the  different  levels  of
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microcirculation found in native tissues, a logical step forward would be to combine both
vascularisation strategies.  This could be done by pre-fabricating a channel network into a
material that can enable pre-vascularisation. However, materials that are adaptable to either
of these strategies require very specific characteristics that are generally not overlapping. On
one hand, top-down fabricated constructs need to retain their predesigned 3D architecture and
their channel network (shape fidelity) during the endothelialisation process and the culture
period,  which  requires  the  material  to  display  a  certain  level  of  stiffness.  The
endothelialisation  of  the  fabricated  channels  is  also  promoted  by  materials  with  higher
stiffness (18,19). On the other hand, materials used in bottom-up strategies have to provide
very specific conditions to endothelial cells to allow cell migration and promote their self-
assembly into micro-capillaries. Hydrogels derived from extracellular matrix, like fibrin and
collagen, have been the most extensively used for these strategies as they provide bioactive
sequences that induce the desired cell behaviour (9,13,20). A key condition for a material to
be  adaptable  to  pre-vascularisation  techniques  is  that  it  needs  to  be  mechanically  soft
generally  below 5 kPa of compression modulus  (18,21,22),  which is  in contrast  with the
higher stiffness needed for 3D shape fidelity of the constructs. It has been shown that small
changes in the polymer concentration (wt%) have a significant impact on the quality of the
developed micro-capillary network (23,24), highlighting how specific these conditions need
to be. Furthermore, during micro-capillary formation, the high degree of cell activity results
in high ECM remodelling and the generation of forces  that can result in contraction of the
hydrogel  (25,26). This phenomenon has been under-reported as pre-vascularisation studies
generally focus on generating discs of small size. However, it has significant implications
when  these  materials  are  translated  to  the  fabrication  of  larger  tissues  with  controlled
architectures through top-down strategies, as it compromises shape fidelity and the required
perfusion of media and endothelial cells into the sample. Thus, there is a difficult balance to
be achieved, especially in terms of mechanical properties, making the combination of bottom-
up and top-down techniques a challenging task.
The chemical modification of bioactive, low-cost materials such as gelatin in combination
with  fast  and  tailorable  crosslinking  techniques  such  as  photo-crosslinking  has  been
previously  applied  to  in  vitro pre-vascularisation  approaches  (18,22,27,28).  For  example,
Chen et al. demonstrated that endothelial colony forming cells (ECFCs) and bone marrow-
derived mesenchymal stem cells (MSCs) co-encapsulated in gelatin-methacryloyl (GelMA)
were  able  to  form  lumenised  capillary-like  structures  when  hydrogels  with  very  low
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compressive modulus (2 kPa) were fabricated  (22). However, none of these materials have
been applied to the fabrication of large tissues that are pre-vascularised and also include a
controllable channel network. The combination of photo-crosslinking and thiol-ene chemistry
for hydrogel fabrication enables very precise tailoring of the network crosslinking density and
the physico-mechanical properties of hydrogels, and has proven to be a promising strategy for
biofabrication techniques that would allow fabricating channel networks and scaling up to
large tissues (29).
The  aim  of  this  chapter  is  to  generate  large  vascularized  tissues,  using  both  top-down
fabricated endothelialised channels and bottom-up self-assembled micro-capillary networks,
utilising a single material platform. A combination of Gelatin-Norbornene (Gel-NOR) with
the  visible-light-activated  photoinitiator  system  Ruthenium  and  Sodium  Persulphate
(Ru/SPS) is used for hydrogel fabrication. By finely tailoring the crosslinking parameters, the
possibility to enable both the formation of micro-capillary networks and the fabrication of
constructs with a complex 3D architecture using a single material platform is demonstrated.
Furthermore,  this  platform  is  used  to  investigate  the  effects  of  pore  diameter  and  fiber
diameter on the formation of micro-capillary networks, as well as endothelialisation of the
fabricated channels.
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5.2. Materials and Methods
5.2.1. Materials
Type A gelatin  from porcine skin,  sodium hydroxide,  dialysis  tubing (MWCO 6-8 kDa),
dithiothreitiol  (DTT),  Tris(2,2′-bipyridyl)dichlororuthenium(II)  hexahydrate  (Ru),  sodium
persulfate (SPS), L-ascorbic acid-2-phosphate (ASAP) and Pluronic® F-127 were purchased
from Sigma-Aldrich. Carbic anhydride was purchased from Acros Organics.
5.2.2. Methods
5.2.2.1. Gelatin Modification 
Gelatin  was  dissolved  in  PBS  (Gibco)  (10wt%,  50  °C)  prior  to  the  addition  of  carbic
anhydride up to a 20wt% concentration. 10 M NaOH was added dropwise (1 mL of NaOH
per 10 mL of 10wt% gelatin) to dissolve the carbic anhydride, and pH was adjusted to 8. The
reaction  continued  for  24  h  at  50  °C  and  the  resulting  solution  was  centrifuged.  The
supernatant  was dialyzed  (MWCO 6-8 kDa) against  deionized  water.  The products  were
freeze-dried and stored at room temperature until use. The DoM was determined to be 27%
on 1H-NMR spectroscopy and fluoroaldehyde assay.
5.2.2.2. Hydrogel Fabrication
Cell-free hydrogels were prepared in PBS. A Gel-NOR precursor solution was mixed with
DTT and Ru/SPS to obtain a final concentration of 5wt% Gel-NOR, functional group ratios
of 1:1-1:24 (NOR:SH) and 0.1/1 to 2/20 mM of Ru/SPS. Samples were photo-crosslinked
using visible light (OmniCure® S1500, Excelitas Technologies with a Rosco IR/UV filter
400 – 450nm, 3min, 300 mW cm-2) in cylindrical moulds (h = 1 mm, Ø = 5 mm) in an open
environment. 
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5.2.2.3. Swelling and Mass Loss Assays
After crosslinking, each hydrogel was weighed (minitial,t0 ), out of which three samples per
hydrogel composition were directly freeze-dried to record their initial dry weights (mdry,t0)
and determine the actual  macromer weight fraction,  which is reported as the ratio of the
initial dry weight to the initial weight. To determine the initial dry weight of the remaining
samples, the factor of the actual macromer fraction and individual initial weight was used
(Eq. 1). 
Actualmacromer fraction=
mdry , t 0
minitial
(1)
The remaining samples were allowed to swell in PBS at 37 ºC for up to 1d. Swollen hydrogel
samples were collected to record wet weight (mswollen). The samples were then freeze-dried to
obtain the freeze dried weight (mdry) and calculate the sol fraction and mass swelling ratio (q)
according to equations 2, 3 and 4: 









The sol fraction of the hydrogels is defined as percent macromers that are not crosslinked into
the hydrogel network, and determined as the mass loss after equilibrium swelling (t = 1 d). 
5.2.2.4. Mechanical Testing
The compressive modulus of the hydrogel discs was measured using an MTS Criterion® 42
mechanical  testing  machine  equipped  with  a  5N  load  cell,  at  RT  in  an  unconfined
environment. The engineering stress-strain profile was obtained by uniaxial compression and







Chapter 5: Biofabrication of Multi-Scale Vascularised Tissues with Controllable 3D Architecture
5.2.2.5. Cell Expansion
Human umbilical vein endothelial cells (HUVECs, obtained from ATCC) were cultured in
Vascular  Basal  Media  (ATCC)  supplemented  with  Endothelial  Cell  Growth  Kit-VEGF
(ATCC) and Penicillin/Streptomycin (Referred to as endothelial growth media, EGM). Bone
marrow-derived mesenchymal stem cells (MSCs, obtained from RoosterBio) were cultured in
α-MEM  (Gibco)  supplemented  with  10%  foetal  calf  serum  (Hyclone),  1%
penicillin/streptomycin, 20 mM of ASAP and 5 ng/mL basic fibroblast growth factor (R&D
Systems).
5.2.2.6. Fabrication and Culture of Cell-Laden Hydrogels
Passage 2 to 3 HUVECs and passage 3 MSCs were trypsinized and encapsulated in Gel-NOR
(5wt% Gel-NOR, DTT at 1:4 SH:NOR ratio, 0.2/2 to 1/10 mM Ru/SPS)  or Matrigel at a
concentration of 5M HUVECs and 1M MSCs/mL and cultured up to 14 days in EGM.
5.2.2.7. 3D Biofabrication of Gel-NOR Constructs with Controlled Porosity 
Large  Gel-NOR  constructs  with  an  interconnected  porous  network  were  biofabricated
through a sacrificial templating method. Pluronic® F-127 (30wt%) was extruded through a
needle at a temperature of 25°C using a BioScaffolder (SYS+ENG, Germany) and deposited
onto a 30°C plate in a layer-by-layer, 0-90° orientation, with Pluronic® F-127 fibre diameter
depending on needle  size and printer  settings  (Table  5.1).  Fibre spacing was adjusted to
match the fibre diameter.



















0.5 0.5 0.3 (23G) 700 8 100
0.75 0.75 0.6 (21G) 500 9 110
1 1 0.9 (19G) 300 13 130
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A  Gel-NOR solution  (5wt%  Gel-NOR,  1:4  SH:NOR  ratio  of  DTT,  0.2/2  or  0.5/5  mM
Ru/SPS,  10*106 HUVECs/mL,  2*106 MSCs/mL)  was  dispensed  throughout  the  printed
construct  using  a  pipette  and  photopolymerised  (400  –  450nm,  3min,  300  mW  cm -2).
Subsequently,  the construct was immersed in cold EGM to dissolve the Pluronic® F-127
scaffold, after which the construct was cultured in EGM (37°C, 20% O2, 5% CO2) for up to
14 days.  The resulting constructs  had a  pore diameter  equal  to the fiber  diameter  of the
printed Pluronics sacrificial template, and a fiber diameter equal to the fiber spacing of the
Pluronics sacrificial template.
5.2.2.8. Viability Assays
Live/dead staining was used to visualize cell viability of encapsulated cells on day 1. In brief,
hydrogel samples were washed with PBS, cut in half, and were incubated with propidium
iodide (1.5 μM, from Invitrogen) and calcein-AM (1 μM, from Invitrogen) in PBS for 15 min
at  RT.  The  samples  were  then  washed with  PBS and left  hydrated  for  imaging  using  a
fluorescent microscope (Zeiss Axioimager Z1 microscope). Live and dead cells were counted
at three locations within the centre of each construct per time point using Image J (version 6.1
Fiji, National Institutes of Health). Viability was calculated using equation 6:
Cell viability (% )=100 x Live cells
(Live cells+Dead cells )
(6)
5.2.2.9. DNA Quantification
Hydrogels were digested at 56° in 1 mg mL-1 proteinase K dissolved in a 10-2 M Tris-HCl
and  103  M disodium  EDTA  solution,  following  a  treatment  with  DNase-free  RNase  A
(Thermo Fisher). Total DNA was quantified using CyQUANT Cell Proliferation Assay Kit
according to manufacturer’s instructions.
5.2.2.10. Metabolic Activity Assays
AlamarBlue® was used to track the cellular health of embedded cells on days 1, 4, 7, 10 and
14.  Briefly,  each  hydrogel  sample  was  incubated  with  350  μL  media  containing
AlamarBlue®  solution,  diluted  according  to  manufacturer’s  instructions,  for  3h.  The
reduction  of  AlamarBlue®  in  the  solution  was  determined  by  reading  absorbance  at
wavelengths of 570 nm and 600 nm using a spectrophotometer (Thermo Scientific Varioskan
Flash,  Darmstadt,  Germany)  followed  by  data  processing  according  to  manufacturer’s
instructions.
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5.2.2.11. Immunofluorescence Examination
Cell-laden hydrogels were collected after 10 and 14 days, washed in PBS, followed by a
fixation in 4% formaldehyde for 45 min at RT. Constructs were then cut in half, blocked with
a solution  of  PBS and 2% BSA for  1h at  RT and permeabilized  using a  0.2% Triton-X
solution.  Primary  anti-CD  31  and  α-Smooth  muscle  actin  (α-SMA)  antibodies  (R&D
Systems) were diluted in blocking buffer (1:100) and applied overnight at 4°C. Samples were
washed three times in 2% BSA for 30 minutes each, followed by an incubation with a goat-
anti-mouse (Alexa Fluor 488, Lifetech) and donkey-anti-rabbit  (Alexa Fluor 594, Abcam)
secondary antibodies diluted in blocking buffer (1:500) in the dark overnight at 4°C. Samples
were then washed 3 times in PBS during 30 min, incubated in a DAPI (1:1000) solution for 2
min and washed three times in PBS. Images were captured using either a Leica TCS SP5
confocal  microscope  (Leica  camera  AG,  Wetzlar,  Germany)  or  a  Zeiss  Axioimager  Z1
fluorescence microscope (Carl  Zeiss Microscopy, Jena,  Germany).  The stages of network
development  in  Gel-NOR samples  were  described  following  previously  reported  criteria
(8,20).
5.2.2.12. Endothelial Cell Network Quantification
Endothelial  cell  networks  were  quantified  from  the  CD31  immunofluorescence  images
obtained on days 10 and 14. The maximum intensity projection was obtained from 100 µm Z-
stacks in 3 different areas of each sample and the total vessel length and number of junctions
were quantified using AngioTool software. 
5.2.2.13. Statistical Analysis
All samples were prepared in triplicates and each experiment was repeated 3 times to study
variability  between  experiments  (N=3)  unless  stated  in  the  specific  figure. Individual
differences between groups and time points were assessed using one or two-way ANOVA
and Holm-Sidak post hoc analysis (GraphPad Prism 7). Statistical significance was accepted
at p<0.05. 
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5.3. Results and Discussion
5.3.1. Effects of NOR:SH Ratio on the Crosslinking Efficiency of Gel-NOR Hydrogels
Using thiol-ene chemistry for hydrogel crosslinking allows the tailoring of a large number of
variables in order to obtain the desired hydrogel physico-mechanical properties. Parameters
such  as  the  macromer  concentration,  degree  of  functionalisation  and  photoinitiator
concentration, which can be modified in other crosslinking chemistries such as methacryloyl-
based reactions (15), are added to parameters such as the concentration, molecular weight and
degree  of  functionalisation  of  the  crosslinker  (29–31).  Crosslinking Gel-NOR is  possible
using different thiol-containing molecules, including short molecules with two thiol groups
such as dithiothreitol (DTT)  (31) or larger molecules with a higher number of thiol groups
such as modified 4-arm poly(ethylene glycol)  (30–32). Munoz et al. reported that Gel-NOR
crosslinked using DTT as a crosslinker resulted in lower mechanical properties than Gel-
NOR crosslinked using  thiolated  PEG-tetra-thiol  (31).  Given that  our  aim is  to  generate
hydrogels with low physico-mechanical properties, DTT was selected as the crosslinker. To
start  studying the  network  properties  of  hydrogels  fabricated  under  different  crosslinking
conditions,  Gel-NOR hydrogels were fabricated using different  DTT concentrations  using
5wt% Gel-NOR and 0.5/5 mM Ru/SPS.  Mass  loss  and swelling  studies  revealed  a  bell-
shaped pattern, where the lowest sol fraction and swelling ratio were measured in hydrogels
crosslinked  using  1:4  NOR:SH  ratio  (Figure  5.1).  These  results  are  in  agreement  with
previous research using thiol-ene chemistry (gelatin functionalized with allyl glycidyl ether,
Gel-AGE) and Ru/SPS as a photoinitiator system, which show that changing the ene:thiol
ratio results in a similar bell-shaped curve of crosslinking efficiency (29). Lower sol fraction
values are the result of a more efficient crosslinking reaction. When bioactive agents such as
cells  or  drugs  are  encapsulated  into  a  hydrogel,  a  key  determinant  of  the  encapsulation
efficiency is the crosslinking efficiency,  where lower crosslinking efficiency results in an
increased loss of encapsulated bioactive agent  (33). Therefore, subsequent characterisation
was performed using the crosslinking condition that resulted in the lowest sol fraction (1:4
NOR:SH ratio).
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Figure 5.1. Effects of the Norbornene:Thiol ratio on the physico-chemical properties of
Gel-NOR hydrogels. (A) Sol fraction and (B) swelling ratio of 5wt% Gel-NOR hydrogels
crosslinked  using  different  Norbornene:Thiol  (NOR:SH)  concentrations.  Ru/SPS
concentrations were kept to 0.5/5 mM in all  conditions.  Significant  differences  (p<0.05)
were found between all conditions except when comparing 1:6 with both 1:1 and 1:2 in sol
fraction,  and  1:2  with  1:6  in  swelling  ratio.  *:  Significant  difference  between  groups
(p<0.05). #: Significant difference (p<0.05) as compared to all other groups. Experiments
were repeated 3 times with 3 technical repeats each (N=3).
5.3.2. Effects of Ru/SPS Concentration on the Physico-Mechanical Properties of Gel-
NOR Hydrogels
To study how the Ru/SPS concentration can affect the physico-mechanical properties of Gel-
NOR hydrogels, Gel-NOR discs were fabricated using 5wt% Gel-NOR, 1:4 NOR:SH and a
range of Ru/SPS concentrations. Their sol fraction, swelling ratio and compressive modulus
were  measured  (Figure  5.2).  Increasing  the  Ru/SPS  concentration  resulted  in  lower  sol
fraction and swelling ratio, ranging from 45% to 11% sol fraction when crosslinked using
0.1/1 and 0.5/5 mM Ru/SPS respectively.  Further increasing the Ru/SPS concentration to
2/20  mM did  not  result  in  lower  sol  fraction.  Increasing  the  Ru/SPS  concentration  also
increased the compressive modulus, ranging from 4 kPa to 9 kPa when crosslinked using
0.1/1  and  1/10  mM  Ru/SPS,  respectively.  However,  further  increasing  the  Ru/SPS
concentrations resulted in a decrease in compressive modulus. Previous literature studying
photo-crosslinked  hydrogels  for  pre-vascularisation  purposes  have  shown positive  results
when their compressive modulus was ≤5 kPa (18,21,22,27). Therefore, Gel-NOR hydrogels
crosslinked using 0.2/2 mM Ru/SPS, which showed a compressive modulus of 5.5 kPa, were
selected to continue with cell encapsulation. To study the effects of compressive modulus and
Ru/SPS concentration in the pre-vascularisation process, hydrogels crosslinked using 0.5/5
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and 1/10 mM Ru/SPS were also included in the experiments. Hydrogels crosslinked using
0.1/1 mM Ru/SPS were not included due to their high sol fraction, as they would result in a
lower cell encapsulation efficiency.
Figure 5.2. Effects of the Ru/SPS concentration on the physico-mechanical properties
of Gel-NOR hydrogels. (A) Sol fraction, (B) swelling ratio and (C) compression modulus of
5wt% Gel-NOR hydrogels crosslinked using DTT 1:4 NOR:SH ratio and a range of Ru/SPS
concentrations.  *:  p<0.05.  #:  Significantly  different  (p<0.05)  to  all  other  groups.
Experiments were repeated 3 times with 3 technical repeats each (N=3).
5.3.3. Effects of Ru/SPS Concentration and Physico-Mechanical Properties of Gel-NOR
Hydrogels on Survival and Proliferation of HUVECs and MSCs
HUVECs (5M cells/mL) and human bone marrow-derived MSCs (1M cells/mL) were co-
encapsulated  in  either  Gel-NOR using  different  Ru/SPS  concentrations  or  Matrigel  as  a
control group. Matrigel was chosen a s positive control due to its demonstrated ability to
allow co-encapsulated endothelial  cells  and support cells  to form capillarie-like structures
(52). Cell viability was measured on day 1 post-encapsulation, and total DNA content and
metabolic activity were measured on days 1, 4, 7, 10 and 14 of culture (Figure 5.3). It was
observed that cell viability decreased from 83% to 74% when Ru/SPS concentrations were
increased from 0.2/2 mM to 0.5/5 mM  Ru/SPS, and cell viability further decreased to 54%
when Gel-NOR hydrogels were crosslinked using 1/10 mM  Ru/SPS . These results suggest
that increasing the Ru/SPS concentrations results in decreased cell viability,  which differs
from previous research encapsulating human articular chondrocytes (HAC) in either Gel-MA/
Collagen using up to 2/20 mM Ru/SPS (34)  or Gel-AGE using 1/10 mM Ru/SPS (29), where
cell viability was >80%. Possible explanations of these differences are either lower gelatin
concentration  used  in  our  study,  which  would  reduce  its  free  radical  scavenging  effects
(35,36), or differences in sensitivity to free radical damage between cell types, which has
previously  been  reported  between MSCs and HUVECs when  exposed to  H2O2 (37).  No
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significant  differences  were found when comparing  co-cultures  encapsulated in Gel-NOR
hydrogels crosslinked using 0.2/2 Ru/SPS with the Matrigel control. 
Total DNA measurements showed a significant decrease in days 1 and 4 for all experimental
groups (p<0.05). This result could be explained by an initial differentiation process, and has
been previously reported in co-cultures of HUVECs and MSCs encapsulated in GelMA (38).
Interestingly,  on  days  1  and  4,  despite  the  differences  in  cell  survival,  no  significant
differences  in  total  DNA  were  observed  between  Gel-NOR hydrogels  crosslinked  using
different Ru/SPS concentrations. Total DNA content remained stable from day 4 to day 10
for  all  Gel-NOR groups,  followed  by an  increase  between  days  10 and 14 in  hydrogels
crosslinked using 0.2/2 and 0.5/5 mM Ru/SPS. Total DNA in Matrigel controls showed  a
increasing trend at each time point between days 4 and 14. On day 14, Matrigel showed the
highest total DNA content per sample (1.16 µg, p<0.05), followed by Gel-NOR crosslinked
using 0.2/2 and 0.5/5 mM Ru/SPS with 0.73 and 0.84 µg respectively (with no significant
differences between these two groups), and finally Gel-NOR crosslinked using 1/10 mM Ru/
SPS with an average of 0.47 µg per sample. The fact that Matrigel is the group with the
highest  total  DNA  from  day  7  onwards  could  be  caused  by  the  presence  of  bioactive
components  in  the  material  such  as  growth  factors,  which  could  result  in  increased
stimulation  of  cell  proliferation  (39).  These  results  suggest  that  the  initial  differentiation
phase could be followed by a slow proliferation phase, with both phases being affected by
differences in mechanical properties, crosslinking density and the presence of bioactive cues
in the hydrogels. 
Metabolic activity measurements revealed that Gel-NOR groups maintained stable levels of
metabolic activity during the culture period, except for a significant decrease in 0.2/2 Ru/SPS
samples between days 1 and 4 and a significant increase in 1/10 Ru/SPS samples between
days  7  and  10  (p<0.05).  At  the  end  of  the  experiment,  all  Gel-NOR  groups  showed
comparable  levels  of metabolic  activity.  Matrigel  groups,  however,  showed an increasing
trend throughout the whole experiment, and had significantly higher metabolic activity than
Gel-NOR groups at day 14 (p<0.05). After normalization to DNA, metabolic activity shows
different trends depending on the experimental group. While both Matrigel and Gel-NOR
1/10 mM Ru/SPS show an increasing trend throughout the whole experiment, both Gel-NOR
groups crosslinked using 0.2/2 and 0.5/5 mM Ru/SPS show a slightly decreasing tendency.
On day 14, all groups showed comparable results (p>0.05) except for Gel-NOR 1/10 mM Ru/
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SPS, which displayed significantly higher metabolic activity. These differences in metabolic
activity could be explained by differences in general cell behaviour, which are further studied
in section 5.3.4. An interesting observation is the fact that Matrigel samples show a lower
normalised metabolic activity as compared to Gel-NOR groups, but at the same time show
higher total DNA counts and overall metabolic activity. A potential explanation to that is that
HUVECs and MSCs could be behaving differently within the samples. Endothelial cells in
Matrigel could be differentiating more quickly during the first days of culture as compared to
Gel-NOR groups,  resulting  in  the  observed  drop  of  DNA  content  and  the  lower  initial
normalised metabolic activity. On the other hand, the population of MSCs in Matrigel could
be proliferating at a faster rate than in Gel-NOR samples, resulting in the steady increases in
total DNA and normalised metabolic activity seen in the experiment. These differences in cell
behaviour could be caused by the presence of bioactive cues in Matrigel hydrogels (39).
Figure 5.3. Effects of the Ru/SPS concentration on the cell survival, proliferation and metabolic
activity of HUVEC/MSC co-cultures encapsulated in Gel-NOR hydrogels. (A) Cell viability, (B)
DNA quantification and (C) metabolic activity of co-encapsulated human umbilical vein endothelial
cells (HUVEC) and human bone marrow-derived mesenchymal stem cells (MSCs) in either 5wt% Gel-
NOR hydrogels crosslinked using DTT  1:4 NOR:SH ratio and a range of Ru/SPS concentrations or
in Matrigel. #: Significantly different (p<0.05) to all other groups. Experiments were repeated 3 times
with 3 technical repeats each (N=3).
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5.3.4. Effects of Ru/SPS Concentration and Physico-Mechanical Properties of Gel-NOR
Hydrogels on Capillary-Like Network Development and Shape Fidelity
Previous studies on pre-vascularisation of hydrogels have showed micro-capillary network
formation  of  co-encapsulated  endothelial  cells  and  support  cells  at  days  10  (18) and  14
(10,16,17,40) of culture. Some studies have also shown improvement of the micro-capillary
network when comparing samples cultured during 7 and 14 days on both fibrin  (10) and
photo-crosslinked PEG (17). The effects of Ru/SPS concentrations and mechanical properties
of the hydrogels on the micro-capillary  networks formed by the encapsulated co-cultures
were studied by CD31 immunostaining of the hydrogels on days 10 and 14 of culture (Figure
5.4A). At both time points, Gel-NOR hydrogels crosslinked using 0.2/2 mM Ru/SPS and
Matrigel constructs showed fully interconnected networks whereas 0.5/5 mM gels show a
partially connected network. Endothelial cells on the surface of Gel-NOR 1/10 mM Ru/SPS
samples didn’t show a micro-capillary organisation, but were progressively endothelialising
the surface. A potential  explanation for these differences in endothelial cell  behaviour are
differences in material stiffness, which have previously been demonstrated to determine the
morphology  of  endothelial  cells  seeded  on  the  surface  of  photo-crosslinked  gelatin-
methacryloyl (GelMA) hydrogels (18). Klotz et al.  seeded endothelial cells on the surface of
GelMA hydrogels with compressive modulus of either 1.2 or 1.8 kPa and found that cells on
softer hydrogels showed a more round morphology and were unable to form a confluent
monolayer, whereas endothelial cells on stiffer gels were able to form a confluent monolayer
after 10 days of culture (18). These differences in cell behaviour could also be related to the
differences seen in metabolic activity in section 5.3.3., where cells encapsulated in Gel-NOR
hydrogels  crosslinked  using  1/10  mM  Ru/SPS  showed  increased  metabolic  activity  as
compared  to  other  groups.  It  is  possible  that  the  promotion  of  endothelialisation  on  the
material surface is also associated with other changes in cell behaviour such as increased cell
proliferation  or decreased  cell  differentiation  when compared to  the promotion  of micro-
capillary network formation, resulting in higher overall metabolic activity of the samples.
Analysis of the network parameters (Figure 5.4B-C) revealed diverging tendencies between
groups. Gel-NOR hydrogels crosslinked using 1/10 mM Ru/SPS were not included in the
analysis as endothelial cells were unable to form micro-capillary networks in that condition.
Cells  encapsulated  in  Gel-NOR  hydrogels  crosslinked  using  0.2/2  mM  Ru/SPS  showed
increases in both junctions density and average vessel length between day 10 and day 14,
whereas  cells  encapsulated  in  Gel-NOR  hydrogels  crosslinked  using  0.5/5  mM  Ru/SPS
179
showed an increase in junctions density but no significant increase in average vessel length.
Matrigel samples, on the other hand, show a significant decrease in both junctions density
and average vessel length between days 10 and 14. A potential explanation to these results is
that  the micro-capillary network has reached a more mature state in Matrigel samples, where
the network was fully developed on day 10 and could have be regressing due to lack of
perfusion. This phenomenon has been previously reported in models of retinal angiogenesis,
where lack of perfusion results  in capillary regression  (41,42).  Gel-NOR samples,  on the
other hand, were still  developing a fully interconnected network between days 10 and 14
regardless  of  the  Ru/SPS  concentration  used  for  crosslinking.  On  days  10  and  14,  the
Matrigel samples showed the highest values in junctions density and average vessel length,
followed by Gel-NOR 0.2/2 and 0.5/5 mM Ru/SPS. A combination of factors differ between
Matrigel  and  Gel-NOR  samples,  which  could  explain  the  observed  differences  in  cell
behaviour. These factors include stiffness, which is reported to be between 10 and 50 Pa (43)
in Matrigel hydrogels at the studied concentrations, and the presence of a variety of ECM
molecules and growth factors that could be promoting the vascularisation process (39). The
differences  between  Gel-NOR  0.2/2  and  0.5/5  mM  Ru/SPS  are  most  likely  caused  by
differences in stiffness and polymer network density, as there were no significant differences
between groups in both total DNA content and metabolic activity, which suggests that the
initial  effect  of  the  photoinitiator  concentration  in  cell  survival  was  not  translated  to
differences in longer-term cell behaviour. 
The interactions between endothelial cells and HUVECs were further studied with a CD31
and α-SMA day 14 immunostaining of the Gel-NOR hydrogels crosslinked using 0.2/2 mM
Ru/SPS (Figure 5.5A). Results showed that MSCs were expressing αSMA and were in close
contact  with the endothelial  cell  network, suggesting that they were developing a smooth
muscle-like phenotype and acting as pericytes for the endothelial cells. Endothelial cells were
starting to develop a lumen, which is a sign of maturation of the network. These results prove
that the photoinitiator concentrations and stiffness of the hydrogel have highly impactful role
on the endothelial cell behaviour. Additionally, the results prove that Gel-NOR hydrogels are
able to provide the right microenvironment for endothelial cells to self-assemble into micro-
capillary structures.
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Figure 5.4. Effects of Ru/SPS Concentration and Physico-Mechanical Properties of Gel-
NOR Hydrogels on Capillary-Like Network Development (Top view). (A) Representative
images and (B-C) network analysis of a CD31 immunostaining of co-encapsulated HUVECs
and MSCs in Gel-NOR 5wt%, DTT 1:4 NOR:SH discs crosslinked using different Ru/SPS mM
concentrations. *: Significant difference (p<0.05) between groups. #: Significant difference
(p<0.05) as compared to all other groups. Scale bars: 200 µm. Mat: Matrigel® group. 0.2/2,
0.5/5 and 1/10 indicate  the  Ru/SPS mM concentration  in  Gel-NOR samples. Experiments
were repeated 3 times with 3 technical repeats each (N=3).
3D biofabrication techniques could allow the fabrication of a controlled channel network in
combination with the self-assembled micro-capillary network, enabling the reproduction of
the complex vascular beds in native tissues and organs.  It  is important  for the fabricated
constructs  to  maintain  their  shape  after  the  biofabrication  process  so that  these  channels
remain open during ECM remodelling and tissue maturation. To understand how different
crosslinking conditions in Gel-NOR would affect shape fidelity after fabrication, the size of
Gel-NOR hydrogels was monitored during the culture process (Figure 5.5B). It was found
that hydrogels fabricated using higher Ru/SPS concentrations contracted significantly less,
with no contraction in hydrogels fabricated using 1/10 mM Ru/SPS. Gel-NOR hydrogels
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fabricated using 0.5/5 or 0.2/2 mM Ru/SPS showed significant contraction on days 14 and 10
respectively. Matrigel controls showed a significant decrease in area as early as day 4 and
showed very  irregular  contraction  patterns  (Supplementary  Figure  S5.1).  On day 14,  the
average area (as imaged from the top) was not significantly different between Matrigel and
Gel-NOR samples crosslinked using 0.2/2 mM Ru/SPS. However, it was observed that, due
to the irregular contraction, Matrigel samples with higher measured area also decreased in
thickness (data not shown), suggesting that the overall volume of the samples would show a
more significant decrease over time as compared to the area measurements. Our data suggests
that the formation of micro-capillary structures is related to the contraction of the sample, as
the only samples that did not contract were Gel-NOR hydrogels crosslinked using 1/10 mM
Ru/SPS that  had  also  showed no micro-capillary  formation  on the  surface.  Furthermore,
groups  that  showed  higher  junctions  density  and  average  vessel  length  also  showed  a
significant decrease in area at earlier time points and had lower measured area on day 14.
These results support previous studies that demonstrate that the formation of micro-capillary
networks is tightly related to ECM remodelling and the generation of mechanical forces by
encapsulated  cells  could  cause  contraction  of  the  samples  (25,26).  When  Gel-NOR was
crosslinked using 0.2/2 mM  Ru/SPS, it was possible to obtain samples with a relevant degree
of  micro-capillary  formation  and  with  more  homogeneous  contraction  as  compared  to
Matrigel,  making  this  condition  a  reasonable  candidate  for  the  biofabrication  of  larger
constructs with a controllable channel network.
When generating tissue engineered constructs of relevant size for clinical translation,  it  is
important to investigate the formation of micro-capillaries both at the surface and the deeper
areas of the construct. Most studies on pre-vascularisation use samples of very small volume
that do not recapitulate the oxygen and nutrient gradients of large tissue constructs, which
could significantly affect micro-capillary formation  in vitro and anastomosis with the host
vessel  network after  implantation.  Furthermore,  cell  behaviour  at  the deeper  areas  of the
samples, which would provide more information on the effects of these gradients, is generally
not  clearly  reported  in  the  literature,  making the information  difficult  to  interpret  (8,17).
Some reports have started including analysis where the deeper areas of the constructs are
studied separately, and it has been reported that the behaviour of endothelial cells and support
cells can differ between cells closer to the surface and cells in deeper areas of the construct
(10,16). 
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Figure 5.5. Lumen formation by endothelial cells in Gel-NOR hydrogels and effects of
Ru/SPS concentration and physico-mechanical  properties  of Gel-NOR hydrogels on
construct shape fidelity. (A) CD31 and alpha-SMA immunostaining of co-cultures in Gel-
NOR 0.2/2 mM Ru/SPS showing the interaction between endothelial cells and MSCs acting
as  pericytes.  (B)  Hydrogel  size  over  time  during  culture  period.  Scale  bars:  50  μm.
Experiments were repeated 3 times with 3 technical repeats each (N=3).
To  study  the  formation  of  micro-capillaries  throughout  the  cross-section  of  Gel-NOR
hydrogels, CD31 and α-SMA immunostaining was performed after sectioning the fabricated
discs  (Supplementary  Figure  S5.2)  and  micro-capillary  network  formation  was  analysed
(Figure  5.6).  Due  to  the  irregular  contraction  observed  in  Matrigel  samples,  it  was  not
possible to differentiate between surface and deeper areas of the samples in a reliable and
repeatable way. Thus, this group was not included in the analysis. Immunostaining on days
10 and 14 showed that endothelial cells were organising into a micro-capillary network in
both  Gel-NOR  0.2/2  and  0.5/5  mM  Ru/SPS.  However,  endothelial  cells  in  Gel-NOR
hydrogels crosslinked using 1/10 mM Ru/SPS showed a round morphology (Supplementary
Figure S5.2 and Figure 5.6A). These differences  are most likely related to differences in
stiffness, which determine cell  elongation and migration inside the hydrogel  (18). On the
other hand, endothelial cells were directly interacting with MSCs expressing α-SMA, which
showed the ability to elongate and migrate in all Gel-NOR conditions (Supplementary Figure
S5.2). 
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Figure 5.6.  Effects of Ru/SPS concentration and physico-mechanical properties of Gel-
NOR hydrogels  on capillary-like network development (Cross-section).  Representative
images  and network  analysis  of  CD31 immunostaining  of  co-encapsulated  HUVECs  and
MSCs in Gel-NOR 5wt%, DTT 1:4 NOR:SH discs crosslinked using different Ru/SPS mM
concentrations. *: Significant difference (p<0.05) between groups. #: Significant difference
(p<0.05) as compared to all other groups. Scale bars: 200 µm. Mat: Matrigel® group. 0.2/2,
0.5/5 and 1/10 indicate  the  Ru/SPS mM concentration  in  Gel-NOR samples. Experiments
were repeated 3 times with 3 technical repeats each (N=3).
The network formed at the deeper areas of Gel-NOR crosslinked using 0.2/2 mM Ru/SPS
was  partially  interconnected,  which  differs  from its  fully  interconnected  surface  network
(Figure  5.6A).  Gel-NOR hydrogels  crosslinked  using  0.5/5  mM  Ru/SPS  also  showed  a
partially interconnected network, in a similar way to its surface network. Interestingly, there
seemed to be a higher number of endothelial cells with spherical shape at the deeper areas of
the constructs as compared to their surface in all groups. Differences in the quality of micro-
capillary  networks  have  previously  been  reported  in  collagen-based  scaffolds  with  co-
encapsulated  HUVECs and MSCs  (16),  where  the  quality  of  the  network  formed at  the
deeper areas of the scaffold was lower than the network formed at the surface. These results
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further support the idea that cell behaviour at the deeper areas of the construct should be
clearly  reported  in  any in  vitro pre-vascularisation  studies.  All  Gel-NOR  groups  show
increasing  junctions  density  and total  vessel  length  over  time at  the  deeper  areas  of  the
scaffold (Figure 5.6B),  which suggests that  these micro-capillary networks are still  being
developed after two weeks of culture. In a similar way to the surface network, the network at
the deeper areas of Gel-NOR discs crosslinked using 0.2/2 mM Ru/SPS hydrogels showed
significantly  higher  junctions  density  and  average  vessel  length  as  compared  to  groups
crosslinked using higher Ru/SPS concentration.  Taken together, these results reinforce the
idea  that  Gel-NOR  crosslinked  using  0.2/2  mM  Ru/SPS  is  a  better  candidate  for  the
biofabrication of large tissue constructs with controllable channel networks.
5.3.5.  3D  Biofabrication  of  Large  Engineered  Constructs  with  Controllable  Design
Parameters Using Gel-NOR Hydrogels
Pre-vascularisation techniques are highly promising due to their ability to reproduce the small
diameter and high density of the capillary networks in native tissues and organs. However,
the majority of studies on pre-vascularisation focus on small tissues (10,14–17). Translation
to larger-sized samples could affect oxygen diffusion and the invasion of host vessels after
implantation regardless of pre-vascularisation, as the invasion of vessels starts at the external
areas of the constructs and progresses towards the centre (14). In this section, the Gel-NOR
hydrogels  studied  in  previous  sections  are  biofabricated  into  larger  constructs  with  a
controllable  pore  and  fiber  diameter.  An  important  factor  to  take  into  account  in
biofabrication  is  the  shape  fidelity  of  the constructs,  especially  when aiming  to generate
personalised  constructs  with tailored  size  and architecture.  Due to  their  higher  degree  of
vascularisation and homogeneous contraction, Gel-NOR 0.2/2 mM Ru/SPS have shown to be
the  group  with  the  most  potential  for  3D  biofabrication  of  large  constructs  with  an
endothelialised porous network and pre-vascularised micro-capillaries. It has been observed
that contraction of the samples was directly related to micro-capillary formation in Gel-NOR
hydrogels  (Section  5.3.4).  Therefore,  it  was  hypothesized  that  Gel-NOR  biofabricated
constructs would undergo a certain degree of contraction. This could result in lack of shape
fidelity of the fabricated porous network, reducing the diffusion of nutrients and oxygen to
the core of the sample. To study how contraction affects the shape fidelity of the porous
network,  large samples were fabricated by 3D printing a sacrificial Pluronics 127 scaffold
with controlled strand size and strand spacing, resulting in Gel-NOR constructs with different
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pore and fiber diameters (Figure 5.7B). The pore diameter of Gel-NOR samples crosslinked
using 0.2/2 or 0.5/5 mM Ru/SPS was tracked during a 14 day culture period (Figure 5.7C-D).
Results showed that samples crosslinked using 0.5/5 mM Ru/SPS didn’t undergo significant
changes in pore diameter. However samples crosslinked using 0.2/2 mM Ru/SPS showed an
average decrease of 40% in pore diameter. Interestingly, changes in the initial pore or fiber
diameter didn’t have significant effects on the average relative loss of pore diameter. These
results suggest that the average final pore diameter can be predicted from the initial  pore
diameter, enabling targeted design regardless of the contraction of the sample. Therefore, it is
possible to generate a controllable porous network that remains open during the whole culture
period using Gel-NOR 0.2/2 mM Ru/SPS, enabling enhanced oxygen and nutrient diffusion.
Importantly, the pores were maintained even though our culture setup did not include media
perfusion throughout the network, which generates transmural pressure and helps maintain
the morphology of microvessels in vivo (42) and in vitro (44).
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Figure 5.7. Shape fidelity of 3D biofabricated large constructs with controllable design
parameters. Constructs  were  biofabricated  by  3D  printing  Pluronics  as  a  sacrificial
material  and  casting  Gel-NOR  0.2/2  or  0.5/5  mM  Ru/SPS,  resulting  in  samples  with
controlled  pore  and fiber  diameter  (500,  750 or  1000 μm).  Pore  diameter  was  always
designed to be equal to fiber diameter.  (A) Schematic view of a biofabricated construct. (B)
Design of the Gel-NOR constructs with controlled pore and fiber diameter. (C) Top view of
the pore sizes on day 1 and 14 of the culture period showing the pore contraction.  (D)
Quantification of pore diameter on day 14 relative to day 1, each dot showing an individual
diameter  measurement.  Scale  bars:  1000  µm.  a,  b:  Groups  of  statistical  significance:
samples  in  each  group  are  not  significantly  different  to  each  other  (p>0.05)  and  are
significantly  different  to  all  samples  from  other  groups  (p<0.05). Experiments  were
repeated  3  times  with  3  technical  repeats  each  (N=3),  and  in  figure D  all  individual
diameter measurements were included in the analysis to account for variation  within the
samples.
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5.3.6. Effects of Pore and Fiber Diameter on Endothelial Cell Morphology at the Deeper
Areas of 3D Biofabricated Constructs
Aside from evaluating the shape fidelity of the constructs, it  is important to evaluate cell
behaviour both at the surface and the deeper areas of the constructs. An important advantage
of biofabricating large constructs with controllable architectures is that it allows us to study
the effects of design parameters on the behaviour of cells. To evaluate the endothelial cell
morphology and behaviour in the 3D biofabricated constructs, a CD31 immunostaining was
performed after sectioning of the samples and the cross-section of the fibers was imaged
(Figure  5.8B-D).  The  general  network  development  stage  was  a  partially  interconnected
network regardless of the fiber diameter, in a similar way to the deeper areas of Gel-NOR
discs. Quantification of the endothelial cell network revealed that groups with 750 and 1000
μm  pore  and  fiber  diameter  had  higher  junctions  density  and  average  vessel  length  as
compared to samples with 500 μm pore and fiber diameter. A potential explanation of these
results is the generation of a hypoxic zone at the deeper areas of the material, which is known
to stimulate angiogenesis  in tissues through the activation of HIF-1  (45,46) and has been
shown to promote differentiation  of  stem cells  to  the endothelial  lineage  (47) as well  as
helping the vascularisation of tissue engineered constructs  (48). The general consensus for
oxygen diffusion in tissue engineered constructs is that a hypoxic zone is generated at a depth
of 100-200 μm (49–51). Therefore, it would be expected that the area of hypoxia in samples
of 500 μm fiber diameter would be significantly smaller as compared to groups with higher
fiber  diameter,  therefore  generating  lower  levels  of  hypoxic  stimulation.  Interestingly,
endothelial cells seemed to have covered the surface of the material in all designs.  
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Figure 5.8. Effects of pore and fiber diameter on endothelial cell morphology at the
deep areas  of  3D biofabricated  constructs.  (A)  Schematic  view of  the  sectioning  and
regions of interest for analysis of the deep areas. (B-D) CD31 immunostaining of HUVEC/
MSCs co-cultures at the deep areas of Gel-NOR constructs crosslinked using 0.2/2 mM
Ru/SPS biofabricated with (B) 500, (C) 750 or (D) 1000 μm pore and fiber diameter (Day
14). Quantification of (A) junctions density and (B) average vessel length.  *: significant
differences  (p<0.01) as compared to all  other groups.  Dashed lines  indicate  regions  of
interest for analysis. Arrows indicate endothelialisation in the internal surfaces of the pores.
Scale bars: 250 µm. Experiments were repeated  2 times with at least 3 technical repeats
each (N=2).
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5.3.7. Effects of Pore and Fiber Diameter on the Degree of Endothelialisation of the
Porous Network
To further study the endothelialisation of the interconnected pores in biofabricated Gel-NOR
samples,  the surfaces  of the  internal  pores  were imaged either  from perpendicular  cross-
section of the pore (Figure 5.9) or from a longitudinal cross-section of the pore (Figure 5.10).
CD31 and α-SMA immunostaining on day 14 revealed that the internal surface of the pores
was fully covered by a layer of endothelial cells and a layer of MSCs expressing α-SMA
(Figure 5.B and 5.10B). These cells seemed to have migrated from the deeper areas to the
surface of the material during the culture period, forming a double layer similar to the tunica
intima and the tunica media of arterioles  and venules (Figure 5.9A).  Micro-capillary-like
structures connected to the endothelialised surface were also observed, along with individual
elongated endothelial cells that could be migrating to the internal surface of the pores (Figure
5.9A). During this process it would have been possible for the surface-to-volume ratio, which
varied depending on pore and fiber diameter, to have resulted in changes in the degree of
endothelialisation. However, the internal surface of the pores was uniformly covered by both
HUVECs and MSCs independently of the pore and fiber diameter of the construct (Figure
5.9B).  Interestingly,  this  endothelialisation  was  not  observed  in  the  discs  of  the  same
formulation,  where endothelial cells at the surface were assembling into a micro-capillary
network (Figure 5.4). A possible explanation to this phenomenon is the 3D architecture of the
samples. The presence of fabricated pores allows MSCs to naturally assemble into a tube
along  the  surface  of  the  pores,  mimicking  the  tunica  intermedia  of  native  vessels  and
potentially  promoting  contraction  and  matrix  remodelling.  Increased  contraction  would
increase the mechanical properties at the surface of the samples, promoting the formation of
an endothelial  cell monolayer instead of a micro-capillary network as shown in Gel-NOR
discs (Figure 5.4). 
190
Chapter 5: Biofabrication of Multi-Scale Vascularised Tissues with Controllable 3D Architecture
Figure  5.9.  Formation  of  endothelialised  pores  within  biofabricated  Gel-NOR  constructs
(Perpendicular cross-section). (A) Schematic view of the samples and regions of interest imaged.
(B) CD31 and α-SMA immunostaining of HUVEC/MSCs co-cultures at the internal surfaces and
deeper areas of Gel-NOR constructs crosslinked using 0.2/2 mM Ru/SPS biofabricated with 750 μm
pore and fiber diameter (Day 14). Scale bars: 200 μm. Arrows indicate endothelial cells connecting
to  the  endothelialised  surface  of  the  pores.  Experiments  were  repeated  2 times  with  at  least  3
technical repeats each (N=2).
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Figure  5.10.  Formation  of  endothelialised  pores  within  biofabricated  Gel-NOR
constructs  (Longitudinal  cross-section). (A)  Schematic  view  of  the  imaged  internal
surfaces in a sectioned 3D biofabricated construct. (B) CD31 and α-SMA immunostaining
of  HUVEC/MSCs  co-cultures  at  the  internal  surfaces  and  deeper  areas  of  Gel-NOR
constructs crosslinked using 0.2/2 mM Ru/SPS biofabricated with 500, 750 or 1000 μm pore
and fiber diameter (Day 14). Scale bars: (A) 200 μm and (B) 500 μm.  Experiments were
repeated 2 times with at least 3 technical repeats each (N=2).
Taken together, these results suggest that 3D design is an important aspect to consider during
the  biofabrication  of  engineered  vascularised  constructs,  affecting  the  behaviour  of
endothelial  cells  both  at  the  surface  and  the  deeper  areas  of  the  constructs.  Firstly,  the
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fabrication of a controllable  interconnected  porous network had significant  effects  on the
endothelial cells at the surface of the constructs, resulting in endothelialisation of the pores as
opposed to the formation of a micro-capillary network that was observed in discs. Secondly,
differences in the fiber diameter of the construct resulted in significant differences in network
parameters  of endothelial  cells  at  the deeper areas  of the construct  (10-20 μm below the
surface or deeper), where higher fiber diameter promoted elongation and interconnection of
endothelial cells. Another important aspect of this study is that the endothelialisation of the
constructs  happened  through  migration  of  the  encapsulated  cells  without  the  need  of
perfusion of endothelial cells. To our knowledge, this is the first report of this phenomenon,
which  could  help  to  avoid  unnecessary  additional  cell  seeding  procedures  during  the
generation of vascularised tissue engineered constructs.
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5.4. Conclusions
The formation of large vascularised tissues analogues that recapitulate the different levels of
vascularisation in native tissues and organs remains one of the major challenges in tissue
engineering, and efforts in this direction have taken two major routes: 3D fabrication-based
top-down approaches and bottom-up approaches based on endothelial cell self-assembly. One
of the major barriers for these two approaches to be combined is in the incompatibility of
present material platforms to be adaptable to both 3D fabrication of channels and to promote
endothelial cell self-assembly into micro-capillary networks.
In  the  present  study,  the  combination  of  a  top-down and  a  bottom-up  approach  for  the
biofabrication of vascularised constructs with different levels of vascularisation using a single
material platform is reported. Combining thiol-ene chemistry with the Ru/SPS visible light
initiated photoinitiator system enabled fine tailoring of the hydrogel mechanical properties
and the obtention of constructs with micro-capillaries and homogeneous contraction. It was
found that contraction of the material is tightly related to the formation of micro-capillary
structures  by  encapsulated  endothelial  cells.  Despite  the  contraction,  it  was  possible  to
biofabricate  large  constructs  with  an  interconnected  porous  network  of  predictable  pore
diameter while allowing the elongation and migration of endothelial cells at the deeper areas
of  the  material.  To  our  knowledge,  this  is  the  first  report  of  the  combination  of  both
approaches  without  the  need  of  support  materials  and  perfusion  of  culture  media  and
endothelial cells. This platform was then used to study the effects of 3D architecture on the
behaviour of endothelial cells both at the surface of the pores and the deeper areas of the
constructs.  Our  data  suggests  that  the  fabrication  of  interconnected  pores  stimulates
endothelial cells to migrate to the surface of the pores and endothelialise them rather than
forming  a  micro-capillary  network.  This  resulted  in  full  endothelialisation  of  the  pores
regardless  of  the  pore  and  fiber  diameters  of  the  construct.  It  was  also  observed  that
increasing the fiber diameter of the constructs can affect the behaviour of endothelial cells at
the deeper areas of the material, potentially by generating hypoxic conditions that stimulate
micro-capillary  formation.  The  role  of  hypoxia  during  the  generation  of  large,  pre-
vascularised tissues is therefore an aspect that should be further studied as part of the efforts
to translate these technologies to studies in larger mammals.
This  study  represents  a  valuable  proof  of  concept  of  the  combination  of  two  major
vascularisation  strategies.  Furthermore,  we  have  used  this  platform  to  provide  relevant
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information  on how 3D design  can  affect  endothelial  cell  behaviour  in  3D biofabricated
vascularised constructs, which will be relevant for future optimisation and clinical translation
of large vascularised constructs.
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5.5. Supplementary Information
Supplementary Figure S5.1. Contraction of Gel-NOR and Matrigel hydrogels after 14
days of cultures with co-encapsulated HUVECs and MSCs.  Representative images of
Matrigel (A-B), Gel-NOR 0.2/2 (C) and 0.5/5 mM Ru/SPS (D) sample size after 14 days of
culture  showing the  variability  in  sample  contraction.  White  dashed lines  indicate  the
initial shape of the constructs. Black dashed lines indicate the final shape of the construct.
Scale bars: 1 mm.
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Supplementary Figure S5.2. Micro-capillary formation in Gel-NOR hydrogels with co-
encapsulated HUVECs and MSCs (cross-section). Representative images of CD31 and α-
Smooth muscle actin immunostaining of co-encapsulated HUVECs and MSCs at the deeper
areas of Gel-NOR 5wt%, DTT 1:4 NOR:SH discs crosslinked using 0.2/2 (Top row), 0.5/5
(Middle row) or 1/10 (bottom row) mM Ru/SPS. Scale bar: 100 µm.
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Chapter 6. Bioassembly of Gel-NOR and PVA-
Tyr Modules for Combinatory Approaches in
Tissue Vascularisation
6.1. Introduction
Combining growth factor  delivery  with  cell  therapy  is  a  common strategy  that  has  been
applied in different contexts such as heart regeneration  (1–3), bone regeneration  (4,5) and
tissue vascularisation  (6), resulting in synergistic positive effects. The combination of these
two strategies increases the complexity in the design of delivery vehicles, as the conditions
for  improved growth factor  delivery  (such as  controlled  release  time,  release  profile  and
concentration) and improved cell delivery (such as presence of bioactive cues or controlled
stiffness) need to be met at the same time. An important aspect to consider when generating
these complex scaffolds is the fabrication technique. Biofabrication allows the combination
of  different  materials  that  meet  these  conditions  while  providing  freedom  in  the  3D
architecture and in the arrangement of materials, cells and growth factors within the scaffold.
Furthermore, it allows the inclusion of support materials that provide the necessary stiffness
for the implantation into load-bearing tissues such as bone (7,8) and the generation of large,
controllable pore structures that improve vascularisation and integration of the implant (9,10),
making it a very flexible strategy for combined approaches in tissue engineering.
Very few studies that use biofabrication have been dedicated to the coordinated delivery of
growth factors and cells to promote tissue vascularisation (6,19). One of the few examples of
this is the study by Jang et al., which aimed to improve cardiac vascularisation by co-printing
two hydrogel bioinks containing either cardiac progenitor cells (CPCs) or MSCs combined
with VEGF. Using an  in vivo mouse model, they demonstrated that co-printing both inks
resulted in improved tissue vascularisation as compared to printing CPCs or MSCs + VEGF
(19). While this study provides evidence of how adequately combining cell types and growth
factors through biofabrication can help tissue vascularisation, the research did not cover the
release profile of VEGF and did not include control bioinks that only delivered VEGF. The
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work  by  Poldervaart  et  al.  did  study  these  aspects  in  more  depth  by  generating  gelatin
microspheres with adsorbed VEGF that resulted in extended release up to 14 days. These
microspheres were incorporated into a Matrigel/alginate bioink with encapsulated endothelial
progenitor  cells  (EPCs),  which  was  bioprinted  to  form  a  scaffold.  After  subcutaneous
implantation  into  mice,  the  study demonstrated  that  slow release  of  VEGF results  in  an
increased number of functional vessels as compared to controls with a burst release pattern
(6). While this study provided more details about the release of growth factors, the bioink did
not  include  support  cells  and  did  not  undergo  in  vitro maturation  to  achieve  pre-
vascularisation.  Furthermore,  the  capabilities  of  biofabrication  were  not  exploited  by
arranging different cell types or materials within the scaffold. The existing information in this
field is very scarce and there are still significant gaps in knowledge: key questions such as
what  endothelial  cells  and  support  cells  result  in  optimal  vascularisation,  or  how  the
arrangement of cells within the scaffold can affect both the pre-vascularisation process and
the implant-host vessel anastomosis, still need to be answered. The presence of growth factor
gradients also needs to be further explored as a key factor that could promote both these
processes. Therefore, the development of models that allow studying these aspects would be
key for the advancement of the field, especially if they allow studying these aspects within
large constructs.
Within biofabrication techniques, bioassembly provides high flexibility on how to organise
bioactive elements in the scaffold (20). This technique is based on the automated deposition
of  previously  fabricated  cell-containing  building  blocks,  such  as  microspheres  or
microtissues,  within  3D  scaffolds.  Bioassembly  provides  high  flexibility  on  the  type  of
building blocks used, which can either be cells or growth factor-releasing materials. These
building blocks can be arranged in a controlled manner within the construct (Figure 6.1A)
and the assembly process allows scalable fabrication of large tissue constructs (Figure 6.1B).
Therefore, it could prove to be a useful tool not only to generate large, vascularized tissues,
but also to study the effects of 3D architecture and organisation of cells and growth factors
within  tissue  engineered  scaffolds.  Another  significant  advantage  of  bioassembly  over
bioprinting  is  that  the  materials  do  not  need  to  have  the  specific  rheological  properties
required for 3D printing. Instead, they only need to be adaptable to the fabrication of building
blocks through less restrictive techniques such as microfluidics or mould casting.
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Figure 6.1. Bioassembly allows controlled arrangement of multiple bioactive modules
and biofabrication of large constructs. Blue and red microspheres represent bioactive
modules  such  as  growth  factor-releasing  materials  or  pre-vascularised  constructs.  (A)
Demonstration  of  the  flexibility  of  bioassembly  on  the  spatial  arrangement  of  multiple
modules  (B)  Illustration  of  the  hybrid  bottom-up  bioassembly  approach  that  allows
biofabrication of large tissue constructs. Adapted from (21)
In this chapter, the necessary tools to fabricate engineered scaffolds that combine the PVA-
Tyr  GF delivery  system and Gel-NOR co-cultures  through  bioassembly  techniques  were
developed. The first aim of this chapter was to fabricate Gel-NOR microspheres including
MSCs and/or endothelial cells and evaluate cell behaviour after the fabrication process. The
second aim was to demonstrate the possible applications of this platform by performing a
proof-of-concept study on how different distributions of endothelial cells and MSCs within
assembled scaffolds can affect their resulting function and behaviour. The third aim was to
fabricate  PVA-Tyr microspheres with different  degradation properties and study how this
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fabrication technique affects the degradation of the material and the release of GFs. The last
aim was to generate hybrid assembled constructs containing PVA-Tyr microspheres and Gel-
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6.2. Materials and Methods
6.2.1. Materials
Dithiothreitol  (DTT),  Tris(2,2′-bipyridyl)dichlororuthenium(II)  hexahydrate  (Ru),  sodium
persulfate (SPS), Phosphate buffered saline (PBS) and L-ascorbic acid-2-phosphate (ASAP)
were purchased from Sigma-Aldrich.  RhVEGF-165 was purchased from Gibco (PHC9394).
bFGF was purchased from R&D Systems (P09038).
Human umbilical vein endothelial cells (HUVEC), vascular cell basal medium, endothelial
cell  growth  kit-VEGF,  trypsin  for  primary  cells  and  trypsin  neutralizing  solution  were
purchased from ATCC. Human bone marrow-derived mesenchymal stem cells (MSCs) were
purchased from RoosterBio. Alpha-MEM, Fetal bovine serum (FBS), Trypsin and Penicillin/
streptomycin were purchased from Gibco.
6.2.2. Methods
6.2.2.1. Cell Expansion
Human umbilical vein endothelial cells (HUVECs, obtained from ATCC) were cultured in
Vascular  Basal  Media  (ATCC)  supplemented  with  Endothelial  Cell  Growth  Kit-VEGF
(ATCC) and Penicillin/Streptomycin (Referred to as endothelial growth media, EGM). Bone
marrow-derived mesenchymal stem cells (MSCs, obtained from RoosterBio) were cultured in
α-MEM  (Gibco)  supplemented  with  10%  foetal  calf  serum  (Hyclone),  1%
penicillin/streptomycin, 20 mM of ASAP and 5 ng/mL basic fibroblast growth factor (R&D
Systems).
6.2.2.2. Hydrogel Fabrication
Dried PVA-Tyr was dissolved in PBS at 80 °C (5.9 wt%). GF and Ru/SPS stock solutions
were prepared in PBS at 10x and 50x of their final concentration respectively. Upon complete
dissolution, the polymer solution was cooled to room temperature (RT) and mixed with the
GF,  Ru  and  SPS stock solutions  to  a  final  PVA-Tyr  concentration  of  5wt%,  0.5/5  mM
Ru/SPS and 500 ng/mL of GF. Dried Gel-NOR was dissolved in PBS at 37 °C and mixed
with Ru, SPS and dithiothreitol (DTT) stock solutions to a final Gel-NOR concentration of
5wt% Gel-NOR, 1:4 NOR:SH ratio for DTT and 0.2/2 mM Ru/SPS. All samples were photo-
crosslinked using visible light (OmniCure® S1500, Excelitas Technologies with a Rosco IR/
UV filter 400 – 450nm, 3min and 300 mW cm-2).
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6.2.2.3. Microsphere Generation
PVA-Tyr  and  Gel-NOR  micro-spheres  were  prepared  by  employing  a  microfluidic  oil-
emulsion setup based on previous work  (22). Briefly, PVA-7Tyr or Gel-NOR were mixed
with  their  respective  crosslinking  agents  and  photoinitiators  following  the  protocol  for
hydrogel fabrication, and the mixtures were pumped through an axisymmetric needle/tubing
microfluidic device. The droplets were polymerized in situ under visible light (400–450 nm,
100 mW cm−2) irradiation to form spherical hydrogel particles. To separate the oil phase
from the hydrogel microspheres, the samples were washed three times using PBS.
6.2.2.4. Cell-Laden Microspheres
Passage 2 to 3 HUVECs and passage 3 MSCs were trypsinized and mixed with Gel-NOR
(5wt% Gel-NOR, DTT at 1:4 SH:NOR ratio, 0.2/2 Ru/SPS) at a concentration of either 6M
HUVECs/mL (HUVECs group), 6M MSCs per mL (MSCs group) or 5M HUVECs and 1M
MSCs/mL  prior  to  pumping  the  mixture  into  the  microfluidics  device.  The  resulting
microspheres were cultured up to 14 days in EGM.
6.2.2.5. Viability Assays
Live/dead staining was used to visualize cell viability of encapsulated cells on day 1 after
encapsulation. Briefly, hydrogel samples were washed with PBS, cut in half, and incubated
with propidium iodide (1.5 μM, from Invitrogen) and calcein-AM (1 μM, from Invitrogen) in
PBS for  15  min  at  RT.  The samples  were  then  washed with  PBS and left  hydrated  for
imaging using a fluorescent microscope (Zeiss Axioimager Z1 microscope). Live and dead
cells were counted at six different microspheres per time point using Image J (version 6.1
Fiji, National Institutes of Health). Viability was calculated using equation 6:




Hydrogels were digested at 56° in 1 mg mL-1 proteinase K dissolved in a 10-2 M Tris-HCl
and  103  M  disodium EDTA  solution,  following  a  treatment  with  DNase-free  RNase  A
(Thermo Fisher). Total DNA was quantified using CyQUANT Cell Proliferation Assay Kit
following the manufacturer’s instructions.
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6.2.2.7. Metabolic Activity Assays
AlamarBlue® was used to track the cellular health of embedded cells at days 1, 4, 7, 10 and
14 after  encapsulation.  Briefly,  each  hydrogel  sample  was incubated  with  350 μL media
containing AlamarBlue® solution, diluted according to manufacturer’s instructions, for 3h.
The reduction  of AlamarBlue® in the  solution was determined by reading absorbance at
wavelengths of 570 nm and 600 nm using a spectrophotometer (Thermo Scientific Varioskan
Flash,  Darmstadt,  Germany)  followed  by  data  processing  according  to  manufacturer’s
instructions.
6.2.2.8. Immunofluorescence Examination
Cell-laden microspheres were collected after 1, 4, 7 and 14 days, washed in PBS, followed by
a fixation in 4% formaldehyde for 45 min at RT. Samples were then blocked with 2% BSA
for 1h at RT and permeabilized using a 0.2% Triton-X solution. Primary anti-CD 31 antibody
(R&D Systems) was diluted in blocking buffer (1:100) and applied overnight at 4°C. Samples
were washed three times in blocking buffer for 30 min each followed by an incubation with a
goat-anti-mouse (Alexa Fluor 488, Lifetech) secondary antibody diluted in blocking buffer
(1:500), in the dark overnight at 4°C. Samples were then washed 3 times in PBS during 5 min
and incubated in a Rhodamine-phalloidin (1:500) solution for 30 min. Samples were then
washed 3 times in PBS during 5 min, incubated in a DAPI (1:1000) solution for 2 min and
washed three times in PBS for 30 min. Images were captured using a Zeiss Axioimager Z1
fluorescence microscope (Carl Zeiss Microscopy, Jena, Germany). From this staining, CD-31
and F-actin positive cells were distinguished as HUVECs, while CD-31 negative and F-actin
positive cells were distinguished as MSCs. The stages of network development in Gel-NOR
samples were described following previously reported criteria (18,23). 
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6.2.2.9. Printing of Load-Bearing Cages and Scaffolds
3D-printed Poly(ϵ-caprolactone) (PCL)  cages  were  fabricated  using  a  BioScaffolder
(SYS+ENG,  Germany).  PCL was  molten  in  the  reservoir  at  120°C  for  45  minutes  and
extruded using a 23G nozzle in a repeating 0°-90°-0°-0°-90°-0° pattern. Cages were printed
with  a  3mm  spacing  in  the  x-axis  and  1.1  mm  spacing  in  the  y-axis  to  include  two
microspheres in the same cage, while scaffolds had a 1.1mm spacing in the x-axis and 1.1
mm spacing in the y-axis to include one microsphere in each space. The auger was set at a
dispensing speed of 32 RPM with x-y traverse speed of 180 mm/min. Temperature of the
printing head was set at 120°C and pressure at 4 bar. Temperature of the base plate was set at
25 °C.
6.2.2.10. Release Assays 
RhVEGF-165,  bFGF  and  BDNF  were  labelled  using  Alexa  Fluor  594  carboxylic  acid,
succinimidyl ester (ThermoFisher) following the manufacturer’s instructions. Unreacted dye
was separated using 3 kDa MWCO centrifuge filter units. During hydrogel and microsphere
fabrication,  labelled  growth  factors  were  mixed  with  the  macromer  solution  before
crosslinking. Hydrogels (20 μL each) with incorporated GFs were fabricated as described in
6.2.2.2  and  microspheres  were  incubated  in  1  mL  of  basal  endothelial  cell  media
supplemented with 1% P/S. Incubation media and microsphere samples were collected at
selected  time  points  up  to  total  hydrogel  degradation.  Fluorescence  in  the  media  was
measured  by  fluorescence  spectroscopy  (Thermo  Scientific  Varioskan  Flash,  Darmstadt,
Germany).  Release  media  from  plain  PVA-Tyr  hydrogels  was  used  as  a  control  for
background subtraction. Images from the microsphere samples were captured using a Zeiss
Axioimager  Z1  fluorescence  microscope  (Carl  Zeiss  Microscopy,  Jena,  Germany),  and
microspheres without loaded growth factors were used as negative controls.
6.2.2.11. Statistical Analysis
All samples were prepared in triplicates and each experiment was repeated three times (N=3)
to study variability between experiments unless otherwise stated in the figures. Individual
differences between groups and time points were assessed using one or two-way ANOVA
and Holm-Sidak post hoc analysis (GraphPad Prism 7). Statistical significance was accepted
at p<0.05. 
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6.3. Results and Discussion
6.3.1.  Generation  and  Evaluation  of  Gel-NOR  Microspheres  Encapsulated  with
Endothelial Cells and Mesenchymal Stem Cells
Our first goal was to generate Gel-NOR microspheres with encapsulated HUVECs, MSCs or
co-cultures for bioassembly applications. Previous research has shown that it is possible to
generate methyl methacrylate polymeric microspheres by employing a microfluidic oil-water
emulsion setup  (22), followed by UV crosslinking using Irgacure 907 as a photoinitiator.
This  technique  was later  applied  in  our group to fabricate  gelatin-methacryloyl  (GelMA)
hydrogel  microspheres  that  were  photo-crosslinked  with  Ru/SPS  (20).  Here,  the  same
technique is applied to generate hydrogel microspheres using Gel-NOR and Ru/SPS.  Gel-
NOR  is  crosslinked  through  a  thiol-ene  step-growth  reaction,  which  is  fundamentally
different to the methacryloyl-based chain-growth reaction of GelMA. These differences could
affect  the  formation  of  microspheres  using this  oil-emulsion  system.  Despite  this,  it  was
possible  to  successfully  generate  Gel-NOR  microspheres  using  the  same  crosslinking
conditions optimised in chapter 5 for the co-culture of HUVECs and MSCs (5 wt% Gel-NOR
crosslinked with DTT 1:4 NOR:SH ratio and 0.2/2 mM Ru/SPS). 
As shown in Chapter 5, the selected crosslinking conditions resulted in high cell survival and
metabolic  activity  by  encapsulated  HUVECs  and  MSCs  in  casted  discs.  However,  the
fabrication method could influence these results. The light attenuation through the tubing and
the  contact  with  an  oil  phase  during  the  crosslinking  could  result  in  differences  in  the
crosslinking efficiency, thereby impacting cell function and behaviour. The contact with the
oil  phase could also have a direct  impact  on cell  health.  To investigate  if  the fabrication
process had a significant effect on cell survival, LIVE/DEAD assay was performed after 24h
hours  of  culture  (Figure  6.2A-C),  which  revealed  high  cell  survival  rates  in  all  groups.
Quantification of the images showed that the survival was above 90% in all groups with no
significant  differences  between  groups  (p>0.05)  (Figure  6.2D).  These  survival  rates  are
similar to the ones obtained in chapter 5, where cell survival in photo-crosslinked Gel-NOR
discs was not significantly different to Matrigel discs. 
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Figure  6.2.  Cell  survival,  proliferation  and  metabolic  activity  in  Gel-NOR
microspheres. Cell survival at day 1 (A-D), proliferation (E) and metabolic activity (F) of
HUVECs and/or MSCs encapsulated in Gel-NOR microspheres (5 wt% Gel-NOR, 0.2/2 mM
Ru/SPS and DTT at 1:4 NOR:SH ratio).  Live cells  are presented in green (stained with
calcein) and dead cells are presented in red (stained with propidium iodide). Scale bars:
500  μm. *: Significant differences (p<0.05) as compared to all other groups at the same
time point. #: Significant differences (p<0.05) as compared to the previous time point of the
same group. All experiments were repeated three times with three technical replicates each
(N=3). Error bars are not visible in time points where they were smaller than the symbol
itself.
DNA quantification (Figure 6.2E) revealed different trends between groups. HUVEC-laden
microspheres showed a significant decrease in total DNA content at each time point, reaching
25% of the day 1 DNA content on day 14. However, microspheres containing MSCs or co-
cultures decreased to approximately 80% of the day 1 DNA content between days 1 and 4
and maintained constant levels after that,  with no significant differences between the two
groups.  These  reductions  in  DNA  content  during  culture  period  have  previously  been
observed  in  similar  models  (24,25).  For  example,  Barati  et  al.  encapsulated  MSCs  and
endothelial  progenitor  cells  (EPCs)  in  patterned  GelMA hydrogels  and  exposed them to
BMP-2 and VEGF released from hydrogel-based nanoparticles. The total DNA content of the
samples  decreased  over  time  regardless  of  the  exposure  to  growth  factors,  which  was
interpreted as a sign of cell differentiation (25). 
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Metabolic  activity  measurements  obtained  using  AlamarBlue®  assay  (Figure  6.2F)  also
showed differences between groups. While HUVEC-laden microspheres maintained constant
levels  of  metabolic  activity  throughout  the  whole  experiment,  the  metabolic  activity  of
microspheres encapsulated with MSCs or co-cultures increased between days 1 and 4, then
maintained  constant  levels  until  day  7.  However,  MSC-laden  microspheres  showed  a
decrease in metabolic activity between days 7 and 14 while co-culture-laden microspheres
remained stable. 
Overall, these results suggest that the co-encapsulation of HUVECs with MSCs within Gel-
NOR microspheres improves the survival and metabolic activity of encapsulated cells during
the culture process, potentially through cell-cell interactions. These interactions have been
previously demonstrated multiple times in 2D (26,27) and 3D models, including microtissues
(28) and  photo-crosslinked  gelatin  methacryloyl  hydrogels  (24),  where  co-cultured
endothelial cells and MSCs showed increased proliferation  (24,27), metabolic activity  (27)
and  expression  of  angiogenic  markers  (24,26,28).  For  example,  Bidarra  et  al.  cultured
HUVECs and MSCs in a 2D model, where co-encapsulated cells showed increased overall
cell number and metabolic activity as compared to HUVECs or MSCs encapsulated alone
(27). Zhang et al. co-encapsulated HUVECs and MSCs in GelMA hydrogels at different cell
ratios,  and found that  the total  DNA content  was lower on day 21 of the experiment  as
compared to day 7 regardless of the cell ratio used. This trend was, however, less marked in
samples with MSCs encapsulated alone (24), similarly to the results observed in the present
experiment. Thus, it was not only possible to generate cell-laden microspheres with different
types  of  encapsulated  cells,  but  these  microspheres  also  showed  high  cell  survival  and
followed  trends  that  have  been  previously  reported  in  the  literature  in  terms  of  their
proliferation and metabolic activity.
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To further study the behaviour of HUVECs and MSCs after their encapsulation in fabricated
Gel-NOR microspheres, CD-31 and F-actin staining was performed 4, 7 and 14 days after
encapsulation.  From this staining,  CD-31 and F-actin  positive cells  were distinguished as
HUVECs,  while  CD-31 negative  and F-actin  positive  cells  were  distinguished as  MSCs.
Figure  6.3  shows  the  maximum  intensity  projection  across  400  μm  of  the  microsphere
thickness, revealing remarkably different cell morphologies between groups. When HUVECs
were encapsulated alone,  they displayed round morphologies and low levels of migration
throughout  the  construct.  After  14  days  of  culture,  most  cells  still  showed  a  round
morphology but some of them started to form aggregates. When MSCs were encapsulated
alone, their morphologies were more elongated as compared to HUVECs and they showed
the  ability  to  migrate  throughout  the  microsphere,  progressively  covering  its  surface.  A
similar phenomenon was observed in co-culture-laden microspheres, where the MSCs also
migrated to the surface of the microsphere and covered it. On the other hand, HUVECs in co-
culture-laden microspheres showed a more elongated morphology from day 4 onwards when
compared to HUVEC that were encapsulated alone. At days 7 and 14, HUVECs were self-
assembling into a partially interconnected network (Figure 6.3, bottom right image). It has
been previously established that endothelial cells need the support of stromal cells to form
stable 3D networks  (23,29), and these results support that body of evidence. Furthermore,
similar network patterns have been observed at the surface of spherical microtissues of co-
cultured MSCs and HUVECs, where HUVECs formed a partially interconnected network at
the surface of the structure (28,30,31).
218
Chapter 6. Bioassembly of Gel-NOR and PVA-Tyr Modules for Combinatory Approaches in Tissue
Vascularisation
Figure  6.3.  Cell  morphology  and  self-organisation  over  time  in  Gel-NOR
microspheres.  Representative  images  of  a  CD-31  and  F-actin  immunostaining  of
HUVECs, MSCs or HUVECs/MSCs co-cultures encapsulated in Gel-NOR microspheres (5
wt% Gel-NOR, 0.2/2 mM Ru/SPS and DTT at 1:4 NOR:SH ratio). CD-31 is presented in
green (anti-CD31 immunostaining), F-actin is represented in red (Phalloidin) and DNA is
represented in blue (DAPI). Scale bars: 500  μm. Experiments were repeated three times
with three technical replicates each (N=3).
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Thorough  examination  of  the  microspheres  with  encapsulated  co-cultures  (Figure  6.4)
revealed morphological differences between HUVECs and MSCs at the surface, intermediate
and  deep  zones  of  the  construct.  The  amount  of  MSCs  was  significantly  lower  at  the
intermediate  and  deep  areas  of  the  microspheres,  suggesting  that  the  MSCs  had  mostly
migrated to the surface. This was potentially triggered by gradients of oxygen and/or growth
factors within the microspheres coming from the culture media, which are known to stimulate
MSC migration  (32,33).  HUVECs,  on  the  other  hand,  were  present  both  at  the  surface,
intermediate  and deep areas  of  the  material,  but  the  morphologies  shown were  different
depending  on  the  area;  while  cells  at  the  surface  were  self-assembling  into  vessel-like
networks, cells  at the intermediate and deep areas showed lower levels of elongation and
clustering.  These  differences  are  in  accordance  with  the  results  shown in  Chapter  5 and
support that cells at the deeper areas of hydrogels do not necessarily behave in the same way
as  cells  at  the  surface,  as  has  been  previously  reported  (34,35).  It  is  possible  that  the
difference in HUVEC morphology at the intermediate and deep areas of the microspheres is
related to the lack of MSCs, which have migrated to the surface and are therefore unable to
support  network  formation  at  the  deeper  areas.  While  the  ideal  result  would  be  a
homogeneous distribution of the vessel network throughout the material,  the generation of
microspheres could potentially allow leveraging this limitation. As long as the microspheres
are smaller than the diffusion limit, which is generally considered to be 200μm of distance
from the surface to the deeper area of the construct  (36), the cells would receive adequate
amounts of nutrients and oxygen. In this context,  the presence of a vessel network at the
surface of the microspheres could be enough to generate an initial microvessel template that
could connect with the host vessel network and support quick vascularisation of the construct.
Alternatively, a possible strategy to stimulate homogeneous vessel formation throughout the
construct  would  be  the  addition  of  ECM  proteins  that  have  demonstrated  to  promote
vascularisation,  such  as  fibrin  or  laminin  (23,37,38).  Most  importantly,  using  other  cell
sources such as endothelial progenitor cells could also have a significant effect in the quality
and quantity of vessels formed (39). Therefore, it should be possible to improve these results
and achieve a better distribution of the vessel network in the future.
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Figure 6.4. Differential cell behaviour within co-cultured Gel-NOR microspheres. Representative
maximum intensity projections of CD-31 and F-actin immunostaining of HUVECs/MSCs co-cultures
encapsulated in Gel-NOR microspheres (5 wt% Gel-NOR, 0.2/2 mM Ru/SPS and DTT at 1:4 NOR:SH
ratio) and cultured during 14 days. (A) Maximum intensity projection of 400 μm thickness and (B)
maximum intensity projection of the surface, intermediate and deep areas of the microspheres. CD-31
is presented in green (anti-CD31 immunostaining),  F-actin is represented in red (Phalloidin) and
nuclei are represented in blue (DAPI). Scale bars: 200  μm. Experiments were repeated three times
with three technical replicates each (N=3).
6.3.2.  Studying  the  Effects  of  Spatial  Organisation  of  Cells  in  Assembled  Gel-NOR
Constructs 
The second goal of this chapter was to perform an initial study to evaluate the interaction of
different  kinds  of  cell-laden  microspheres  when  assembled  together.  When  cell-laden
microspheres  are  assembled  into  a  larger  scaffold,  cells  encapsulated  in  different
microspheres  interact  with  each  other  both  directly  through  cell-cell  interactions  (if  the
microspheres  are  in  direct  contact)  and  indirectly  through  soluble  signals  (40).  These
interactions could result in changes in cell function and behaviour. For example, fusion of
vascular spheroids derived from mouse allantoic tissue has been previously reported in the
literature (41), and this phenomenon was not observable in a single sphere model under the
same conditions  (42).  Thus,  observing  individual  microspheres  is  not  the  most  adequate
representation of what would happen in an assembled scaffold. 
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To study how different cell distributions would affect cell behaviour and microsphere fusion,
a  proof-of  concept  experiment  was performed by assembling  microsphere  pairs  into  3D-
printed  PCL  cages  (Figure  6.5A-B).  After  14  days  of  culture,  a  CD-31  and  F-actin
immunostaining  was  performed  on  the  samples  to  evaluate  cell  distribution  and  general
morphology (Figure 6.5C). When HUVEC or MSC-laden microspheres were in direct contact
with  cell-free  microspheres,  little  to  no  migration  was  detected  towards  the  cell-free
microspheres (Figure 6.5C, top row). However,  when co-culture-laden microspheres were
assembled with cell-free microspheres, some of the HUVECs and MSCs seemed to be able to
migrate  onto  the  empty  microsphere  (Figure  6.5C).  These  observations  correlate  with
previous  reports  where  endothelial  cells  and  MSCs  showed  increased  migration  when
cultured together (33,43).
When two HUVEC-laden microspheres were cultured together, no fusion or interconnected
structures between microspheres were observed (Figure 6.5C, middle row). This agrees with
the  small  amount  of  cell  migration  and  clustering  observed  in  individual  HUVEC-laden
microspheres.  When two MSC-laden microspheres  were assembled together,  microsphere
fusion was observed (Figure 6.5C, middle row). These results correlate with the high capacity
of MSCs to migrate throughout the material  (33), which is also observable in individually
cultured microspheres (Figures 6.3 and 6.4). In fact, MSCs had also migrated onto the PCL
scaffolds  at  day  14  in  many  of  the  samples  (Figure  6.5C).  When  co-culture  laden
microspheres were assembled together, microsphere fusion was also observed. Interestingly,
the  assembled  structures  that  HUVECs  formed  in  co-culture  microspheres  were  also
interconnected between both microspheres (Figure 6.5C, middle row). These results suggest
that the presence of MSCs, either encapsulated individually or in co-cultures, is necessary for
microsphere fusion. Furthermore, the presence of MSCs could be promoting the formation of
interconnected HUVEC structures between microspheres. Therefore, it  is possible that the
assembly of co-culture-laden microspheres into a larger construct could potentially result in a
large,  interconnected structure of endothelial  cells  that could provide nutrient and oxygen
supply to the whole construct. 
222
Chapter 6. Bioassembly of Gel-NOR and PVA-Tyr Modules for Combinatory Approaches in Tissue
Vascularisation
Figure  6.5.  Interactions  between  assembled  cell-laden  vascular  microspheres. (A)
Brightfield  microscopy  image  of  the  experimental  setup  with  assembled  Gel-NOR
microspheres in a 3D-printed PCL cage. (B) Schematic view of the experimental setup with
assembled Gel-NOR microspheres in a 3D-printed PCL cage. (C) Representative images of
a  CD-31 and F-actin immunostaining of HUVECs, MSCs or HUVECs/MSCs co-cultures
encapsulated in Gel-NOR microspheres (5 wt% Gel-NOR, 0.2/2 mM Ru/SPS and DTT at
1:4 NOR:SH ratio) and assembled in different combinations. CD-31 is presented in green
(anti-CD31 immunostaining) and F-actin is represented in red (Phalloidin). Scale bars:
500 μm. Dashed lines represent the contour of the microspheres and the PCL cages. This
experiment was repeated once (N=1).
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When MSC-laden  microspheres  were  assembled  with  HUVEC-laden  microspheres,  some
MSC migration onto the HUVEC-laden microspheres was observed (Figure 6.5C, bottom left
image). Furthermore, the direct contact of these migrated MSCs with HUVECs seemed to
promote the formation of interconnected structures by HUVECs, fulfilling a similar role to
MSCs directly  co-encapsulated  with HUVECs. When co-culture-laden microspheres  were
assembled  with  HUVEC-laden  microspheres,  the  observed  MSC  migration  towards  the
HUVEC-laden  microsphere  was  lower  (Figure  6.5C,  bottom  middle  image).  A  possible
explanation  of  this  phenomenon  is  that,  when  HUVECs  are  present  in  one  of  the
microspheres,  the formation of a  signal  gradient  could be strongly attracting  MSCs from
adjacent  microspheres.  It  has  been  shown that  MSCs  migration  is  stimulated  by  growth
factors  such  as  VEGF,  BDNF or  PDGF-ββ  (33),  which  are  secreted  by  HUVECs  (44).
However, when HUVECs are present in the same microsphere as MSCs, such signal gradient
is not formed, resulting in a lower level stimulation of MSC migration. Despite the reduced
migration,  HUVECs  that  were  closer  to  the  co-culture  microsphere  and  in  contact  with
migrated  MSCs  did  seem  to  show  an  increased  ability  to  assemble  into  interconnected
structures (Figure 6.5C, bottom middle image).  When co-culture-laden microspheres were
assembled with MSC-laden microspheres, a high degree of microsphere fusion was observed.
However, little to no migratory activity of HUVECs was observed (Figure 6.5C, bottom right
image).
Overall, the results of this experiment are preliminary (N=1) and the observations described
would require further confirmation studies. However, these results provide interesting initial
information on how different cell distributions would affect cell function and microsphere
fusion.  For optimal microsphere fusion, it  seems recommendable to encapsulate MSCs in
each microsphere due to their increased proliferation and migration capabilities as compared
to HUVECs. For endothelial cell assembly, better results were observed when HUVECs were
directly  co-encapsulated  with  MSCs  or  when  they  were  individually  encapsulated  and
assembled together with MSC-laden microspheres. However, for vascularisation purposes it
is  desirable  to  have  these  interconnected  endothelial  cell  structures  distributed
homogeneously throughout the scaffold, especially when fabricating large tissue engineered
constructs.  Therefore,  it  seems recommendable  to  co-encapsulate  HUVECs and MSCs in
each individual sphere for the fabrication of larger engineered constructs. 
Importantly, most of the changes in cell function observed in this assembled model fit already
existing data  on the interactions between HUVECs and MSCs  (33,43,45).  Therefore,  this
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experiment illustrates the potential of this setup as a model of the interactions of different cell
types within fabricated constructs. As stated in the introduction, the effects of the distribution
of  cells  and  materials  within  the  scaffold  is  one  of  the  largest  knowledge  gaps  in
biofabrication. This model could help answer some of these questions and provide relevant
information to the field.
6.3.3. Generating and Evaluating PVA-Tyr Microspheres
The third goal of this chapter was to generate GF-loaded PVA-Tyr microspheres and to study
the  effects  that  a  different  fabrication  technique  would  have  on  the  degradation  and GF
release profiles of PVA-Tyr hydrogels. PVA-Tyr hydrogel microspheres were successfully
generated  using  the  same  microfluidics  setup  used  to  fabricate  Gel-NOR  microspheres.
Figure 6.6 shows representative images of the microspheres at day 1 after their fabrication.
Figure  6.6. PVA-Tyr  microspheres  fabricated  with  different  Ru/SPS  concentrations.
Representative images of 5wt% PVA-Tyr microspheres fabricated at 0.5/5, 1/10 or 2/20 Ru/SPS
mM concentrations at day one after fabrication. Scale bars: 500 µm. Experiments were repeated
three times with three technical replicates each (N=3).
It has been previously shown that differences in the size and shape of biomaterial constructs
can affect their degradation time both in vitro and in vivo. In a comprehensive study, Artzi et
al. studied the degradation profile of PEG:Dextran fabricated in the shape of disks, blocks or
hollow cylinders both in vitro and in a mouse subcutaneous model. The study found that the
degradation profiles differed between groups in both setups  (46), where hollow cylinders
were  the  fastest  group  to  degrade,  followed  by  blocks  and  discs.  These  differences  in
degradation  were  directly  related  to  their  surface  to  volume  ratio,  where  hollow  mesh
cylinders had the highest, followed by blocks and discs. Therefore, the translation of PVA-
Tyr discs to microspheres could results in large differences in their degradation profile, not
only due to the difference in volume but also their  difference in shape,  both resulting in
differences in surface-to-volume ratio. While the sphere is the geometrical shape with the
lowest surface-to-volume ratio, the large differences in volume (20 mm3 for discs against
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approximately 0.5 mm3 for microspheres) are more impactful for the surface-to-volume ratio
than the geometrical shape. Therefore, we hypothesized that PVA-Tyr microspheres would
degrade faster than PVA-Tyr discs. However, when comparing the degradation time of PVA-
Tyr discs and microspheres (Table 6.1), it was found that both geometries were comparable
in the studied crosslinking conditions.  A potential  explanation of the differences between
these results  and previous  research is  that  PVA-Tyr hydrogels follow a bulk degradation
process, as opposed to the surface erosion degradation shown by PEG:Dextran (46).
Table 6.1. Degradation time of PVA-Tyr hydrogels in the  form of discs and microspheres.
Degradation time of the discs is reported as the average time point in which each sample collapsed
during shaking of the PBS solution. Degradation time of the microspheres is reported as the time
point in which all the microspheres had collapsed during shaking. Experiments were repeated three
times with three technical replicates each (N=3).
Form Ru/SPS (mM) Degradation time (Days)
Disc 0.5/5 8 ± 1
Microsphere 0.5/5 9
Disc 1/10 42 ± 2
Microsphere 1/10 40
Disc 2/20 63 ± 1
Microsphere 2/20 65
The size of the microspheres was tracked during the degradation period using bright-field
microscopy (Figure 6.7). The initial diameter of PVA-Tyr microspheres crosslinked under all
conditions was below 1 mm, but changed depending on the concentration of Ru/SPS utilised.
This  was  expected  from the  different  swelling  ratios  observed in  chapter  3,  which  were
caused by different degrees of crosslinking. The evolution of the microsphere size followed
similar trends as the swelling ratio of discs crosslinked under the same conditions (Chapter 3,
Supplementary Figure S3.1B): microspheres crosslinked at 0.5/5 mM Ru/SPS consistently
showed increases in size between time points, whereas microspheres crosslinked at higher
Ru/SPS concentrations  showed an  initial  phase  with  no increases  in  size,  followed by a
second phase where the size started to increase between time points in a consistent manner
(Figure  6.7).  These  results  are  relevant  for  the  adaptation  of  these  microspheres  to
bioassembly,  as the size of the microspheres  needs  to  initially  fit  the size of  the  printed
scaffold so that the microspheres do not fall during the culture period or post-implantation.
The  size  of  the  microspheres  can  be  adapted  by  changing  different  parameters  of  the
fabrication process (22), and the size of the scaffold can also be easily adapted by changing
the printing design. The fact that the size of the microspheres increases with time, which is
another sign of the bulk degradation process, is a positive result as it means that they would
not fall from the printed scaffold during the degradation process.
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Figure  6.7.  Diameter  of  PVA-Tyr  microspheres  throughout  the  degradation  process. *:
Significant difference (p<0.05) as compared to previous time points of the same condition. Error
bars are not visible in time points where they were smaller than the symbol itself. Experiments were
repeated three times with three technical replicates each (N=3).
Taken together, the results on degradation time and sphere size show that the degradation
profile  of  the  microspheres  follows  similar  trends  as  in  discs.  Therefore,  not  only  it  is
possible  to  achieve  controlled  degradation  of  these  microspheres,  but  the  library  of
degradation profiles developed in chapter 3 can be directly translated to microspheres. 
To  study  the  changes  in  GF  release  profile  from  microspheres  as  compared  to  discs,
fluorescently labelled VEGF, bFGF and BDNF were incorporated in both PVA-Tyr discs and
microspheres.  The  release  of  GFs  was  tracked  through  fluorescence  imaging  of  the
microspheres (Figure 6.8) and through fluorescence spectroscopy of exposed culture media
(Figure 6.9). 
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Figure  6.8.  Fluorescently-labelled  growth  factor  release  from  PVA-Tyr  microspheres
(Images). Fluorescence images of PVA-Tyr microspheres crosslinked at 5wt% of PVA-7Tyr, 0.5/5
mM Ru/SPS  loaded  with  fluorescently  labelled  VEGF,  bFGF or  BDNF.  Scale  bars:  500  µm.
Experiments were repeated three times with three technical replicates each (N=3).
Fluorescence imaging (Figure 6.8) shows that GFs were present in the microspheres during
the whole degradation period,  where the average fluorescence intensity  of the GF-loaded
microspheres was always significantly higher than the PVA-Tyr control (data not shown).
Release measurements (Figure 6.9) show that the percentage release in the first 24 hours of
exposure to media is significantly higher in discs than in microspheres (70-75% and 30-35%
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respectively). These results were in contrast to the observed degradation times, where there
were  no  differences  between  discs  and  microspheres.  A  possible  explanation  of  the
differences in the initial release is a loss of incorporated GF during the PBS washes needed to
separate the microspheres from the oil phase after fabrication. As these washes happen before
the beginning of the release studies, any GF lost during the process would not be detected.
Interestingly, the resulting release profile is more linear, which makes it more suitable for
regenerative medicine applications where burst release is not desirable  (47). On the other
hand, these results  also mean that there is a significant  loss of GF during the fabrication
process  (calculated  to  be  around  55%  of  the  initially  loaded  GF  for  this  crosslinking
condition), making this fabrication method less efficient. However, only GFs that have not
been covalently incorporated in the network (not retained) can be lost during these initial
washings. As shown in Chapter 3 (Figures 3.3A and 3.4A), the retention can be improved by
increasing the Ru/SPS concentration, and therefore it was hypothesized that increasing the
Ru/SPS concentrations would result in a more efficient GF incorporation during microsphere
fabrication.
 
Figure  6.9.  Fluorescently-labelled  growth  factor  release  from  PVA-Tyr  discs  and
microspheres. Growth factor release from PVA-Tyr discs and microspheres crosslinked at 5wt%
PVA-7Tyr, 1wt% Gelatin and 0.5/5 Ru/SPS loaded with fluorescently labelled VEGF, bFGF or
BDNF. Experiments were repeated three times with three technical replicates each (N=3). Error
bars are not visible in time points where they were smaller than the symbol itself.
Overall,  the  results  from  this  section  show  that  it  was  possible  to  generate  PVA-Tyr
microspheres with controllable degradation times. Their degradation follows trends that are
comparable  to  fabricated  discs,  making our library  of degradation  profiles  translatable  to
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PVA-Tyr microspheres. Their bulk degradation process makes them increase in size during
the degradation process, which will facilitate their application to bioassembly. It was possible
to load VEGF, bFGF and BDNF in the microspheres and study their release profile, which
was more linear  than the release from discs.  However,  this  was at  the expense of losing
around half the amount of GF that was initially incorporated into the microspheres, reducing
the efficiency of the system.
6.3.4. Proof-of-Concept of the Combined Assembly of Gel-NOR and PVA-Tyr
In addition to controlling the distribution of cells within the construct, bioassembly allows the
combination  of  microspheres  made  of  different  materials,  which  can  be  used  for  the
combined delivery of growth factors and cells  in a controlled manner.  By controlling the
arrangement of these microspheres, it would theoretically be possible to generate controlled
growth factor gradients within the scaffold that attract cells to specific areas of interest or that
stimulate  differentiation  in  certain  patterns  (Figure  6.10A-B),  mimicking  the  complex
architecture of targeted tissues. For example, cortical bone is comprised by osteons, which
are  structures  formed  of  a  central  channel  with  blood  vessels  surrounded  by  ECM  and
osteoblasts  (48).  A  potential  way  to  mimic  that  would  be  to  arrange  the  GF-releasing
microspheres in the center and surrounding them by cell-laden microspheres. Other tissues
such as articular cartilage present polarized structures that are formed by gradients of growth
factors. By arranging the GF-releasing microspheres on one side of the construct, it would
theoretically  be  possible  to  generate  a  GF  gradient  and  observe  their  effects  on  cell
behaviour.
To demonstrate that it is possible to generate 3D conformations that mimic different types of
tissues, Gel-NOR and PVA-Tyr microspheres were assembled into larger 3D-printed PCL
scaffolds  in  different  conformations  (Figures  6.10A-B).  As  expected  from  our  previous
results, the PVA-Tyr microspheres were totally degraded at day 14 of culture (Figures 6.10C-
D), endothelial cells were assembling into interconnected structures (Figure 6.10D) and α-
SMA was detectable in MSCs (Figures6.10C-D). 
These results show that it is possible to combine bioassembly techniques with the material
platforms  developed in  this  thesis,  and represent  a  proof-of  concept  (N=1)  of the  future
research that these tools could enable.  As stated in the introduction,  there is currently no
research that combines growth factor delivery with the generation of pre-vascularised tissue
analogues for vascularisation purposes. This platform could allow evaluation of the effects of
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growth factor  delivery both during the pre-vascularisation  process and after implantation.
Furthermore, the optimal 3D organisation of cells and GFs for vascularisation should also be
studied, and this setup provides the tools to do so.
Figure 6.10: Proof-of-concept of different potential arrangements of Gel-NOR and PVA-Tyr
microspheres for controlled generation of growth factor gradients within bioassembled large
scaffolds.  (A-B)  Schematic  view  of  PCL  scaffolds  with  assembled  Gel-NOR  and  PVA-Tyr
microspheres generating growth factor gradients within the scaffold. (C-D) Representative images
of  a  CD-31  and  α-SMA  immunostaining  of  HUVECs,  MSCs  or  HUVECs/MSCs  co-cultures
encapsulated  in  Gel-NOR microspheres  (5  wt% Gel-NOR,  0.2/2  mM Ru/SPS and DTT at  1:4
NOR:SH ratio) and assembled together with PVA-Tyr microspheres (5 wt%, 0.5/5 mM Ru/SPS), at
day 14 of culture in EGM. Dashed lines indicate the PCL scaffold and the initial positioning of the
PVA-Tyr microspheres. P: PVA-Tyr microspheres fully degraded after two weeks of culture. Scale
bars: 1mm (C) and 0.5 mm (D). This experiment was repeated once (N=1).
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6.4. Conclusions
The field of regenerative medicine is evolving towards the combination of different cells,
materials and bioactive molecules to provide optimal levels of tissue regeneration (13). While
several  studies  confirm  that  combining  these  elements  can  result  in  synergistic  positive
effects  (1–6), there is  little  knowledge on the ideal  ways to  combine them. Bioassembly
allows the combination of these elements and provides control over their spatial arrangement
(12). Additionally,  it  allows generating large tissue analogues in a layer-by-layer fashion,
facilitating translation to a clinical setting. Very few studies provide evidence of what is the
ideal  spatial  and  temporal  arrangement  of  materials,  cells  and  growth  factors  within
biofabricated scaffolds. Furthermore, there are no studies yet that combine the stimulation of
angiogenesis with pre-vascularisation techniques. Adapting the platforms developed in this
thesis to their use as building blocks for bioassembly could allow large tissue models to be
fabricated  to  study the effects  of  different  cell  and growth factor  arrangements  on tissue
vascularisation.
In  this  chapter,  PVA-Tyr  and  Gel-NOR  microsphere  modules  were  generated  for
bioassembly  applications.  It  was  demonstrated  that  both  materials  can  be  fabricated  into
microspheres with encapsulated cells and growth factors using a microfluidics system. The
fabrication process did not alter the desirable properties of Gel-NOR, as both the HUVECs
and MSCSs were still able to migrate and proliferate throughout the material. Furthermore,
encapsulated HUVECs were able to undergo vasculogenesis and form interconnected vessel-
like structures within the Gel-NOR microspheres when co-cultured with MSCs. Furthermore,
it was possible to obtain proof-of-concept results on how these microspheres can be arranged
to study the optimal  distribution  of endothelial  cells  and MSCs within 3D constructs  for
vascularisation purposes. The results suggest that both HUVECs and MSCs should be co-
encapsulated  in  each  microsphere  for  improved  microsphere  fusion  and  homogeneous
endothelial  cell  network distribution.  When generating GF-loaded PVA-Tyr microspheres,
the fabrication process impacted the initial GF retention within the PVA-Tyr microspheres.
However,  PVA-Tyr microspheres still  showed a linear GFs release profile throughout the
degradation  process.  Finally,  the  possibility  of  arranging  PVA-Tyr  and  Gel-NOR
microspheres in a controlled and designed manner was demonstrated. The tools developed in
this chapter should prove useful for future research in the combination of multiple strategies
for tissue vascularisation.
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7.1. Conclusions
In  Chapter  1, a  brief  introduction  to  vascularisation  in  the  human  body  was  provided,
together  with  an  introduction  to  the  main  tissue  engineering  strategies  to  promote
vascularisation and their current challenges. The aims of the thesis were also outlined.
In  Chapter  2,  the  main  strategies  for  growth  factor  delivery  and  for  the  generation  of
vascularised tissues were reviewed and discussed in depth. Their limitations and current gaps
in the literature were identified. 
This  thesis  systematically  investigated  new  hydrogel-based  strategies  to  promote
vascularisation, focusing on three main aims: Developing a growth factor delivery system to
promote vascularisation, combining top-down and bottom-up strategies for the generation of
large  vascularised  tissue  analogues,  and  combining  approaches  for  tissue  vascularisation
through bioassembly. In this chapter, the achievements in each of these aims are reviewed
and their implications for vascular tissue engineering are discussed, together with potential
future research perspectives.
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Aim I: Developing a Growth Factor Delivery System to Promote Vascularisation
In Chapter 3, the potential of PVA-Tyr hydrogels as a GF delivery system was investigated.
The aim was to generate a novel GF delivery system that could covalently incorporate native
growth factors and finely tailor their release profile, making it a flexible tool that could be
adapted to different tissue engineering applications. It was demonstrated that, by changing the
degree of tyramination, macromer concentration and Ru/SPS concentration, hydrogels with
highly  tailorable  degradation  profiles  from  seven  days  to  up  to  three  months  could  be
fabricated.  The release profile of covalently incorporated BSA, VEGF, bFGF and BDNF
from different PVA-Tyr formulations consistently showed a linear tendency that lasted up to
total degradation of the hydrogel, demonstrating potential for long term release applications
and highly tailorable release profiles. It was shown that the encapsulation of VEGF, bFGF or
BDNF in PVA-Tyr did not result in differences in the incorporation rate or release profile of
the system, which facilitates the adaptation of the system to deliver of different GFs for a
range of  applications.  Furthermore,  proteinase  K was  used  as  a  model  to  show that  the
degradation  of  PVA-Tyr  hydrogels  is  driven  by  hydrolysis  even  after  the  covalent
incorporation of high concentrations of protein. Finally, 2D and 3D in vitro models were used
to demonstrate that VEGF, bFGF and BDNF still retain functionality after exposure to the
oxidative  stress  of  photo-crosslinking  and  to  the  chemical  modifications  associated  with
covalent incorporation. To our knowledge, no other GF delivery system has shown to provide
such controllable release profiles in combination with the ability to covalently incorporate a
wide range of proteins in the native state.
In Chapter 4, the PVA-Tyr system was adapted to promote vascularisation in a very specific
clinical  setting:  revascularisation  of  the  femoral  head.  Considering  the  design  criteria
reviewed in Chapter 2, VEGF was chosen to promote migration of blood vessels into the
avascular femoral head. The degradation time of the hydrogels was chosen to be between 1
and 2 weeks to promote an early vascularisation process. Furthermore, it was identified that
the  interaction  of  the  system with  cells  in  the  surrounding  microenvironment  should  be
improved to promote the penetration of new vessels,  and the release profile and delivery
method had to be considered for the specific surgical setting.
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The ability of the system to directly interact with cells in the surrounding environment was
improved by covalently incorporating gelatin into PVA-Tyr hydrogels. The addition of 1 wt
% gelatin promoted the attachment of endothelial cells and didn’t have a negative impact any
of the key attributes of PVA-Tyr hydrogels (degradation time, resistance protease degradation
and controlled release time frame of GFs). These results show the potential of the system to
incorporate multiple  proteins while still  providing controlled GF release.  The system was
further adapted to the specific surgical procedure by performing the photo-crosslinking prior
to the injection into the site of injury, which allowed avoiding unnecessary risks of uneven
crosslinking or burst release into the body. Finally, PVA-Tyr hydrogels with incorporated
gelatin and VEGF were applied in a piglet in vivo model of avascular necrosis. While the
data from the in vivo experiment is still not conclusive and needs to be further analysed, there
seems to be a tendency to improve the maintenance of the femoral head after injection of the
PVA-Tyr hydrogels.
There are some aspects of the system that still need to be further investigated. Studies on the
effects of increased Ru/SPS concentration in GF bioactivity should be performed. Potential
strategies to reduce oxidative stress such as the addition of protective proteins in the hydrogel
should be studied to avoid any loss of bioactivity that the crosslinking process could cause.
We have, however, provided evidence showing that the process of covalent incorporation
does not inactivate the studied GFs and, therefore, that this type of cross-linking is a viable
strategy for long term GF delivery. Another key aspect for future study is the degradation
profile  of  PVA-Tyr  hydrogels  in  an  in  vivo environment.  While  we  have  studied  the
susceptibility of the system to protease degradation in vitro, other factors that could affect the
process are present in the in vivo environment. Finally, the concentration of GF that needs to
be delivered can only be determined through in vivo experimentation and will need to be
studied for each application that the PVA-Tyr system is adapted to.
There is a range of other potential applications that the system could be translated to aside
from delivery of single or multiple  GFs. The capability  of the system to incorporate  any
tyrosine-containing protein could be used to incorporate  protein and cell  suspensions that
would otherwise be hard to deliver in a controlled manner due to their heterogeneity. One
example of this type of suspensions is platelet-rich plasma (PRP). Despite the presence of a
wide range of GFs in PRP, the benefits of its clinical application though direct injection have
been dubious so far  (1–3). In a similar way to GF delivery, these negative results could be
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related to the lack of control over its release. Some studies have aimed to control the release
of the GFs in PRP by incorporating it into hydrogels (4–6), but none of these platforms show
the level of control over the release profile that PVA-Tyr would provide. The flexibility of
the PVA-Tyr system provides can still open the door to many more novel applications in the
future.
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Aim II: Combining Top-down and Bottom-up Approaches for the Generation of Large
Vascularised Tissue Analogues
The in vitro generation of large vascularised tissues analogues that recapitulate the different
levels of vascularisation in native tissues and organs remains one of the major challenges in
tissue engineering, and efforts in this direction have taken two major routes: 3D fabrication-
based  top-down  approaches  and  bottom-up  approaches  based  on  endothelial  cell  self-
assembly.  One of  the  major  barriers  for  these  two approaches  to  be  combined  is  in  the
incompatibility of present material platforms to be adaptable to both 3D biofabrication and to
promote endothelial cell self-assembly into microvessel networks.
In  Chapter  5,  the  combination  of  a  top-down  and  a  bottom-up  approach  for  the
biofabrication of vascularised constructs with different levels of vascularisation using a single
material platform is reported. Combining thiol-ene chemistry with the visible light initiated
photoinitiator system Ru/SPS allowed fine tailoring of the hydrogel mechanical properties
and obtain constructs with microvasculature and homogeneous contraction. It was found that
contraction  of  the material  is  tightly  related to  the formation  of  vessel-like structures  by
encapsulated endothelial cells. Despite the contraction, it was possible to biofabricate large
constructs with an interconnected pore network of predictable diameter and spacing while
allowing the elongation and migration of endothelial cells at the deeper areas of the material.
To our knowledge, this was the first report of the combination of both approaches without the
need of support materials and perfusion of culture media and endothelial cells. This platform
was then used to study the effects of 3D architecture on the behaviour of endothelial cells
both on the surface and at  the deeper areas  of the constructs.  Our data  suggests that  the
fabrication of interconnected pores stimulates endothelial cells to migrate to the surface of the
pores and endothelialise them rather than forming a microvessel network. This resulted in full
endothelialisation of the pore network regardless of the pore diameter. It was also observed
that increasing the pore spacing of the constructs can affect the behaviour of endothelial cells
at the deeper areas of the material, potentially by generating hypoxic conditions that stimulate
microvessel formation. These results show that the fabrication parameters have an impact on
cell behaviour and should be thoroughly studied to find the architecture that results in optimal
outcomes. The role of hypoxia during the generation of large, pre-vascularised tissues is also
an aspect that should be further studied as part of the efforts to translate these technologies to
studies in larger mammals.
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The findings from this chapter is a valuable proof of concept for the field as one of the first
attempts  to  combine top-down and bottom-up approaches,  in  order  to  fabricate  clinically
relevant large vascularised tissues. Furthermore, we have used this novel platform to provide
relevant  information  on  how  3D  design  can  affect  endothelial  cell  behaviour  in  3D
biofabricated  vascularised  constructs,  which  will  be  relevant  for  future  optimisation  and
translation of large vascularised constructs. 
However, the quality of the microvessels at the deeper areas of biofabricated constructs was
lacking in comparison to previous studies using fibrin and collagen. The addition of ECM
proteins with bioactive properties such as fibrin or laminin into Gel-NOR hydrogels could
help improve the formation of micro-capillaries, but could also result in changes in the degree
and homogeneity of the contraction after fabrication. This would be an interesting line of
research to continue using the Gel-NOR platform and biofabrication technologies.
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Aim III: Combining Approaches for Tissue Vascularisation Through Bioassembly
The field of regenerative medicine is evolving towards the combination of different cells,
materials  and bioactive  molecules  to provide optimal  levels  of tissue regeneration.  While
several  studies  confirm  that  combining  these  elements  can  result  in  synergistic  positive
effects, there is little knowledge on the ideal ways to combine them. Bioassembly allows the
combination  of  these  elements  and  provides  control  over  their  spatial  arrangement.
Additionally,  it  allows  generating  large  tissue  analogues  in  a  layer-by-layer  fashion,
facilitating translation to a clinical setting. Very few studies provide evidence of what is the
ideal  spatial  and  temporal  arrangement  of  materials,  cells  and  growth  factors  within
biofabricated scaffolds. Furthermore, there are no studies yet that combine the stimulation of
angiogenesis with pre-vascularisation techniques. Adapting the platforms developed in this
thesis to their use as building blocks for bioassembly could allow the fabrication of large
tissue models that allow studying the effects of different cell and growth factor arrangements
on tissue vascularisation.
In Chapter 6, PVA-Tyr and Gel-NOR microsphere modules were generated for bioassembly
applications. It was demonstrated that both materials can be fabricated into microspheres with
encapsulated cells and GFs using a microfluidics system. The fabrication process did not alter
the desirable properties of Gel-NOR, as both the HUVECs and MSCSs were still  able to
migrate and proliferate throughout the material.  Furthermore,  encapsulated HUVECs were
able to undergo vasculogenesis and form interconnected vessel-like structures within the Gel-
NOR microspheres when co-cultured with MSCs. Using these pre-vascularised modules, it
was possible to obtain proof-of-concept results on how these microspheres can be arranged to
study  the  optimal  distribution  of  endothelial  cells  and  MSCs  within  3D  constructs  for
vascularisation purposes. The results suggest that both HUVECs and MSCs should be co-
encapsulated  in  each  microsphere  for  improved  microsphere  fusion  and  homogeneous
endothelial  cell  network distribution.  When generating GF-loaded PVA-Tyr microspheres,
the fabrication process impacted the initial GF retention within the PVA-Tyr microspheres.
However,  PVA-Tyr microspheres still  showed a linear GFs release profile throughout the
degradation  process.  Finally,  the  possibility  of  arranging  PVA-Tyr  and  Gel-NOR
microspheres in a controlled and designed manner was demonstrated. 
The tools developed in this chapter should prove useful for future vascularisation research in
in different ways. Firstly, and in contrast to the Gel-NOR biofabrication method described in
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Chapter  5,  it  could allow the  generation  of  large  vascularised  tissues  by combining pre-
vascularised modules with other cell-containing modules after a separate in vitro culture and
differentiation process, allowing to provide each module with the conditions needed for the
desired cell  behaviour.  Secondly,  it  allows combining pre-vascularised modules with GF-
containing modules, enabling research on the impact of spatial and temporal arrangement of
these factors in vascularised tissues. The GF-releasing microspheres could contain different
GFs and could release them during different  periods of time,  providing a high degree of
control over the microenvironment. 
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Chapter 7. Conclusions and Future Perspectives
7.2.  Future Perspectives
The stimulation of vascularisation through GF delivery has shown to be dependent on a series
of parameters such as the GF used, its concentration and its release profile. The translation of
any  GF  therapy  to  a  clinical  setting  will  therefore  require  testing  a  large  amount  of
parameters.   While  PVA-Tyr  system  has  shown  the  flexibility  to  adapt  any  of  these
parameters to the requirements of each therapy, technologies for high throughput screening of
release conditions and better in vitro models that closely resemble in vivo conditions should
be developed for quicker identification and translation of potential candidates.
The generation  of  large  vascularised  tissues  in  vitro  is  still  far  from clinical  application.
While some techniques such as pre-vascularisation and biofabrication have shown promise
on generating microvessels of different diameters,  no techniques so far have been able to
reproduce the complex vascular beds in native tissues and organs. Novel techniques to scale
up the fabrication of vascularised tissue analogues are needed, together with techniques to
evaluate the adequate functionality of the fabricated vessels in terms of oxygen and nutrient
diffusion to the encapsulated cells.
While  the  generation  of  constructs  that  only  contain  blood  vessels  could  be  of  use  for
ischemic disease or for implantation in tissues that have inherent regenerative capabilities
such as bone, other tissues would not be able to rely on vessels alone to recover functionality.
The next challenge will be finding ways to fabricate tissues that not only contain vessels, but
also contain the different types of functional cells of the targeted tissue in a way that restores
or improves tissue function. For that purpose, techniques such as bioassembly could be of
great  help.  The ability  to  generate  smaller  modules  under isolated conditions  that  can be
assembled  together  makes  this  technology  appealing  to  achieve  complex  tissue
biofabrication. Research aiming to optimise these conditions and techniques for automated
module production would be of great help to the field.
The large evolution process that resulted in the appearance and success of the human species
on Earth also resulted in our organisms being extremely complex and diverse. The field of
regenerative medicine will  continue studying and trying to reproduce small  pieces of this
puzzle to circumvent the limitations of our body. While there is still a lot of research to be
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